Pharma & Biotech Sector Financials, Performance and Ratios
-
Sector Score
38.8 /100
Rank 11 out of 27 Sectors -
Advance/Decline
351/317
-
No. of Companies668
-
Avg. Market Cap9,325
-
Price to Earning Ratio9.77
-
Price to Earning Growth Ratio1.03
-
Price to Book Ratio19.57
-
Return on Equity13.81
-
Return on Capital Employed-
-
Return on Assets8.66
-
Dividend yield 1 year %0.62 %
-
Net Profit Growth Annual YoY %-67.66 %
-
Net Profit Growth Qtr YoY %-23.65 %
-
Net Profit Growth Qtr QoQ %148.86 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Pharma & Biotech Sector Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Pharma & Biotech Peer comparison
Compare all stocks in Pharma & Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
467,367.2
|
264.5
|
L
 0.2%
H
261.2
266.6
|
L
 2.9%
H
257.8
266.6
|
L
 1.0%
H
246.8
266.9
|
L
 22.2%
H
221.9
267.5
|
L
 18.9%
H
190.8
267.5
|
L
 72.2%
H
135.9
267.5
|
L
 148.6%
H
105.9
267.5
|
L
 318.0%
H
55.1
267.5
|
| Adc Therapeutics SA |
|
143.0
|
1.1
|
L
 6.7%
H
1.0
1.1
|
L
 4.7%
H
1.0
1.1
|
L
 16.7%
H
1.0
1.4
|
L
 2.8%
H
0.9
1.5
|
L
 -67.3%
H
0.8
5.0
|
L
 45.5%
H
0.4
6.0
|
L
 -96.0%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
7,021.6
|
20.2
|
L
 7.8%
H
18.8
21.2
|
L
 18.5%
H
16.6
21.2
|
L
 12.6%
H
16.6
21.2
|
L
 24.4%
H
15.9
21.2
|
L
 105.5%
H
9.5
21.2
|
L
 369.9%
H
3.4
21.2
|
L
 307.3%
H
1.2
21.2
|
L
 -22.9%
H
1.2
27.3
|
| Annovis Bio Inc |
|
50.8
|
1.2
|
L
 4.4%
H
1.2
1.2
|
L
 6.3%
H
1.0
1.2
|
L
 -33.5%
H
1.0
1.9
|
L
 -32%
H
1.0
2.2
|
L
 -48.7%
H
1.0
5.5
|
L
 -88.8%
H
1.0
22.5
|
L
 -96.2%
H
1.0
39.7
|
L
H
1.0
132
|
| Bausch Health Companies Inc |
|
2,109.3
|
5.6
|
L
 -0.5%
H
5.6
5.7
|
L
 -3.8%
H
5.6
6.1
|
L
 -17.2%
H
5.6
7.0
|
L
 18.2%
H
4.3
7.3
|
L
 -16.2%
H
4.3
8
|
L
 -32.4%
H
4.0
11.5
|
L
 -78.4%
H
4.0
29.6
|
L
 -78.6%
H
4.0
34.8
|
| Bristol-Myers Squibb |
|
127,914.8
|
62.6
|
L
 -0.7%
H
62.6
63.4
|
L
 -1.6%
H
62.2
65.3
|
L
 -4.4%
H
62.2
68.2
|
L
 16.0%
H
54
68.6
|
L
 39.1%
H
42.5
68.6
|
L
 6.5%
H
39.4
68.6
|
L
 3.5%
H
39.4
81.4
|
L
 12.7%
H
39.4
81.4
|
| Bellring Brands Inc |
|
1,040.7
|
9.0
|
L
 -0.3%
H
8.8
9.2
|
L
 -2.1%
H
8.8
9.6
|
L
 -14.4%
H
8.8
11.1
|
L
 -5.4%
H
8.8
14.3
|
L
 -75.1%
H
7.8
37.3
|
L
 -78.0%
H
7.8
80.7
|
L
 -71.3%
H
7.8
80.7
|
L
H
7.8
80.7
|
| Emergent Biosolutions Inc |
|
335.8
|
6.6
|
L
 -3.7%
H
6.5
6.9
|
L
 5.1%
H
6.2
7.1
|
L
 35.9%
H
4.8
7.1
|
L
 -18.1%
H
4.4
8.6
|
L
 -20.2%
H
4.4
14.1
|
L
 79.5%
H
1.4
15.1
|
L
 -88.4%
H
1.4
57.1
|
L
 -76.6%
H
1.4
137.6
|
| Elanco Animal Health Inc |
|
11,206.5
|
22.4
|
L
 0.0%
H
22.2
22.6
|
L
 -3.2%
H
22.2
23.6
|
L
 -4.8%
H
22.2
25.4
|
L
 -7.4%
H
21.3
28.0
|
L
 16.8%
H
18.5
28.0
|
L
 92.7%
H
8.0
28.0
|
L
 -29.5%
H
7.9
35
|
L
H
7.9
37.6
|
| GSK PLC (ADR) |
|
102,339.3
|
51.1
|
L
 1.7%
H
50.5
51.3
|
L
 6.1%
H
49.5
51.3
|
L
 -1.7%
H
47.9
52.6
|
L
 0.8%
H
47.9
55.8
|
L
 25.6%
H
39.3
61.7
|
L
 34.2%
H
31.7
61.7
|
L
 29.2%
H
28.5
61.7
|
L
 16.5%
H
28.5
61.7
|
| IQVIA |
|
44,422.2
|
269.9
|
L
 1.3%
H
265.3
270.9
|
L
 3.1%
H
262.6
273.9
|
L
 5.4%
H
252.5
273.9
|
L
 60.9%
H
163.4
273.9
|
L
 44.2%
H
154.5
273.9
|
L
 31.4%
H
134.6
273.9
|
L
 6.6%
H
134.6
285.6
|
L
 248.4%
H
70.1
285.6
|
| Johnson & Johnson |
|
649,395.4
|
269.5
|
L
 -0.2%
H
268.5
273.7
|
L
 1.5%
H
260.7
273.7
|
L
 0.8%
H
260.7
281.1
|
L
 18.0%
H
227.5
281.1
|
L
 52.9%
H
174.1
281.1
|
L
 65.4%
H
140.7
281.1
|
L
 64.5%
H
140.7
281.1
|
L
 128.5%
H
109.2
281.1
|
| Eli Lilly |
|
1,038,332.9
|
1,164.9
|
L
 1.0%
H
1134.4
1170.9
|
L
 4.4%
H
1130.5
1170.9
|
L
 -6.4%
H
1113.3
1271.2
|
L
 6.0%
H
1079.2
1292.7
|
L
 54.9%
H
712.1
1292.7
|
L
 104.5%
H
516.6
1292.7
|
L
 402.9%
H
220.2
1292.7
|
L
 1358.3%
H
64.2
1292.7
|
| Merck & Company |
|
368,842.2
|
149.5
|
L
 1.8%
H
145.6
150.5
|
L
 3.9%
H
142.3
150.5
|
L
 0.3%
H
142.3
156.9
|
L
 31.3%
H
113
156.9
|
L
 83.4%
H
77.6
156.9
|
L
 39.3%
H
73.3
156.9
|
L
 107.8%
H
71.5
156.9
|
L
 153.0%
H
50.4
156.9
|
| Nuvation Bio Inc (Class A) |
|
2,131.3
|
6.1
|
L
 3.8%
H
5.9
6.1
|
L
H
5.6
6.2
|
L
 -11.1%
H
5.6
7.2
|
L
 9.2%
H
5.3
7.6
|
L
 88.5%
H
3.0
9.8
|
L
 349.6%
H
1.0
9.8
|
L
 -35.1%
H
1.0
10.5
|
L
H
1.0
15.2
|
| Novo Nordisk (ADR) |
|
175,831.4
|
39.8
|
L
 -8.0%
H
39.5
41.2
|
L
 -7.6%
H
39.5
43.7
|
L
 -13.7%
H
39.5
48.7
|
L
 -7.9%
H
39.5
52.1
|
L
 -35.2%
H
35.1
64.2
|
L
 -58.0%
H
35.1
148.2
|
L
 -20.1%
H
35.1
148.2
|
L
 72.2%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
267,962.8
|
141.0
|
L
 0.4%
H
141.0
142.2
|
L
 2.8%
H
137.4
142.2
|
L
 -9.8%
H
137
164.5
|
L
 -4.2%
H
137
164.5
|
L
 14.7%
H
121.6
170.5
|
L
 36.1%
H
92.2
170.5
|
L
 70.3%
H
74.1
170.5
|
L
 96.7%
H
59.2
170.5
|
| Organon & Co. |
|
3,592.5
|
13.7
|
L
H
13.7
13.8
|
L
 0.3%
H
13.6
13.8
|
L
 -0.4%
H
13.6
13.8
|
L
 1.9%
H
13.4
13.8
|
L
 30.9%
H
5.7
13.8
|
L
 -27.7%
H
5.7
23.1
|
L
 -58.5%
H
5.7
39.5
|
L
H
5.7
39.5
|
| Prestige Consumer Healthcare Inc |
|
2,217.1
|
46.8
|
L
 4.1%
H
44.5
47
|
L
 -0.3%
H
44.5
48.4
|
L
 -7.4%
H
44.5
54.0
|
L
 -0.4%
H
44.5
56.0
|
L
 -25.8%
H
42.6
71.1
|
L
 -19.3%
H
42.6
90.0
|
L
 -10.9%
H
42.6
90.0
|
L
 -0.2%
H
26.3
90.0
|
| Pfizer |
|
158,108.9
|
27.7
|
L
 0.3%
H
27.5
27.9
|
L
 0.1%
H
27.2
28.2
|
L
 -0.2%
H
27.2
29.2
|
L
 10.0%
H
23.6
29.2
|
L
 15.4%
H
23.6
29.2
|
L
 -17.5%
H
20.9
34.1
|
L
 -37.2%
H
20.9
61.7
|
L
 -13.4%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,960.8
|
14.1
|
L
 4.2%
H
13.6
14.2
|
L
 3.4%
H
13.2
14.3
|
L
 3.1%
H
13.2
15
|
L
 37.9%
H
9.4
15
|
L
 -33.5%
H
9.2
22.7
|
L
 -57.7%
H
9.2
34.6
|
L
 -67.4%
H
9.2
50.9
|
L
 -84.9%
H
9.2
99.1
|
| Arcus Biosciences Inc |
|
3,304.3
|
26.0
|
L
 2.8%
H
25.1
26.0
|
L
 5.5%
H
23.3
26.0
|
L
 -12.1%
H
23.3
31.6
|
L
 6.8%
H
23.3
31.7
|
L
 109.4%
H
12.2
31.7
|
L
 31.1%
H
6.5
31.7
|
L
 -26.1%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
10,329.1
|
12.4
|
L
 1.7%
H
12.3
12.5
|
L
 4.2%
H
11.5
12.5
|
L
 2.4%
H
11.5
12.5
|
L
 -6.7%
H
11.4
15.7
|
L
 -16.6%
H
11.4
15.7
|
L
 -9.1%
H
11.4
74.9
|
L
 -4.7%
H
9.6
74.9
|
L
 31.4%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
60,325.3
|
18.9
|
L
 -0.1%
H
18.8
19.0
|
L
 3.5%
H
18.5
19.1
|
L
 4.2%
H
18.0
19.1
|
L
 20.9%
H
15.4
19.1
|
L
 25.4%
H
13.0
19.1
|
L
 16.0%
H
12.6
19.1
|
L
 10.7%
H
12.3
19.1
|
L
 -17.3%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
46,681.8
|
40.1
|
L
 2.8%
H
38.4
40.8
|
L
 8.3%
H
37
40.8
|
L
 8.8%
H
35.4
40.8
|
L
 27.3%
H
29.6
40.8
|
L
 118.3%
H
18.2
40.8
|
L
 274.4%
H
8.1
40.8
|
L
 361.0%
H
6.8
40.8
|
L
 -20.5%
H
6.1
51.5
|
| Usana Health Sciences Inc |
|
267.7
|
14.5
|
L
 2.5%
H
14.1
14.5
|
L
 -3.5%
H
14.0
15.6
|
L
 9.9%
H
13.1
15.8
|
L
 -23.3%
H
12.6
23.6
|
L
 -51.3%
H
12.6
30.1
|
L
 -75.6%
H
12.6
60.9
|
L
 -83.5%
H
12.6
104.0
|
L
 -78.4%
H
12.6
138.0
|
| Zoetis (Class A) |
|
29,475.2
|
71.3
|
L
 -0.1%
H
70.3
72.5
|
L
 -2.3%
H
70.3
74.8
|
L
 -4.9%
H
70.3
78.8
|
L
 -9.4%
H
70.3
80.2
|
L
 -51.1%
H
70.3
148.8
|
L
 -60.7%
H
70.3
201.9
|
L
 -64.1%
H
70.3
249.3
|
L
 41.0%
H
46.9
249.3
|
| Biohaven Ltd |
|
2,147.8
|
14.2
|
L
 4.4%
H
13.6
14.5
|
L
 11.9%
H
11.9
14.5
|
L
 5.3%
H
11.9
18.2
|
L
 4.8%
H
11.9
18.2
|
L
 -0.7%
H
7.5
18.6
|
L
 -16.6%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Haleon PLC (ADR) |
|
41,161.8
|
9.4
|
L
 0.9%
H
9.2
9.4
|
L
 1.9%
H
9.1
9.4
|
L
 -5.2%
H
9.1
10.3
|
L
 4.5%
H
8.8
10.3
|
L
 2.2%
H
8.7
11.3
|
L
 12.6%
H
7.7
11.4
|
L
H
5.6
11.4
|
L
H
5.6
11.4
|
| Whitehawk Therapeutics Inc |
|
230.3
|
4.0
|
L
 -3.8%
H
4
4.2
|
L
 -1.7%
H
4.0
4.3
|
L
 -16.4%
H
4.0
5.1
|
L
 -8.6%
H
3.4
5.1
|
L
 110.4%
H
1.8
5.5
|
L
 -22.9%
H
1.2
5.7
|
L
 -86.1%
H
1.2
33.0
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
4,102.4
|
12.7
|
L
 0.2%
H
12.4
12.9
|
L
 16.3%
H
10.7
13.2
|
L
 9.4%
H
10.3
13.2
|
L
 128.9%
H
5.0
13.2
|
L
 180.7%
H
2.7
13.2
|
L
 149.2%
H
1.9
13.2
|
L
 -38.7%
H
1.9
22.1
|
L
H
1.9
71.9
|
| Abeona Therapeutics Inc |
|
324.2
|
5.7
|
L
 1.8%
H
5.6
5.7
|
L
 4.6%
H
5.2
5.8
|
L
 -4.9%
H
5.2
6.3
|
L
 -1.7%
H
5.2
7.7
|
L
 5.4%
H
4
7.7
|
L
 49.2%
H
3.1
9.0
|
L
 -81.3%
H
2.2
31
|
L
 -96.1%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
6,182.7
|
93.4
|
L
 -1.7%
H
91.8
96
|
L
 1.1%
H
90.4
98.3
|
L
 -11.0%
H
86
109.5
|
L
 29.1%
H
79
115.5
|
L
 500.5%
H
14.9
115.5
|
L
 279.6%
H
2.2
115.5
|
L
 160.3%
H
2.2
115.5
|
L
 -85.1%
H
2.2
648
|
| Acumen Pharma Inc |
|
187.3
|
2.6
|
L
 -2.3%
H
2.6
2.6
|
L
 -11.3%
H
2.5
3.0
|
L
 -18.8%
H
2.5
3.3
|
L
 14.6%
H
2.1
3.3
|
L
 105.6%
H
1.2
3.6
|
L
 -47.3%
H
0.9
5.1
|
L
 -82.5%
H
0.9
16.5
|
L
H
0.9
27.0
|
| Absci Corp |
|
1,685.2
|
9.8
|
L
 1.8%
H
9.5
10.2
|
L
 19.6%
H
7.8
10.2
|
L
 5.8%
H
7.8
10.2
|
L
 32.5%
H
6.7
12.1
|
L
 276.3%
H
2.2
12.1
|
L
 546.1%
H
1.1
12.1
|
L
 -10.5%
H
1.1
18.1
|
L
H
1.1
31.5
|
| Arbutus Biopharma Corp |
|
990.5
|
5
|
L
 -0.2%
H
5.0
5.1
|
L
 -2.3%
H
5.0
5.2
|
L
 4.8%
H
5.0
5.5
|
L
 9.9%
H
4.3
5.5
|
L
 17.7%
H
3.5
5.5
|
L
 150%
H
1.7
5.5
|
L
 16.6%
H
1.7
6.5
|
L
 30.2%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
30.7
|
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
 17.4%
H
1.0
1.2
|
L
 29.2%
H
0.7
1.2
|
L
 -14.8%
H
0.7
2.2
|
L
 -59.5%
H
0.7
3.4
|
L
 9.5%
H
0.4
5.5
|
L
 -95.4%
H
0.4
116.9
|
L
 -99.7%
H
0.4
378
|
| Acadia Pharma Inc |
|
4,548.9
|
26.4
|
L
 -3.3%
H
26.3
27.4
|
L
 -5.1%
H
26.3
28.1
|
L
 -9.1%
H
26.3
30.8
|
L
 22.1%
H
21.6
31.0
|
L
 8.1%
H
19.7
31.0
|
L
 11.0%
H
13.4
32.6
|
L
 58.0%
H
12.2
33.9
|
L
 -26.6%
H
12.2
58.7
|
| Adicet Bio Inc |
|
83.6
|
8.9
|
L
 -2.7%
H
8.8
9.2
|
L
 -6.2%
H
7.9
9.8
|
L
 -4.8%
H
7.9
10.0
|
L
 10.3%
H
7.4
10.0
|
L
 -29.8%
H
6.0
17.4
|
L
 -65.1%
H
6.0
60.3
|
L
 -91.9%
H
6.0
349.9
|
L
H
6.0
349.9
|
| Achieve Life Sciences Inc |
|
828.4
|
8.1
|
L
 0.9%
H
7.8
8.1
|
L
 14.0%
H
7.0
8.1
|
L
 0.4%
H
7.0
8.6
|
L
 66.0%
H
4.9
8.6
|
L
 185.5%
H
2.6
8.6
|
L
 82.5%
H
1.8
8.6
|
L
 1.6%
H
1.8
10.3
|
L
 -99.3%
H
1.8
2035
|
| AC Immune SA |
|
264.5
|
2.7
|
L
 1.1%
H
2.6
2.7
|
L
 -3.6%
H
2.6
2.8
|
L
 0.8%
H
2.6
3
|
L
 10.8%
H
2.1
3
|
L
 8.6%
H
2.1
4
|
L
 -13.6%
H
1.4
5.1
|
L
 -60.4%
H
1.4
8.1
|
L
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
819.9
|
5.6
|
L
 1.3%
H
5.4
5.6
|
L
 4.7%
H
5.0
5.7
|
L
 -12.0%
H
5.0
6.6
|
L
 23.8%
H
4.5
6.6
|
L
 191.6%
H
1.7
6.6
|
L
 -17.7%
H
0.6
7.0
|
L
 -67.0%
H
0.6
20.0
|
L
 -77.2%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
86.1
|
2.0
|
L
 8.7%
H
1.9
2.0
|
L
 0.5%
H
1.7
2.0
|
L
 -8.6%
H
1.7
2.3
|
L
 28.0%
H
1.4
2.4
|
L
 23.3%
H
1.3
3.6
|
L
 -79.0%
H
1.1
11.9
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
19.8
|
1.2
|
L
 0.9%
H
1.2
1.2
|
L
 -5.7%
H
1.2
1.3
|
L
 -1.7%
H
1.2
1.3
|
L
 7.3%
H
1.0
1.5
|
L
 37.7%
H
0.7
1.6
|
L
 56%
H
0.4
1.6
|
L
 -94.2%
H
0.4
21.6
|
L
 -98.3%
H
0.4
115
|
| Grace Therapeutics Inc |
|
44.2
|
2.1
|
L
 -0.5%
H
2.1
2.2
|
L
 -5.4%
H
2.1
2.3
|
L
 -1.9%
H
2.1
2.5
|
L
 -11.8%
H
1.9
2.6
|
L
 -32.3%
H
1.8
5.2
|
L
 9.4%
H
1.7
5.2
|
L
 -82.8%
H
1.7
14.3
|
L
 -97.9%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
5.7
|
1.3
|
L
 -4.3%
H
1.3
1.4
|
L
 -5%
H
1.3
1.4
|
L
 -8.3%
H
1.3
1.5
|
L
 -13.6%
H
1.3
1.9
|
L
 -67.6%
H
1.3
8.3
|
L
 -95.7%
H
1.3
176.4
|
L
 -98.6%
H
1.3
176.4
|
L
H
1.3
176.4
|
| Adial Pharma Inc |
|
12.9
|
4.4
|
L
 -9.5%
H
4.2
4.8
|
L
 -10.2%
H
4.2
5.4
|
L
 -25.4%
H
4.2
7.2
|
L
 69.2%
H
2.3
7.2
|
L
 -49.7%
H
1.3
10.8
|
L
 -93.0%
H
1.3
107.5
|
L
 -99.8%
H
1.3
3175
|
L
H
1.3
5900
|
| Adma Biologics Inc |
|
2,127.9
|
9.5
|
L
 4.3%
H
9.1
9.5
|
L
 2.9%
H
8.5
9.5
|
L
 -2.7%
H
8.5
10.0
|
L
 14.3%
H
8.2
10.4
|
L
 -40.3%
H
7.2
20.5
|
L
 167.6%
H
3.1
25.7
|
L
 660%
H
1.0
25.7
|
L
 33.4%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
4,446.3
|
27.9
|
L
 -2.6%
H
27.7
28.8
|
L
 15.1%
H
24.0
28.8
|
L
 9.5%
H
23.5
28.8
|
L
 -60.3%
H
20.9
91.2
|
L
 -47.9%
H
20.9
91.2
|
L
 34.5%
H
9.1
91.2
|
L
 -81.5%
H
9.1
158.5
|
L
H
9.1
285
|
| Agenus Inc |
|
376.2
|
8.3
|
L
 6.1%
H
7.6
8.6
|
L
 20.0%
H
6.8
8.6
|
L
 11.2%
H
6.7
8.6
|
L
 177.7%
H
2.9
8.9
|
L
 90.2%
H
2.7
8.9
|
L
 -65.3%
H
1.4
196
|
L
 -92.7%
H
1.4
196
|
L
 -93.9%
H
1.4
196
|
| Agios Pharma Inc |
|
2,026.9
|
34.0
|
L
 2.7%
H
33.3
34.1
|
L
 1.0%
H
32.2
34.4
|
L
 1.0%
H
32.2
35.4
|
L
 -0.6%
H
29.2
44.1
|
L
 -10.0%
H
22.2
46
|
L
 38.2%
H
19.8
62.6
|
L
 -26.4%
H
16.8
62.6
|
L
 -31.9%
H
16.8
99.8
|
| Aeglea BioTherapeutics Inc |
|
372.6
|
92.0
|
L
 2.0%
H
89.7
94.1
|
L
 1.6%
H
88.5
95.2
|
L
 -14.6%
H
84
110.2
|
L
 4.2%
H
81.7
110.2
|
L
 518.5%
H
14.5
110.2
|
L
 747.4%
H
8.4
110.2
|
L
 -51.6%
H
2.7
212.5
|
L
 -46.5%
H
2.7
300
|
| Akebia Therapeutics Inc |
|
260.5
|
0.9
|
L
 2.2%
H
0.9
1.0
|
L
 -1.1%
H
0.9
1.0
|
L
 2.2%
H
0.9
1.1
|
L
 -12.2%
H
0.8
1.5
|
L
 -66.7%
H
0.8
3.2
|
L
 -21.7%
H
0.8
4.1
|
L
 -66.4%
H
0.2
4.1
|
L
 -89.8%
H
0.2
20.3
|
| Change Agents Corp |
|
2.3
|
2.1
|
L
 -0.5%
H
2
2.1
|
L
 -7.6%
H
1.8
2.2
|
L
 -41.1%
H
1.8
4.7
|
L
 -69.7%
H
1.8
7.3
|
L
 -96.2%
H
1.8
55.4
|
L
 -99.3%
H
1.8
1350
|
L
 -99.9%
H
1.8
3450
|
L
H
1.8
40500
|
| Aldeyra Therapeutics Inc |
|
81.4
|
1.4
|
L
 -0.7%
H
1.3
1.4
|
L
 0.8%
H
1.3
1.5
|
L
 -10%
H
1.3
1.6
|
L
 -31.1%
H
1.3
2.5
|
L
 -72.6%
H
1.1
5.9
|
L
 -78.6%
H
1.1
7.2
|
L
 -83.1%
H
1.1
12.0
|
L
 -81.6%
H
1.1
16.7
|
| Alector Inc |
|
215.5
|
1.9
|
L
 1.1%
H
1.9
1.9
|
L
 -9.8%
H
1.8
2.2
|
L
 -14.6%
H
1.8
2.8
|
L
 10.3%
H
1.4
2.8
|
L
 -36.3%
H
1.1
3.4
|
L
 -68.2%
H
0.9
8.9
|
L
 -92.5%
H
0.9
27
|
L
H
0.9
43.3
|
| Aligos Therapeutics Inc |
|
34.3
|
5.5
|
L
 4.8%
H
5.2
5.9
|
L
 5.2%
H
4.8
5.9
|
L
 -14.8%
H
4.8
7.7
|
L
 4.0%
H
4.0
7.8
|
L
 -43.2%
H
4.0
13.7
|
L
 -72.2%
H
3.8
46.3
|
L
 -98.6%
H
3.8
449.3
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
7,411.8
|
44.2
|
L
 1.8%
H
43.1
44.8
|
L
 -3.9%
H
43.1
47.4
|
L
 -8%
H
43.1
49.6
|
L
 -1.8%
H
43.1
55.7
|
L
 59.0%
H
27.0
55.7
|
L
 46.5%
H
22.0
55.7
|
L
 49.2%
H
21.2
55.7
|
L
 -11.2%
H
12.0
71.2
|
| Allogene Therapeutics Inc |
|
583.9
|
1.7
|
L
H
1.6
1.7
|
L
 -5.1%
H
1.6
1.8
|
L
 -19.5%
H
1.6
2.2
|
L
 -15.5%
H
1.6
2.3
|
L
 45.7%
H
1.0
4.5
|
L
 -55.2%
H
0.9
5.8
|
L
 -93.2%
H
0.9
27.9
|
L
H
0.9
55
|
| Allarity Therapeutics Inc |
|
18.6
|
1.2
|
L
 -3.3%
H
1.1
1.2
|
L
 -4.1%
H
1.1
1.3
|
L
 -18.2%
H
1.1
1.5
|
L
 -18.2%
H
1.0
1.6
|
L
 -24.0%
H
0.8
1.8
|
L
 -92.6%
H
0.1
116
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
32,692.2
|
244.3
|
L
 2.0%
H
238.0
247.1
|
L
 -1.8%
H
236
252.8
|
L
 6.6%
H
223.6
272.1
|
L
 -12.1%
H
197.8
380
|
L
 -46.1%
H
197.8
495.6
|
L
 39.2%
H
142.0
495.6
|
L
 33.2%
H
117.6
495.6
|
L
 212.9%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
69.0
|
0.8
|
L
H
0.8
0.8
|
L
 2.6%
H
0.7
0.8
|
L
 1.3%
H
0.7
1.0
|
L
 -13.0%
H
0.7
1.1
|
L
 -33.9%
H
0.7
2.2
|
L
 -49.0%
H
0.7
7.4
|
L
 -96.3%
H
0.7
22.4
|
L
H
0.7
309.6
|
| Altimmune Inc |
|
636.1
|
3.3
|
L
 0.6%
H
3.2
3.3
|
L
H
3.2
3.4
|
L
 10.9%
H
3.0
3.6
|
L
 21.1%
H
2.7
3.6
|
L
 -13.5%
H
2.6
6.4
|
L
 21.1%
H
2.1
14.8
|
L
 -77.6%
H
2.1
23.5
|
L
 -99.6%
H
1.5
1050
|
| Alvotech |
|
2,098.1
|
5.9
|
L
 0.2%
H
5.7
6.0
|
L
 11.2%
H
4.9
6.0
|
L
 37.7%
H
4.3
6.0
|
L
 50%
H
3.0
6.0
|
L
 -25.4%
H
2.9
9.3
|
L
 -35.4%
H
2.9
18
|
L
H
2.9
18
|
L
H
2.9
18
|
| Kalaris Therapeutics Inc |
|
77.1
|
3.2
|
L
 1.3%
H
3.1
3.3
|
L
 -4.1%
H
3.0
3.4
|
L
 -21.4%
H
3.0
4.3
|
L
 -31.4%
H
3.0
6.3
|
L
 -28.6%
H
3.0
11.9
|
L
 42.1%
H
0.4
12.9
|
L
 -85.9%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Alx Oncology Holdings Inc |
|
229.5
|
1.7
|
L
 -2.4%
H
1.7
1.7
|
L
 -14.4%
H
1.7
2.0
|
L
 -16.6%
H
1.7
2.1
|
L
 8.5%
H
1.5
2.4
|
L
 37.2%
H
1.1
2.7
|
L
 -65.6%
H
0.4
17.8
|
L
 -97.8%
H
0.4
79
|
L
H
0.4
117.5
|
| Alzamend Neuro Inc |
|
9.4
|
1.9
|
L
 2.7%
H
1.9
1.9
|
L
 12.8%
H
1.7
1.9
|
L
 19.0%
H
1.4
1.9
|
L
 59.0%
H
1.1
1.9
|
L
 -19.2%
H
0.8
2.7
|
L
 -99.4%
H
0.8
351
|
L
 -99.9%
H
0.8
4819.5
|
L
H
0.8
45292.5
|
| Amgen |
|
212,554.9
|
393.2
|
L
 2.0%
H
381.9
394.5
|
L
 4.2%
H
374.5
394.5
|
L
 -8.8%
H
374.5
447.0
|
L
 16.5%
H
337.6
447.0
|
L
 37.8%
H
269.8
447.0
|
L
 44.8%
H
249.7
447.0
|
L
 82.8%
H
198.6
447.0
|
L
 126.8%
H
133.6
447.0
|
| Amylyx Pharma Inc |
|
4,133.8
|
32.4
|
L
 -0.1%
H
31.9
33.2
|
L
 2.4%
H
31.6
34.3
|
L
 -18.3%
H
31.4
41.1
|
L
 106.7%
H
15.7
41.1
|
L
 143.4%
H
10.8
41.1
|
L
 74.5%
H
1.6
41.1
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
1,041.3
|
24.5
|
L
 3.6%
H
23.5
25.4
|
L
 2.9%
H
23.5
25.4
|
L
 12.9%
H
21.3
25.4
|
L
 30.1%
H
18.2
25.4
|
L
 -11.4%
H
16.6
29.5
|
L
 -47.0%
H
16.6
65.9
|
L
 30.8%
H
16.6
67.7
|
L
 15.1%
H
12.1
67.7
|
| AnaptysBio Inc |
|
1,626.1
|
54.9
|
L
 -0.5%
H
54.1
56
|
L
 2.0%
H
53.2
56
|
L
 -3.1%
H
53.2
59.1
|
L
 -4.5%
H
49.7
70.9
|
L
 163.5%
H
20.5
73.3
|
L
 205.1%
H
12.2
73.3
|
L
 106.8%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,811.2
|
78.9
|
L
 3.6%
H
75
79.4
|
L
 12.3%
H
70
79.4
|
L
 2.0%
H
69.6
79.4
|
L
 -0.8%
H
69.6
87.2
|
L
 -18.5%
H
69.6
97.5
|
L
 30.3%
H
48.2
99.5
|
L
 169.1%
H
22.3
99.5
|
L
 21.6%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
93.9
|
2.7
|
L
 -2.5%
H
2.7
2.8
|
L
 -2.2%
H
2.6
2.9
|
L
 -24.8%
H
2.6
3.9
|
L
 -7.2%
H
2.4
3.9
|
L
 -18.2%
H
2.3
5.5
|
L
 -19.6%
H
2.1
5.5
|
L
 -42.4%
H
2.1
6.5
|
L
 -5.3%
H
0.6
8.1
|
| Annexon Inc |
|
800.0
|
4.2
|
L
 -0.2%
H
4.1
4.4
|
L
 7.1%
H
3.8
4.4
|
L
 -18.5%
H
3.8
5.3
|
L
 -13.9%
H
3.8
6.6
|
L
 47.6%
H
2.5
7.2
|
L
 61.1%
H
1.3
8.4
|
L
 -80.1%
H
1.3
22.5
|
L
H
1.3
38.0
|
| AN2 Therapeutics Inc |
|
187.2
|
5.0
|
L
 -1.8%
H
4.9
5.3
|
L
 -8.3%
H
4.8
5.6
|
L
 -14.3%
H
4.8
6.2
|
L
 -0.8%
H
4.1
7.2
|
L
 275.8%
H
1
7.2
|
L
 -62.4%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Niki BioSolutions Inc |
|
4.0
|
5.0
|
L
 5.3%
H
4.7
5
|
L
 -13.0%
H
4.7
5.9
|
L
 -39.4%
H
4.7
9.7
|
L
 -40.3%
H
4.7
12.2
|
L
 -72.1%
H
4.7
25.9
|
L
 -79.9%
H
4.6
174.9
|
L
 -98.1%
H
4.6
282
|
L
H
4.6
3328
|
| Aprea Therapeutics Inc |
|
9.3
|
0.7
|
L
 -2.6%
H
0.7
0.8
|
L
 -3.9%
H
0.7
0.8
|
L
 15.6%
H
0.6
1.2
|
L
 2.8%
H
0.6
1.2
|
L
 -48.6%
H
0.6
1.7
|
L
 -83.0%
H
0.6
8.9
|
L
 -99.2%
H
0.6
113.4
|
L
H
0.6
1062.2
|
| Aptevo Therapeutics Inc |
|
3.3
|
1.8
|
L
 -1.6%
H
1.8
1.9
|
L
 -0.6%
H
1.7
1.9
|
L
 -34.4%
H
1.4
2.9
|
L
 -61.2%
H
1.4
4.9
|
L
 -94.3%
H
1.4
35.6
|
L
 -100.0%
H
1.4
287179.2
|
L
 -100.0%
H
1.4
12940587.7
|
L
 -100.0%
H
1.4
52102512
|
| AquaBounty Tech Inc |
|
5.7
|
1.1
|
L
 -2.6%
H
1.1
1.2
|
L
 -9.0%
H
1.1
1.2
|
L
 -15.3%
H
1.0
1.4
|
L
 18.1%
H
0.9
1.6
|
L
 -27.9%
H
0.8
3.0
|
L
 -77.0%
H
0.5
6.1
|
L
 -98.6%
H
0.5
90
|
L
H
0.5
610
|
| Aquestive Therapeutics Inc |
|
599.9
|
4.8
|
L
 3.7%
H
4.6
4.8
|
L
H
4.5
5
|
L
 6.2%
H
4.5
5.5
|
L
 1.5%
H
3.6
5.5
|
L
 -15.7%
H
2.9
7.6
|
L
 179.5%
H
1.3
7.6
|
L
 18.3%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
417.5
|
14.7
|
L
 -8.4%
H
14.6
16.6
|
L
 -0.3%
H
14.4
18.0
|
L
 33.7%
H
11.1
18.0
|
L
 95.1%
H
5.5
18.0
|
L
 -28.2%
H
5.5
24.2
|
L
 -44.6%
H
5.5
45
|
L
 -71.0%
H
5.5
54.7
|
L
 -54.5%
H
4.1
129.7
|
| Ardelyx Inc |
|
903.7
|
3.5
|
L
 2.3%
H
3.4
3.5
|
L
 -2.2%
H
3.3
3.6
|
L
 -10.3%
H
3.3
4.0
|
L
 -42.2%
H
3.3
6.5
|
L
 -43.6%
H
3.3
8.4
|
L
 -9.3%
H
3.2
10.1
|
L
 175.6%
H
0.5
10.1
|
L
 -69.4%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
3,263.0
|
26.0
|
L
 2.3%
H
25.2
26.1
|
L
 8.7%
H
23.1
26.8
|
L
 2.4%
H
23.1
26.8
|
L
 -1.0%
H
23.1
29.8
|
L
 49.4%
H
16.6
31.8
|
L
 341.5%
H
1.8
31.8
|
L
 18.8%
H
1.8
31.8
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
2.2
|
4.1
|
L
 4.1%
H
3.9
4.2
|
L
 -24.5%
H
3.5
5.7
|
L
 -36.0%
H
3.5
6.8
|
L
 -63.8%
H
3.5
11.6
|
L
 -97.3%
H
3.5
179.2
|
L
 -98.3%
H
3.5
772.2
|
L
 -99.8%
H
3.5
3207.6
|
L
H
3.5
419904
|
| Arvinas Inc |
|
542.7
|
8.3
|
L
 0.1%
H
8.2
8.4
|
L
 -1.8%
H
8.1
8.7
|
L
 -8.0%
H
8.1
9.7
|
L
 8.2%
H
7.5
9.7
|
L
 10.4%
H
7.0
14.5
|
L
 -65.7%
H
5.9
53.1
|
L
 -91.0%
H
5.9
97.3
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
9,716.9
|
68.8
|
L
 3.5%
H
66.1
69.3
|
L
 -17.0%
H
64.5
83.6
|
L
 -21.4%
H
64.5
90.2
|
L
 -15.9%
H
64.5
95.5
|
L
 124.1%
H
30.7
95.5
|
L
 154.7%
H
9.6
95.5
|
L
 10.2%
H
9.6
95.5
|
L
 834.6%
H
1.2
95.5
|
| Assembly Biosciences Inc |
|
518.0
|
25.4
|
L
 1.9%
H
24.9
25.7
|
L
 -14.6%
H
24.8
30.5
|
L
 -24.1%
H
24.8
37.0
|
L
 4.1%
H
24.0
37.0
|
L
 4.0%
H
21.8
39.7
|
L
 119.7%
H
7.7
39.7
|
L
 -34.8%
H
7.7
42.6
|
L
 -71.0%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
487.5
|
3.2
|
L
 4.6%
H
3.2
3.3
|
L
 -3.9%
H
3.0
3.4
|
L
 -19.5%
H
3.0
4.4
|
L
 -55.7%
H
3.0
7.6
|
L
 -67.8%
H
3.0
14.5
|
L
 238.3%
H
0.9
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| LeonaBio Inc |
|
59.6
|
6.3
|
L
 -6.8%
H
6.2
6.8
|
L
 -8.5%
H
6.2
7.8
|
L
 -17.8%
H
6.2
8.4
|
L
 -22.6%
H
6.2
10.1
|
L
 63.6%
H
3.6
14.2
|
L
 -69.1%
H
2.2
43.0
|
L
 -93.5%
H
2.2
166.5
|
L
H
2.2
347.9
|
| ETHZilla Corp |
|
64.9
|
4.9
|
L
 5.6%
H
4.7
5.0
|
L
 7.7%
H
4.3
5.0
|
L
 -15.9%
H
4.3
6.2
|
L
 -2.6%
H
4.3
7.2
|
L
 -80.6%
H
1.8
27.2
|
L
 -96.4%
H
1.8
177.5
|
L
 -100.0%
H
1.8
26448
|
L
H
1.8
49571
|
| Atossa Therapeutics Inc |
|
22.5
|
2.3
|
L
 1.4%
H
2.3
2.4
|
L
 -10.4%
H
2.2
2.6
|
L
 -13.1%
H
2.2
2.7
|
L
 11.9%
H
1.7
3.0
|
L
 -82.3%
H
1.7
19.4
|
L
 -80.5%
H
1.7
34.7
|
L
 -95.4%
H
1.7
53.1
|
L
 -99.4%
H
1.7
468
|
| Atara Biotherapeutics Inc |
|
94.2
|
9.4
|
L
 -3.2%
H
9.3
9.9
|
L
H
8.9
10.4
|
L
H
8.8
11.3
|
L
 -6.9%
H
7.4
12
|
L
 -22.2%
H
3.9
19.1
|
L
 -78.7%
H
0.4
48.6
|
L
 -97.7%
H
0.4
501
|
L
 -98.1%
H
0.4
1361.3
|
| Aurinia Pharma Inc |
|
2,210.0
|
16.6
|
L
 -1.7%
H
16.6
16.9
|
L
 3.2%
H
15.9
17.2
|
L
 -3.8%
H
15.9
17.3
|
L
 0.9%
H
14.4
19.3
|
L
 27.8%
H
10.3
19.3
|
L
 99.2%
H
4.7
19.3
|
L
 -20.6%
H
4.1
34.0
|
L
 683.5%
H
2.0
34.0
|
| Aura Biosciences Inc |
|
659.6
|
6.4
|
L
 -1.2%
H
6.3
6.5
|
L
 -9.1%
H
6.3
7.2
|
L
 -18.2%
H
6.3
8.1
|
L
 0.3%
H
6.3
8.4
|
L
 4.6%
H
4.7
9.5
|
L
 -34.6%
H
4.3
12.4
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Atea Pharma Inc |
|
435.5
|
5.4
|
L
 1.9%
H
5.3
5.5
|
L
 2.3%
H
5.1
5.5
|
L
 1.3%
H
5.1
5.9
|
L
 24.5%
H
3.8
5.9
|
L
 88.5%
H
2.8
6.5
|
L
 70.8%
H
2.5
6.5
|
L
 -81.2%
H
2.5
46.9
|
L
H
2.5
94.2
|
| Tectonic Therapeutic Inc |
|
520.6
|
26.6
|
L
 -1.4%
H
26.3
27.4
|
L
 -8.3%
H
26.3
30.7
|
L
 -26.1%
H
26.3
38.9
|
L
 -11.3%
H
26.3
39.5
|
L
 77.8%
H
14.4
39.5
|
L
 46.0%
H
1.4
61.1
|
L
 -64.3%
H
1.4
79.4
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
1,064.6
|
16.7
|
L
 -1.2%
H
16.5
17.7
|
L
 -6.4%
H
16.2
18.8
|
L
 -21.2%
H
16.2
22.4
|
L
 -0.5%
H
16.2
25
|
L
 125.6%
H
7.3
28
|
L
 -96.3%
H
6.6
1134.5
|
L
 -96.8%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Avalo Therapeutics Inc |
|
867.2
|
16.2
|
L
 -2.4%
H
15.9
16.8
|
L
 0.3%
H
15.4
17.2
|
L
 -18.4%
H
15.4
20.9
|
L
 10%
H
14.7
21.0
|
L
 36.7%
H
10.7
24.3
|
L
 14600%
H
0.0
34.5
|
L
 -43.6%
H
0.0
34.5
|
L
 -68.3%
H
0.0
91.8
|
| Anavex Life Sciences Corp |
|
222.5
|
2.4
|
L
 -0.8%
H
2.4
2.4
|
L
 -8.4%
H
2.3
2.6
|
L
 -23.3%
H
2.3
3.7
|
L
 -12.1%
H
2.3
3.7
|
L
 -71.6%
H
2.3
10.4
|
L
 -66.9%
H
2.3
14.4
|
L
 -85.8%
H
2.3
23.7
|
L
 -9.1%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
10,763.7
|
205.5
|
L
 -1.1%
H
203.4
210.9
|
L
 -6.9%
H
201.9
223.3
|
L
 -1.2%
H
197.1
229.6
|
L
 -18.0%
H
197.1
253
|
L
 77.2%
H
114.9
260.2
|
L
 178.8%
H
55.0
260.2
|
L
 603.0%
H
20.6
260.2
|
L
 2572.2%
H
1.9
260.2
|
| Aytu BioPharma Inc |
|
22.8
|
2.1
|
L
H
2.1
2.2
|
L
 6.5%
H
1.9
2.2
|
L
 -7.0%
H
1.9
2.4
|
L
 -8.2%
H
1.9
2.5
|
L
 -13.1%
H
1.7
3.1
|
L
 34.2%
H
1.0
3.5
|
L
 -96.5%
H
1.0
65.8
|
L
 -100.0%
H
1.0
311200
|
| Aziyo Biologics Inc (Class A) |
|
-
|
0.9
|
L
H
0.9
0.9
|
L
 4.9%
H
0.8
0.9
|
L
 -5.6%
H
0.8
1.1
|
L
 -19.8%
H
0.8
1.1
|
L
 -22.0%
H
0.5
1.4
|
L
 -47.2%
H
0.5
2.6
|
L
 -88.6%
H
0.5
9.0
|
L
H
0.5
18.2
|
| Adagene Inc (ADR) |
|
215.5
|
3.2
|
L
 -3.0%
H
3.2
3.4
|
L
 -5.6%
H
2.9
3.6
|
L
 -21.5%
H
2.9
4.1
|
L
 -18.5%
H
2.9
4.9
|
L
 56.6%
H
1.3
4.9
|
L
 126.1%
H
1.2
4.9
|
L
 -78.2%
H
0.9
15.0
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
4.5
|
3.5
|
L
 3.8%
H
3.3
3.5
|
L
 1.2%
H
3.1
3.5
|
L
 -22.8%
H
3.1
6.1
|
L
 -43.1%
H
3.1
6.8
|
L
 -60.7%
H
3.1
12.0
|
L
 -51.0%
H
3.1
27.9
|
L
 -98.1%
H
3.1
194
|
L
H
3.1
750.4
|
| Akari Therapeutics PLC (ADR) |
|
18.3
|
9.4
|
L
 2.4%
H
9.1
9.8
|
L
 -17.0%
H
9.1
11.6
|
L
 20.4%
H
7.4
12.2
|
L
 -14.3%
H
6.5
15.5
|
L
 -71.1%
H
3.0
49.6
|
L
 -93.5%
H
3.0
176
|
L
 -99.3%
H
3.0
1463.5
|
L
 -99.9%
H
3.0
17759.8
|
| Amarin Corp (ADR) |
|
284.7
|
13.5
|
L
 -1.1%
H
13.4
13.8
|
L
 -2.3%
H
13.4
14.1
|
L
 -4.1%
H
13.2
15.2
|
L
 -15.9%
H
13.2
17.3
|
L
 -12.2%
H
13.0
20.9
|
L
 1318.9%
H
0.4
20.9
|
L
 165.4%
H
0.4
20.9
|
L
 408.7%
H
0.4
26.1
|
| Argen X SE (ADR) |
|
61,822.8
|
988.2
|
L
 -0.2%
H
986.6
1002.0
|
L
 0.4%
H
974.3
1008.3
|
L
 -4.8%
H
974.3
1072.8
|
L
 12.6%
H
826.4
1072.8
|
L
 34.1%
H
661.9
1072.8
|
L
 92.3%
H
327.7
1072.8
|
L
 215.7%
H
249.5
1072.8
|
L
H
17.3
1072.8
|
| Ascendis Pharma A/S (ADR) |
|
14,586.4
|
237.6
|
L
 0.4%
H
237
241.5
|
L
 -9.8%
H
228.6
265.5
|
L
 -6.8%
H
228.6
272.5
|
L
 2.9%
H
222.8
282.2
|
L
 20.2%
H
186.1
282.2
|
L
 148.5%
H
85.3
282.2
|
L
 50.7%
H
61.6
282.2
|
L
 1102.4%
H
17.2
282.2
|
| Alterity Therapeutics Ltd (ADR) |
|
68.8
|
3.8
|
L
 -3.3%
H
3.7
3.9
|
L
 -6.7%
H
3.5
4.0
|
L
 -15.1%
H
3.5
5.0
|
L
 -22.5%
H
3.5
5.9
|
L
 -15.6%
H
2.7
5.9
|
L
 41.0%
H
1
7
|
L
 -70.2%
H
1
13.8
|
L
 -92.5%
H
1
51.5
|
| Autolus Therapeutics PLC (ADR) |
|
516.4
|
1.9
|
L
H
1.9
2.0
|
L
 3.2%
H
1.8
2.0
|
L
 -21.1%
H
1.8
2.5
|
L
 28.5%
H
1.4
2.6
|
L
 44.8%
H
1.2
2.6
|
L
 -30.0%
H
1.1
7.5
|
L
 -69.6%
H
1.1
7.9
|
L
H
1.1
53.2
|
| Astrazeneca plc |
|
521,205.3
|
168.1
|
L
 1.2%
H
167.1
169
|
L
 5.0%
H
160.7
169
|
L
 2.2%
H
156.7
170.2
|
L
 -3.9%
H
153.4
196.4
|
L
 -10.8%
H
153.4
212.7
|
L
 -10.8%
H
153.4
212.7
|
L
 -10.8%
H
153.4
212.7
|
L
 -10.8%
H
153.4
212.7
|
| BridgeBio Pharma Inc |
|
13,015.9
|
66.6
|
L
 -0.1%
H
65.8
67.3
|
L
 -8.1%
H
65.8
73.7
|
L
 -19.7%
H
65.8
83.4
|
L
 0.5%
H
65.8
93.4
|
L
 27.1%
H
48.8
93.4
|
L
 140.1%
H
21.6
93.4
|
L
 35.3%
H
5.0
93.4
|
L
H
5.0
93.4
|
| BioCardia Inc |
|
16.3
|
1.1
|
L
 -7.7%
H
1.1
1.2
|
L
H
1.1
1.4
|
L
 11.3%
H
1.0
1.4
|
L
 11.3%
H
0.8
1.4
|
L
 -6.9%
H
0.8
1.8
|
L
 -81.6%
H
0.8
23.3
|
L
 -97.6%
H
0.8
59.4
|
L
 -99.4%
H
0.8
2073.6
|
| Biocryst Pharma Inc |
|
2,238.5
|
8.8
|
L
 0.9%
H
8.6
8.8
|
L
 7.9%
H
8.0
8.8
|
L
 -9.3%
H
8.0
10.2
|
L
 -2.6%
H
8.0
11.2
|
L
 13.8%
H
6
11.2
|
L
 23.2%
H
4.0
11.3
|
L
 -41.7%
H
4.0
20.0
|
L
 93.4%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
36.1
|
4.2
|
L
 -1.4%
H
4.0
4.2
|
L
 14.3%
H
3.5
4.4
|
L
 5.6%
H
3.4
4.4
|
L
 43.1%
H
2.9
4.4
|
L
 -54.6%
H
2.6
14.7
|
L
 -100.0%
H
2.6
9540
|
L
 -100.0%
H
2.6
18526.5
|
L
 -100.0%
H
2.6
80097.7
|
| Black Diamond Therapeutics Inc |
|
112.0
|
2.0
|
L
 -0.5%
H
1.9
2.0
|
L
 -1.5%
H
1.9
2.0
|
L
 -9.3%
H
1.9
2.3
|
L
 17.5%
H
1.6
2.3
|
L
 -40.6%
H
1.6
4.9
|
L
 -43.5%
H
1.2
7.7
|
L
 -79.6%
H
1.2
10.0
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
2,609.0
|
25.3
|
L
 1.2%
H
24.8
25.7
|
L
 5.3%
H
22.7
25.7
|
L
 -11.0%
H
22.7
31.5
|
L
 -26.0%
H
22.7
38.3
|
L
 3.9%
H
20.2
38.3
|
L
 0.1%
H
13.5
49.5
|
L
 -73.5%
H
13.5
100.1
|
L
H
13
138.5
|
| Biofrontera Inc |
|
17.2
|
1.2
|
L
 -12.1%
H
1.1
1.3
|
L
 -25.2%
H
1.1
1.6
|
L
 -21.6%
H
1.1
1.7
|
L
 17.2%
H
0.9
1.7
|
L
 28.9%
H
0.6
1.7
|
L
 -86.5%
H
0.5
9.5
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biogen |
|
32,368.5
|
219.1
|
L
 1.7%
H
214.6
221.9
|
L
 0.9%
H
213.5
222.2
|
L
 2.2%
H
208.9
225.8
|
L
 11.4%
H
186.0
225.8
|
L
 53.7%
H
135.4
225.8
|
L
 -15.9%
H
110.0
269.4
|
L
 -26.6%
H
110.0
319.8
|
L
 -22.5%
H
110.0
468.6
|
| BioVie Inc |
|
13.9
|
1.6
|
L
 1.2%
H
1.6
1.8
|
L
 -15.5%
H
1.6
2.1
|
L
 -12.4%
H
1.6
2.5
|
L
 -7.4%
H
0.8
3.8
|
L
 -12.4%
H
0.8
3.8
|
L
 -99.4%
H
0.8
582
|
L
 -99.8%
H
0.8
1438
|
L
 -99.9%
H
0.8
5625
|
| Biomea Fusion Inc |
|
123.9
|
1.7
|
L
 -6.6%
H
1.7
1.9
|
L
 -1.7%
H
1.7
1.9
|
L
 25.7%
H
1.3
2.1
|
L
 44.9%
H
1.1
2.1
|
L
 -12.3%
H
0.9
3.0
|
L
 -87.7%
H
0.9
22.7
|
L
 -83.5%
H
0.9
43.7
|
L
H
0.9
43.7
|
| Biomarin pharma Inc - Registered Shares |
|
12,400.3
|
64.1
|
L
 0.2%
H
63.6
65.0
|
L
 -2.5%
H
63.6
66.9
|
L
 -5.4%
H
63.6
68.3
|
L
 17.1%
H
55.0
71.0
|
L
 17.8%
H
49.3
71.0
|
L
 -27.5%
H
49.3
99.6
|
L
 -17.2%
H
49.3
117.8
|
L
 -34.6%
H
49.3
131.9
|
| Bionano Genomics Inc |
|
21.6
|
1.8
|
L
 5.8%
H
1.7
1.9
|
L
 50%
H
1.2
2.2
|
L
 51.2%
H
1.2
2.2
|
L
 60.5%
H
1
2.2
|
L
 2.2%
H
1
2.2
|
L
 -39%
H
0.1
11.6
|
L
 -96.5%
H
0.1
62.8
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
379.5
|
10.9
|
L
 -1.3%
H
10.7
11.1
|
L
 -10.8%
H
10.7
12.4
|
L
 -16.4%
H
10.7
14.0
|
L
 -10.5%
H
10.7
14.3
|
L
 -19.1%
H
9.9
16.8
|
L
 270.1%
H
2.7
17.2
|
L
 -82.9%
H
1.9
81.3
|
L
 -97.0%
H
1.9
1371.3
|
| Bolt Biotherapeutics Inc |
|
6.9
|
3.6
|
L
 0.8%
H
3.4
3.6
|
L
 -9.1%
H
3.1
4.4
|
L
 12.2%
H
3.1
4.4
|
L
 -10.0%
H
3.1
4.5
|
L
 -31.4%
H
3.1
7.2
|
L
 -83.5%
H
3.1
31.2
|
L
 -98.7%
H
3.1
299.6
|
L
H
3.1
861.4
|
| Bon Natural Life Ltd |
|
9.8
|
1.2
|
L
 1.7%
H
1.2
1.2
|
L
 9.0%
H
1.0
1.2
|
L
 5.2%
H
1.0
1.2
|
L
 -0.8%
H
1.0
1.3
|
L
 -39.2%
H
1.0
2.3
|
L
 -98.8%
H
1.0
173.5
|
L
 -100.0%
H
1.0
2785
|
L
 -100.0%
H
1.0
22532.5
|
| Blue Water Biotech Inc |
|
11.8
|
0.7
|
L
 3.1%
H
0.6
0.7
|
L
 -13.2%
H
0.6
0.8
|
L
 -1.5%
H
0.6
1.1
|
L
 -29.8%
H
0.6
1.2
|
L
 -77.8%
H
0.1
6.7
|
L
 13.8%
H
0.1
6.7
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
30.4
|
0.7
|
L
 -1.3%
H
0.7
0.8
|
L
 -2.6%
H
0.7
0.8
|
L
 2.8%
H
0.6
0.8
|
L
 -54.0%
H
0.6
1.9
|
L
 -61.5%
H
0.6
2.4
|
L
 -8.6%
H
0.6
4
|
L
 -95.2%
H
0.5
18.0
|
L
H
0.5
48.5
|
| Bicycle Therapeutics PLC (ADR) |
|
254.1
|
3.6
|
L
 -0.6%
H
3.6
3.8
|
L
 -6.0%
H
3.6
4.0
|
L
 -14.4%
H
3.6
4.5
|
L
 -9.3%
H
3.6
4.5
|
L
 -47.6%
H
3.6
9.2
|
L
 -83.2%
H
3.6
28.7
|
L
 -91.4%
H
3.6
62.1
|
L
H
3.6
62.1
|
| Biodexa Pharma PLC (ADR) |
|
0.7
|
0.7
|
L
 -6.9%
H
0.6
0.7
|
L
 -47.7%
H
0.6
1.5
|
L
 -46.0%
H
0.6
1.6
|
L
 -77.8%
H
0.6
3.1
|
L
 -97.9%
H
0.6
59.4
|
L
 -100.0%
H
0.6
275312.5
|
L
 -100.0%
H
0.6
95995000
|
L
 -100.0%
H
0.6
9324807736.6
|
| BeiGene Ltd (ADR) |
|
38,953.4
|
365.7
|
L
 4.2%
H
358.2
367
|
L
 5.5%
H
342.9
367
|
L
 -1.0%
H
337.0
380
|
L
 35.4%
H
265.3
380
|
L
 9.4%
H
254.0
385.2
|
L
 89.6%
H
127.0
385.2
|
L
 -8.2%
H
118.2
405.1
|
L
 1080.3%
H
26.4
426.6
|
| Bioline Rx Ltd (ADR) |
|
12.0
|
2.5
|
L
 -0.4%
H
2.5
2.6
|
L
 -1.2%
H
2.4
2.6
|
L
 -10.1%
H
2.4
3.1
|
L
 -21.5%
H
2.4
3.5
|
L
 -34.0%
H
2.2
4.6
|
L
 -97.2%
H
0.1
88
|
L
 -97.7%
H
0.1
126
|
L
 -99.6%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
6,983.2
|
173.4
|
L
 1.4%
H
171.1
175.0
|
L
 -0.2%
H
166.3
178.0
|
L
 7.1%
H
150.2
198.6
|
L
 18.7%
H
141.0
198.6
|
L
 147.0%
H
68.2
200
|
L
 462.8%
H
28.5
200
|
L
H
6
200
|
L
H
6
200
|
| Neuphoria Therapeutics Inc |
|
20.1
|
3.7
|
L
 0.3%
H
3.7
3.8
|
L
 -0.5%
H
3.7
3.8
|
L
 -6.1%
H
3.7
4.1
|
L
 -13.9%
H
3.2
4.6
|
L
 -63.3%
H
3.2
21.4
|
L
 253.3%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| BioNTech SE (ADR) |
|
24,618.0
|
98
|
L
 2.0%
H
96.6
99.0
|
L
 1.3%
H
95.3
103
|
L
 -11.6%
H
95.3
120.3
|
L
 7.8%
H
88.2
120.3
|
L
 1.9%
H
79.5
124
|
L
 -9.8%
H
76.5
131.5
|
L
 -71.1%
H
76.5
374.6
|
L
H
12.5
464
|
| Biondvax Pharma Ltd (ADR) |
|
-
|
1.7
|
L
 8.3%
H
1.6
1.8
|
L
 1.8%
H
1.4
2.7
|
L
 -42.5%
H
1.4
3.6
|
L
 428.1%
H
0.2
3.6
|
L
 7.6%
H
0.2
3.6
|
L
 69%
H
0.2
6.2
|
L
 -92.5%
H
0.2
99
|
L
 -95.3%
H
0.2
620
|
| Cabaletta Bio Inc |
|
417.1
|
2.5
|
L
 -3.5%
H
2.5
2.7
|
L
 -9.9%
H
2.5
3.0
|
L
 -22.9%
H
2.5
3.8
|
L
 -13.4%
H
2.5
3.8
|
L
 12.3%
H
2
4.2
|
L
 -84.7%
H
1.0
26.4
|
L
 -79.8%
H
0.6
26.4
|
L
H
0.6
26.4
|
| Candel Therapeutics Inc |
|
857.8
|
11.2
|
L
 3.3%
H
11.1
11.9
|
L
 6.4%
H
10.3
11.9
|
L
 -9.2%
H
9.9
14
|
L
 34.9%
H
8.4
14
|
L
 133.1%
H
4.4
14
|
L
 892.0%
H
0.7
14.6
|
L
 57.0%
H
0.7
14.6
|
L
H
0.7
14.8
|
| CalciMedica Inc |
|
12.7
|
1.9
|
L
 -3.1%
H
1.9
2.0
|
L
 -6.1%
H
1.9
2.1
|
L
 -36.3%
H
1.9
3
|
L
 -50.8%
H
1.9
5.8
|
L
 -87.7%
H
1.9
36
|
L
 -86.1%
H
1.9
41.9
|
L
 -99.3%
H
1.9
265.3
|
L
H
1.9
2651.6
|
| Capricor Therapeutics Inc |
|
517.4
|
8.9
|
L
 -1.8%
H
8.8
9.3
|
L
 6.3%
H
8.4
9.8
|
L
 30.1%
H
6.0
11
|
L
 -68.6%
H
3.0
30.9
|
L
 33.8%
H
3.0
40.4
|
L
 53.4%
H
2.7
40.4
|
L
 89.8%
H
2.6
40.4
|
L
 -76.3%
H
0.9
42.5
|
| Tvardi Therapeutics Inc |
|
21.5
|
1.6
|
L
 -1.2%
H
1.6
1.7
|
L
 -13.9%
H
1.6
2
|
L
 -12.0%
H
1.6
2
|
L
 -38.8%
H
1.5
5.7
|
L
 -95.8%
H
1.5
43.7
|
L
 -97.5%
H
1.5
67.3
|
L
 -99.7%
H
1.5
681.5
|
L
 -99.4%
H
1.5
1067.3
|
| Crescent Biopharma Inc |
|
-
|
16.3
|
L
 -3.8%
H
15.8
17.0
|
L
 -16.3%
H
15.8
20.4
|
L
 0.1%
H
15.8
22.3
|
L
 -8.1%
H
14.0
22.3
|
L
 25.8%
H
8.7
27.4
|
L
 97.7%
H
4.8
27.4
|
L
 35.9%
H
0.9
27.4
|
L
 -67.6%
H
0.9
90.3
|
| C4 Therapeutics Inc |
|
406.0
|
3.3
|
L
 -2.7%
H
3.2
3.5
|
L
 -6.0%
H
3.2
3.6
|
L
 -18.1%
H
3.2
4.3
|
L
 -20.5%
H
3.2
5.2
|
L
 4.4%
H
1.7
5.2
|
L
 49.3%
H
1.1
11.9
|
L
 -93.2%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Niagen Bioscience Inc |
|
240.5
|
3.0
|
L
 1.7%
H
3.0
3.0
|
L
H
2.9
3.1
|
L
 -3.5%
H
2.9
3.3
|
L
 -13.1%
H
2.9
3.6
|
L
 -69.2%
H
2.9
10.5
|
L
 120.3%
H
1.3
14.7
|
L
 -53.2%
H
1.2
14.7
|
L
 2.0%
H
1.2
23.7
|
| Cullinan Oncology Inc |
|
1,374.0
|
21.4
|
L
 1.3%
H
21.0
21.8
|
L
 3.7%
H
18.5
21.8
|
L
 -0.1%
H
18.5
23.2
|
L
 42.1%
H
15.3
23.2
|
L
 244.4%
H
5.7
23.2
|
L
 124.0%
H
5.7
30.2
|
L
 -12.5%
H
5.7
30.2
|
L
H
5.7
59.9
|
| Compugen Ltd |
|
231.1
|
2.4
|
L
 -2.0%
H
2.4
2.5
|
L
 -1.2%
H
2.4
2.5
|
L
 -7.9%
H
2.4
2.9
|
L
 21.4%
H
2.0
2.9
|
L
 83.5%
H
1.3
3.2
|
L
 139.2%
H
0.5
3.2
|
L
 -60.8%
H
0.5
7.5
|
L
 -63.4%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
95.1
|
1
|
L
 -3.9%
H
1
1.1
|
L
 2.0%
H
1.0
1.1
|
L
 4.2%
H
1.0
1.1
|
L
 -31.0%
H
0.9
1.8
|
L
 -28.6%
H
0.6
2.1
|
L
 -20%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Coherus Biosciences Inc |
|
211.7
|
1.4
|
L
 1.5%
H
1.3
1.4
|
L
 3.0%
H
1.2
1.4
|
L
 3.8%
H
1.2
1.5
|
L
 -7.4%
H
1.1
1.7
|
L
 -14.9%
H
1.1
2.6
|
L
 -69.6%
H
0.7
4.5
|
L
 -92.1%
H
0.7
19.3
|
L
 -95.7%
H
0.7
31.7
|
| Cingulate Inc |
|
76.1
|
5.2
|
L
 -0.2%
H
5.2
5.5
|
L
 4.2%
H
4.8
5.5
|
L
 -1.9%
H
4.8
5.9
|
L
 4.8%
H
4.2
6.0
|
L
 47.7%
H
3.2
11.9
|
L
 597.3%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Celldex Therapeutics Inc |
|
2,975.5
|
37.9
|
L
 -0.9%
H
37.5
41.6
|
L
 2.7%
H
37.3
41.6
|
L
 -5.1%
H
36.8
42.1
|
L
 16.8%
H
32.3
45.1
|
L
 54.0%
H
22.1
45.1
|
L
 44.3%
H
14.4
53.2
|
L
 -26.0%
H
14.4
57.2
|
L
 -31.5%
H
1.5
75.3
|
| Clene Inc |
|
64.5
|
4.5
|
L
 4.4%
H
4.4
4.7
|
L
 27.2%
H
3.3
4.7
|
L
 3.9%
H
3.3
4.8
|
L
 -24.5%
H
3.3
6.6
|
L
 -29.0%
H
3.3
13.5
|
L
 -52.9%
H
2.3
13.5
|
L
 -96.9%
H
2.3
159.6
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
22.2
|
2.4
|
L
 -1.3%
H
2.4
2.4
|
L
 1.7%
H
2.3
2.5
|
L
 -9.3%
H
2.3
2.6
|
L
 -15.8%
H
2.3
3.1
|
L
 -54.8%
H
2.2
6.5
|
L
 -96.2%
H
2.2
133.5
|
L
 -99.2%
H
2.2
309.2
|
L
 -100.0%
H
2.2
9567
|
| Compass Therapeutics Inc |
|
327.8
|
1.8
|
L
 -4.2%
H
1.8
1.9
|
L
 -9%
H
1.8
2.0
|
L
 -22.9%
H
1.8
2.6
|
L
 -9.9%
H
1.8
2.6
|
L
 -46.3%
H
1.6
6.9
|
L
 -5.2%
H
0.8
6.9
|
L
 -48.7%
H
0.8
6.9
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
7.6
|
5.2
|
L
 2.2%
H
5.1
5.5
|
L
 -10.6%
H
5.1
5.7
|
L
 -13%
H
5.1
6.2
|
L
 11.1%
H
3.9
6.2
|
L
 -34.6%
H
1.9
10.6
|
L
 -100.0%
H
1.9
4125000
|
L
 -100.0%
H
1.9
73350000
|
L
H
1.9
256050000
|
| Context Therapeutics Inc |
|
34.9
|
0.4
|
L
 2.7%
H
0.4
0.4
|
L
 8.6%
H
0.4
0.4
|
L
 -26.9%
H
0.3
0.6
|
L
 -39.7%
H
0.3
0.7
|
L
 -60.8%
H
0.3
3.6
|
L
 -57.8%
H
0.3
3.6
|
L
H
0.3
10.9
|
L
H
0.3
10.9
|
| Cocrystal Pharma Inc |
|
22.9
|
1.2
|
L
 -1.7%
H
1.2
1.3
|
L
 -4.0%
H
1.1
1.3
|
L
 1.7%
H
1.1
1.3
|
L
 19%
H
0.8
1.3
|
L
 -10.5%
H
0.8
2.0
|
L
 -40.5%
H
0.8
3.3
|
L
 -90.3%
H
0.8
13.0
|
L
 -99.3%
H
0.8
190.8
|
| Co-Diagnostics Inc |
|
7.1
|
1.0
|
L
 6.3%
H
1.0
1.0
|
L
 -9.8%
H
0.9
1.2
|
L
 -12.2%
H
0.9
1.3
|
L
 -70.0%
H
0.9
4.6
|
L
 -92.3%
H
0.9
46.5
|
L
 -96.7%
H
0.9
66.9
|
L
 -99.6%
H
0.9
327
|
L
H
0.9
929.7
|
| Z Squared Inc |
|
139.9
|
2.6
|
L
 -1.5%
H
2.5
2.8
|
L
 -14.0%
H
2.1
3.3
|
L
 -33.3%
H
2.1
4.6
|
L
 -84.2%
H
2.1
16.6
|
L
 -81.0%
H
2.1
21.4
|
L
 -86.0%
H
2.1
27.6
|
L
 -73.4%
H
2.1
242.6
|
L
H
2.1
242.6
|
| Cogent Biosciences Inc |
|
5,552.8
|
32
|
L
 1.6%
H
31.4
32.5
|
L
 -4.2%
H
31.4
33.9
|
L
 -9.4%
H
31.4
37.7
|
L
 -7.4%
H
31.4
43.4
|
L
 167.3%
H
11.6
43.7
|
L
 221.0%
H
3.7
43.7
|
L
 263.6%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Collegium pharma Inc |
|
714.2
|
23.0
|
L
 1.2%
H
22.5
23.2
|
L
 1.3%
H
21.7
23.2
|
L
 -16.3%
H
21.7
28.3
|
L
 -31.3%
H
21.7
38.5
|
L
 -35.6%
H
21.7
50.8
|
L
 1.1%
H
21.0
50.8
|
L
 17.4%
H
14.0
50.8
|
L
 94.9%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
12,297.3
|
113.8
|
L
 3.2%
H
109
116.7
|
L
 0.9%
H
108.4
117.9
|
L
 -6.0%
H
108.3
126.4
|
L
 42.4%
H
77.4
126.4
|
L
 41.3%
H
28.7
126.4
|
L
 255.1%
H
20.8
126.4
|
L
 457.4%
H
15.8
126.4
|
L
 1808.7%
H
5.9
126.4
|
| Cosmos Health Inc |
|
34.2
|
0.3
|
L
 6.3%
H
0.3
0.3
|
L
 36%
H
0.2
0.4
|
L
 61.9%
H
0.2
0.4
|
L
 61.9%
H
0.2
0.4
|
L
 -64.2%
H
0.2
1.3
|
L
 -77.9%
H
0.2
2.1
|
L
 -99.7%
H
0.2
150
|
L
 -99.8%
H
0.2
312.5
|
| Coya Therapeutics Inc |
|
116.1
|
5.0
|
L
 1.2%
H
4.8
5.0
|
L
 13.0%
H
4.3
5.1
|
L
 1.9%
H
4.3
5.3
|
L
 0.6%
H
3.9
6.2
|
L
 -10%
H
3.7
7.8
|
L
 25.3%
H
3.2
10.7
|
L
H
3.2
10.7
|
L
H
3.2
10.7
|
| Cumberland Pharma Inc |
|
113.7
|
7.6
|
L
 3.7%
H
7.1
7.6
|
L
 18.8%
H
6.4
7.6
|
L
 1.2%
H
6.2
9.3
|
L
 32.7%
H
5.4
9.3
|
L
 141.0%
H
1.9
9.3
|
L
 238.8%
H
1.0
9.3
|
L
 172.0%
H
1.0
9.3
|
L
 53.0%
H
1.0
9.3
|
| Corbus Pharma Holdings Inc |
|
148.0
|
7.7
|
L
 2.3%
H
7.4
7.8
|
L
 -5.8%
H
6.3
8.7
|
L
 -22.3%
H
6.3
11.6
|
L
 -7.4%
H
6.3
11.6
|
L
 -33.5%
H
6.3
20.6
|
L
 13.2%
H
3.0
61.9
|
L
 -74.8%
H
2.1
61.9
|
L
 -96.3%
H
2.1
323.4
|
| Caribou Biosciences Inc |
|
139.4
|
1.3
|
L
H
1.3
1.4
|
L
 2.4%
H
1.3
1.4
|
L
 -19.3%
H
1.3
1.8
|
L
 -20.7%
H
1.3
2.1
|
L
 -23.1%
H
1.3
3.5
|
L
 -75.3%
H
0.7
8.3
|
L
 -94.5%
H
0.7
26.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
226.0
|
1.9
|
L
 -1.1%
H
1.8
1.9
|
L
 -7%
H
1.8
2.0
|
L
 -1.1%
H
1.8
2.3
|
L
 75.5%
H
1.0
2.3
|
L
 66.1%
H
0.9
2.3
|
L
 87.9%
H
0.7
3.1
|
L
 -52.4%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
2.4
|
1.0
|
L
 -2%
H
1.0
1.1
|
L
 -13.3%
H
1.0
1.2
|
L
 -39.1%
H
1.0
1.7
|
L
 -88.4%
H
1.0
11.4
|
L
 -97.1%
H
1.0
34.9
|
L
 -99.4%
H
1.0
349.8
|
L
 -100.0%
H
1.0
3400
|
L
 -100.0%
H
1.0
7440
|
| CorMedix Inc |
|
605.6
|
7.8
|
L
 0.7%
H
7.6
7.8
|
L
 -0.6%
H
7.6
7.9
|
L
 -5.6%
H
7.6
8.7
|
L
 -10.4%
H
7.1
9.1
|
L
 -30.6%
H
6.1
13.0
|
L
 114.0%
H
2.6
17.4
|
L
 72.7%
H
2.6
17.4
|
L
 -46.2%
H
0.9
18.8
|
| Cronos Grp Inc |
|
1,226.8
|
3.3
|
L
 -0.6%
H
3.3
3.4
|
L
 6.1%
H
3.1
3.4
|
L
 3.4%
H
3.1
3.6
|
L
 22.9%
H
2.6
3.6
|
L
 27.1%
H
2.3
3.6
|
L
 52.8%
H
1.6
3.6
|
L
 -41.8%
H
1.6
6.8
|
L
 484.2%
H
0.3
25.1
|
| CRISPR Therapeutics AG |
|
5,640.1
|
58.3
|
L
 3.1%
H
56.9
59.2
|
L
 12.8%
H
51.3
59.3
|
L
 0.4%
H
51.3
62.5
|
L
 7.8%
H
45.9
63.5
|
L
 -6.4%
H
44.1
78.5
|
L
 25.3%
H
30.0
91.1
|
L
 -49.9%
H
30.0
122.3
|
L
H
11.6
220.2
|
| Corvus Pharma Inc |
|
1,044.8
|
12.4
|
L
 -1.1%
H
12.3
12.8
|
L
 -3.8%
H
12.2
13.3
|
L
 -13.3%
H
12.2
15.1
|
L
 4.3%
H
12.1
16.5
|
L
 111.6%
H
5.7
27.0
|
L
 711.8%
H
1.1
27.0
|
L
 101.3%
H
0.6
27.0
|
L
 -17.2%
H
0.6
27.0
|
| Champions Oncology Inc |
|
73.2
|
5.3
|
L
 -0.8%
H
5.1
5.3
|
L
 3.1%
H
4.6
5.6
|
L
 1.5%
H
4.6
5.6
|
L
 -16.8%
H
4.6
7
|
L
 -19.8%
H
4.6
8.3
|
L
 -1.7%
H
3.6
12.0
|
L
 -48.9%
H
3.6
12.0
|
L
 211.2%
H
1.6
17.9
|
| CytomX Therapeutics Inc |
|
601.4
|
2.8
|
L
H
2.7
2.8
|
L
 -16.1%
H
2.7
3.4
|
L
 -16.1%
H
2.7
3.9
|
L
 -6.4%
H
2.7
4.0
|
L
 39.4%
H
2.0
8.2
|
L
 102.9%
H
0.4
8.2
|
L
 -46.8%
H
0.4
8.2
|
L
 -83.9%
H
0.4
35
|
| Cue Biopharma Inc |
|
205.4
|
28.3
|
L
 -23.7%
H
23.8
41.5
|
L
 -1.6%
H
23.8
41.5
|
L
 14.9%
H
22.6
41.5
|
L
 -0.7%
H
22.6
45.5
|
L
 40.2%
H
5.0
45.5
|
L
 -59.6%
H
5.0
97.5
|
L
 -92.9%
H
5.0
552.6
|
L
H
5.0
950.7
|
| Cadrenal Therapeutics Inc |
|
3.9
|
1.1
|
L
 1.9%
H
1.1
1.1
|
L
H
1.0
1.2
|
L
 -31.5%
H
1
2.3
|
L
 -68.9%
H
1
3.9
|
L
 -91.7%
H
1
14.6
|
L
 51.4%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Cyclacel Pharma Inc |
|
6.3
|
1.0
|
L
 1.1%
H
0.9
1.0
|
L
 9.2%
H
0.7
1.2
|
L
 8.0%
H
0.7
1.2
|
L
 25%
H
0.6
1.2
|
L
 -79.6%
H
0.6
6.7
|
L
 -99.9%
H
0.6
2721.6
|
L
 -100.0%
H
0.6
21960
|
L
 -100.0%
H
0.6
784800
|
| Korsana Biosciences Inc |
|
1,512.4
|
33.2
|
L
 -5.1%
H
31.9
34.4
|
L
 4.1%
H
29.4
35.5
|
L
 16.6%
H
19.7
36.3
|
L
 48.3%
H
19.7
36.3
|
L
 99.3%
H
7.2
59.4
|
L
 31.1%
H
7.2
59.4
|
L
 -92.3%
H
7.2
507.2
|
L
H
7.2
3199
|
| Cytokinetics Inc |
|
9,392.4
|
67.6
|
L
 -1.8%
H
67.4
69.5
|
L
 -8.4%
H
67.4
74.7
|
L
 -12.5%
H
67.4
79.9
|
L
 -14.2%
H
67.4
88.3
|
L
 38.8%
H
47.2
88.3
|
L
 111.3%
H
26.0
110
|
L
 108.3%
H
26.0
110
|
L
 666.0%
H
5.8
110
|
| Cellectis (ADR) |
|
152.1
|
1.5
|
L
 -1.3%
H
1.5
1.6
|
L
 -51.3%
H
1.3
2.4
|
L
 -56.5%
H
1.3
3.6
|
L
 -49.3%
H
1.3
3.6
|
L
 -56.1%
H
1.3
5.5
|
L
 -7.4%
H
1.0
5.5
|
L
 -88.8%
H
1.0
14.2
|
L
 -93.9%
H
1.0
38.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
18.2
|
2.5
|
L
 -5.0%
H
2.5
2.7
|
L
 -3.9%
H
2.4
2.9
|
L
 19.8%
H
2.0
3.0
|
L
 63.2%
H
1.4
3.0
|
L
 -6.4%
H
1.4
3.6
|
L
 -39.8%
H
1.4
10.2
|
L
 -94.9%
H
1.4
52.8
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
2,078.5
|
15.0
|
L
 -1.2%
H
14.9
15.6
|
L
 4.6%
H
13.7
15.6
|
L
 8.6%
H
12.7
15.9
|
L
 19.8%
H
10.6
15.9
|
L
 206.3%
H
4.8
15.9
|
L
 82.6%
H
2.3
15.9
|
L
 -52.2%
H
2.3
49.5
|
L
H
2.3
61.7
|
| Connect Biopharma Holdings Ltd (ADR) |
|
73.6
|
1.3
|
L
 3.1%
H
1.2
1.3
|
L
 -35.3%
H
1.1
1.8
|
L
 -42.1%
H
1.1
2.9
|
L
 -34%
H
1.1
2.9
|
L
 -15.9%
H
1.1
3.8
|
L
 85.9%
H
0.5
3.8
|
L
 -93.4%
H
0.5
25.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
15.9
|
0.8
|
L
 3.9%
H
0.8
0.8
|
L
 14.1%
H
0.7
0.8
|
L
H
0.7
0.9
|
L
 -62.7%
H
0.7
2.2
|
L
 -61.8%
H
0.7
3.8
|
L
 -85.2%
H
0.3
9.2
|
L
 -96.0%
H
0.3
30.1
|
L
 -99.3%
H
0.3
429.6
|
| Journey Medical Corp |
|
197.3
|
7.0
|
L
 -4.4%
H
6.9
7.5
|
L
 -3.3%
H
6.9
7.7
|
L
 -6.7%
H
6.9
8.2
|
L
 12.4%
H
6
8.2
|
L
 -4.3%
H
4.3
9.6
|
L
 161.8%
H
2.6
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| DiaMedica Therapeutics Inc |
|
391.5
|
7.3
|
L
 6.0%
H
6.8
7.4
|
L
 12.2%
H
6.4
7.4
|
L
 11.4%
H
6.2
7.4
|
L
 24.1%
H
5.8
8.5
|
L
 6.5%
H
5.2
10.4
|
L
 143.6%
H
1.9
10.4
|
L
 90.6%
H
1.1
10.4
|
L
 84.3%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
3,272.1
|
20.5
|
L
 3.8%
H
19.4
20.6
|
L
 -2.9%
H
19.4
21.6
|
L
 -18.0%
H
19.4
25.4
|
L
 -12.2%
H
19.4
27.3
|
L
 60.6%
H
12.6
27.3
|
L
 -7.9%
H
10.6
33.3
|
L
 -58.9%
H
10.6
56.1
|
L
H
10.6
93.9
|
| Dermata Therapeutics Inc |
|
5.7
|
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
 -3.4%
H
1.1
1.3
|
L
 -16.7%
H
1.1
1.7
|
L
 -1.7%
H
1.0
1.7
|
L
 -78.8%
H
1.0
5.9
|
L
 2.7%
H
0.2
7.1
|
L
 -98.5%
H
0.2
111.2
|
L
H
0.2
111.2
|
| Bright Minds Biosciences Inc |
|
583.4
|
59.5
|
L
 -2.5%
H
59.2
62.0
|
L
 -5.9%
H
57.6
63.9
|
L
 -24.3%
H
57.6
82.5
|
L
 -2.0%
H
57.6
87
|
L
 11.6%
H
48.9
123.8
|
L
 3397.6%
H
0.9
123.8
|
L
 98.2%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
785.4
|
12.6
|
L
 2.5%
H
12.1
12.7
|
L
 -14.2%
H
12.1
14.8
|
L
 -19.3%
H
12.1
16.0
|
L
 0.9%
H
11.4
16.1
|
L
 107.4%
H
5.3
17.3
|
L
 410.2%
H
2.0
17.3
|
L
 -19.3%
H
1.9
26.3
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
179.4
|
6.5
|
L
 -2.6%
H
6.4
6.8
|
L
 -9.3%
H
6.4
7.3
|
L
 -25.5%
H
6.4
9.1
|
L
 -4.6%
H
6.4
9.6
|
L
 36.0%
H
3.5
9.6
|
L
 1411.6%
H
0.3
19.4
|
L
 -47.6%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
3,197.1
|
17.1
|
L
 0.1%
H
16.8
17.6
|
L
 -6.0%
H
16.8
19.1
|
L
 -34.1%
H
16.8
26.9
|
L
 -13.5%
H
16.8
27.3
|
L
 30.4%
H
11.9
27.3
|
L
 83.7%
H
6.4
47.5
|
L
 7.7%
H
4.3
47.5
|
L
H
4.3
47.5
|
| DBV Tech (ADR) |
|
760.5
|
12.1
|
L
 -2.0%
H
12
12.3
|
L
 2.1%
H
11.7
12.6
|
L
 -15.0%
H
11.7
15.1
|
L
 -22.1%
H
11.7
17.4
|
L
 27.4%
H
8.9
26.2
|
L
 -17.4%
H
0.5
26.2
|
L
 -76.1%
H
0.5
56
|
L
 -96.6%
H
0.5
505.7
|
| Editas Medicine Inc |
|
434.6
|
2.8
|
L
 4.8%
H
2.7
2.9
|
L
 4.8%
H
2.6
2.9
|
L
 -3.7%
H
2.6
3.5
|
L
 5.2%
H
2.5
3.8
|
L
H
1.7
4.5
|
L
 -64.4%
H
0.9
11.7
|
L
 -95.1%
H
0.9
62.4
|
L
 -81.0%
H
0.9
100.0
|
| Edesa Biotech Inc |
|
39.6
|
4.1
|
L
 -0.7%
H
4.0
4.2
|
L
 -2.8%
H
3.8
4.4
|
L
 -13.7%
H
3.8
5.1
|
L
 -44.1%
H
3.8
8.9
|
L
 66.4%
H
0.7
20.3
|
L
 -31.7%
H
0.7
20.3
|
L
 -95.1%
H
0.7
72.3
|
L
 -99.5%
H
0.7
882
|
| Eledon Pharma Inc |
|
218.6
|
2.7
|
L
 2.7%
H
2.6
2.7
|
L
 -3.2%
H
2.6
2.9
|
L
 -23.6%
H
2.6
3.6
|
L
 -31.4%
H
2.6
4.5
|
L
 5.5%
H
1.4
4.6
|
L
 120.5%
H
1.1
5.4
|
L
 -61.6%
H
1.1
7.4
|
L
 -98.8%
H
1.1
338.6
|
| Eloxx Pharma |
|
59.1
|
17.2
|
L
 -1.5%
H
17.1
18.3
|
L
 9.1%
H
15
19.0
|
L
 -4.7%
H
13.8
23.4
|
L
 23.0%
H
10
23.4
|
L
 322.4%
H
8.2
23.4
|
L
 210.8%
H
0
23.4
|
L
 -76.0%
H
0
75.6
|
L
 -89.0%
H
0
984
|
| Elicio Therapeutics Inc |
|
50.2
|
1.9
|
L
 1.1%
H
1.9
2.0
|
L
 -6.8%
H
1.7
2.1
|
L
 -38.0%
H
1.7
3.1
|
L
 -50.4%
H
1.7
5.4
|
L
 -83.1%
H
1.7
16
|
L
 -77.9%
H
1.7
16
|
L
 -98.1%
H
1.7
107.5
|
L
H
1.7
263
|
| Enliven Therapeutics Inc |
|
3,580.7
|
48.9
|
L
 -1.2%
H
48.0
49.5
|
L
 -10.0%
H
48.0
55.8
|
L
 -17.1%
H
48.0
62
|
L
 8.4%
H
45.0
62.3
|
L
 157.8%
H
14.8
62.3
|
L
 262%
H
9.8
62.3
|
L
 191.6%
H
3.9
62.3
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
783.4
|
13.6
|
L
 -2.9%
H
13.5
14.2
|
L
 -4.3%
H
13.4
15.0
|
L
 -19.9%
H
13.1
18.3
|
L
 19.1%
H
11.4
18.3
|
L
 490.5%
H
1.5
18.3
|
L
 416.7%
H
1.1
18.3
|
L
 -16.8%
H
1.1
20.9
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
12.1
|
0.7
|
L
 -14.8%
H
0.7
0.9
|
L
 -28.1%
H
0.6
1.0
|
L
 -54%
H
0.6
1.7
|
L
 11.3%
H
0.4
7.6
|
L
 -33.7%
H
0.4
7.6
|
L
 -60.8%
H
0.4
7.6
|
L
 -93.7%
H
0.4
11.6
|
L
 -99.0%
H
0.4
74.8
|
| Enochian Biosciences Inc |
|
-
|
2.3
|
L
 -1.3%
H
2.2
2.4
|
L
 -3.4%
H
2.1
2.6
|
L
 4.6%
H
2.1
2.9
|
L
 -39.2%
H
1.9
4.8
|
L
 1177.8%
H
0.1
5.0
|
L
 618.8%
H
0.1
5.0
|
L
 -66.5%
H
0.1
13.8
|
L
 187.5%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
8.2
|
0.4
|
L
 -8.7%
H
0.4
0.5
|
L
 -14.3%
H
0.4
0.5
|
L
 10.5%
H
0.4
0.5
|
L
 55.6%
H
0.2
1.0
|
L
 -80.3%
H
0.2
2.8
|
L
 -74.9%
H
0.1
9.9
|
L
 -99.9%
H
0.1
1680
|
L
H
0.1
5757.6
|
| Enanta Pharma Inc |
|
352.7
|
12.1
|
L
 -0.7%
H
11.9
12.3
|
L
 -6.6%
H
11.9
13.1
|
L
 -7.8%
H
11.9
15.1
|
L
 -4.3%
H
11.9
15.5
|
L
 58.5%
H
7.1
17.2
|
L
 -4.0%
H
4.1
17.8
|
L
 -78.8%
H
4.1
102
|
L
 -54.7%
H
4.1
127.8
|
| Entera Bio Ltd |
|
512.5
|
3.0
|
L
H
2.9
3.0
|
L
 4.2%
H
2.7
3.1
|
L
 -8.1%
H
2.7
3.6
|
L
 144.6%
H
1.2
4.2
|
L
 64.4%
H
0.9
4.2
|
L
 335.3%
H
0.5
4.2
|
L
 -36.2%
H
0.5
5.2
|
L
H
0.5
10.2
|
| Enveric Biosciences Inc |
|
7.0
|
1.6
|
L
 -3.7%
H
1.6
1.7
|
L
 9.9%
H
1.4
1.7
|
L
 12.2%
H
1.2
1.7
|
L
 21.9%
H
1.2
1.8
|
L
 -78.4%
H
1.2
13.3
|
L
 -99.6%
H
1.2
525.6
|
L
 -100.0%
H
1.2
22320
|
L
 -100.0%
H
1.2
12150000
|
| Evolus Inc |
|
527.7
|
8.0
|
L
 1.7%
H
7.8
8
|
L
 1.9%
H
7.6
8.3
|
L
 -4.3%
H
7.6
9.3
|
L
 20.5%
H
5.4
9.3
|
L
 27.0%
H
3.9
9.3
|
L
 -13.1%
H
3.9
17.8
|
L
 0.4%
H
3.9
17.8
|
L
H
2.9
39.5
|
| Equillium Inc |
|
120.5
|
1.9
|
L
 -1.0%
H
1.9
2.0
|
L
 -10.0%
H
1.8
2.1
|
L
 -16.3%
H
1.8
2.7
|
L
 -37.7%
H
1.8
3.5
|
L
 30.1%
H
0.8
3.5
|
L
 140.5%
H
0.3
3.5
|
L
 -68.4%
H
0.3
7.1
|
L
H
0.3
27.1
|
| Erasca Inc |
|
5,260.4
|
15.0
|
L
 1.8%
H
14.6
15.3
|
L
 -5.3%
H
14.5
16.6
|
L
 -11.9%
H
14.5
20.4
|
L
 10.0%
H
14.0
21.6
|
L
 717.4%
H
1.8
24.3
|
L
 545.5%
H
1.0
24.3
|
L
 -23.7%
H
1.0
24.3
|
L
H
1.0
24.5
|
| Eterna Therapeutics Inc |
|
4.6
|
4.0
|
L
 3.4%
H
3.8
4.0
|
L
 -4.8%
H
3.7
4.7
|
L
 -12.4%
H
3.7
5.5
|
L
 -36.1%
H
3.3
9.9
|
L
 -88.1%
H
3.2
71.5
|
L
 -99.5%
H
3.2
984.4
|
L
 -100.0%
H
3.2
77662.5
|
L
 -100.0%
H
3.2
605025
|
| Eton Pharma Inc |
|
1,580.9
|
55.3
|
L
 -0.3%
H
53.6
56.7
|
L
 -3.1%
H
53.6
59.0
|
L
 -7.7%
H
53.6
66.4
|
L
 70.3%
H
31.9
66.4
|
L
 201.6%
H
14.3
66.4
|
L
 1089.5%
H
3.0
66.4
|
L
 1035.7%
H
2.0
66.4
|
L
H
2.0
66.4
|
| Evogene Ltd |
|
7.3
|
0.5
|
L
 -8%
H
0.5
0.5
|
L
 -4.2%
H
0.5
0.5
|
L
 -17.9%
H
0.5
0.6
|
L
 -11.5%
H
0.4
0.8
|
L
 -61.0%
H
0.4
1.5
|
L
 -93.2%
H
0.4
10.4
|
L
 -98.4%
H
0.4
29.9
|
L
 -99.3%
H
0.4
102.4
|
| Edgewise Therapeutics Inc |
|
4,848.1
|
44.6
|
L
 -1.5%
H
44.1
46.0
|
L
 0.5%
H
42.6
48.5
|
L
 3.1%
H
40.6
48.5
|
L
 21.3%
H
36.0
48.5
|
L
 213.0%
H
14.3
48.5
|
L
 620%
H
5.1
48.5
|
L
 159.1%
H
5.1
48.5
|
L
H
5.1
48.5
|
| Exelixis Inc |
|
14,178.1
|
57.2
|
L
 -2.0%
H
56.9
58.8
|
L
 2.0%
H
54.9
59.2
|
L
 6.6%
H
53.4
59.7
|
L
 10.2%
H
50.0
59.7
|
L
 42.7%
H
33.8
59.7
|
L
 166.0%
H
18.6
59.7
|
L
 188.7%
H
14.9
59.7
|
L
 304.1%
H
10.0
59.7
|
| Hyperion DeFi Inc |
|
59.8
|
3.9
|
L
 -1.8%
H
3.8
4.1
|
L
 10.3%
H
3.2
4.1
|
L
 22.6%
H
3.0
4.1
|
L
 11.6%
H
2.3
4.1
|
L
 -65.9%
H
2.3
11.9
|
L
 -97.1%
H
0.0
205.6
|
L
 -98.9%
H
0.0
530.4
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
346.6
|
4.0
|
L
 4.4%
H
3.8
4.1
|
L
 -5.0%
H
3.4
4.3
|
L
 -25.6%
H
3.4
5.5
|
L
 -70.4%
H
3.4
15.9
|
L
 -69.7%
H
3.4
19.1
|
L
 -53.1%
H
3.4
31.0
|
L
 -62.1%
H
2.2
31.0
|
L
 -88.4%
H
2.2
39.4
|
| Evaxion Biotech A/S (ADR) |
|
29.0
|
3.2
|
L
 -1.8%
H
3.2
3.3
|
L
 2.6%
H
3
3.3
|
L
 -2.1%
H
2.9
3.6
|
L
 5.3%
H
2.8
3.6
|
L
 3.9%
H
2.8
12.2
|
L
 -52.8%
H
0.8
13.6
|
L
 -96.0%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
303.1
|
2.5
|
L
H
2.4
2.6
|
L
 9.5%
H
2.3
2.7
|
L
 3.3%
H
2.2
2.7
|
L
 21.1%
H
1.8
3.2
|
L
 163.5%
H
0.9
3.2
|
L
 12.4%
H
0.7
8.8
|
L
 -96.2%
H
0.7
70.9
|
L
 -20.7%
H
0.7
121.2
|
| Fortress Biotech Inc |
|
80.4
|
2.4
|
L
 -4.0%
H
2.4
2.5
|
L
 -4.4%
H
2.4
2.6
|
L
 -13%
H
2.4
3.0
|
L
 -19.4%
H
2.4
3.8
|
L
 -34.3%
H
2.2
4.5
|
L
 -51.3%
H
1.2
5.3
|
L
 -94.9%
H
1.2
57.2
|
L
 -94.2%
H
1.2
91.5
|
| 4D Molecular Therapeutics Inc |
|
841.9
|
15.2
|
L
 0.1%
H
14.7
15.7
|
L
 15.7%
H
13.2
15.7
|
L
 -5.3%
H
12.9
16.9
|
L
 57.8%
H
9.4
16.9
|
L
 130.9%
H
6.5
16.9
|
L
 5.1%
H
2.2
36.3
|
L
 -54.3%
H
2.2
36.3
|
L
H
2.2
55.1
|
| Fennec Pharma Inc |
|
382.6
|
10.9
|
L
 2.7%
H
10.4
10.9
|
L
 -0.5%
H
10.1
11.1
|
L
 -3.9%
H
10.1
12.8
|
L
 20.4%
H
9.1
13.3
|
L
 25.8%
H
5.7
13.3
|
L
 43.2%
H
4.0
13.3
|
L
 28.4%
H
3.8
13.3
|
L
 440.1%
H
1.6
15.0
|
| Kyntra Bio Inc |
|
29.2
|
7.2
|
L
 1.7%
H
7.0
7.3
|
L
 -9.7%
H
6.7
8.1
|
L
 -1.6%
H
6.7
8.7
|
L
 7.5%
H
6.7
8.7
|
L
 -36.3%
H
6.3
12.6
|
L
 -67.1%
H
4.5
73.3
|
L
 -97.4%
H
4.5
642.3
|
L
 -98.7%
H
4.5
1713.8
|
| Foghorn Therapeutics Inc |
|
246.4
|
4.2
|
L
 0.2%
H
4.1
4.2
|
L
 -6.1%
H
4.1
4.6
|
L
 -40.8%
H
4.1
7.4
|
L
H
4.0
7.6
|
L
 -17.3%
H
3.3
7.6
|
L
 -31.7%
H
2.7
10.2
|
L
 -69.3%
H
2.7
24.3
|
L
H
2.7
28.3
|
| Q32 Bio Inc |
|
311.7
|
10.5
|
L
 -0.7%
H
10.3
10.8
|
L
 -5.7%
H
10.3
11.4
|
L
 -34.0%
H
10.3
17.0
|
L
 -12.0%
H
10.3
23.6
|
L
 466.0%
H
1.8
23.6
|
L
 -50.7%
H
1.3
53.8
|
L
 -92.9%
H
1.3
160.2
|
L
H
1.3
572.4
|
| ZeroStack Corp |
|
94.2
|
4.3
|
L
 -8.3%
H
4.1
5.2
|
L
 -10.7%
H
4.1
5.2
|
L
 -26.7%
H
4.0
6.9
|
L
 6.9%
H
1.3
12.4
|
L
 -84.1%
H
1.3
47
|
L
 -91.6%
H
1.3
114.2
|
L
 -99.9%
H
1.3
5834.4
|
L
H
1.3
16731
|
| Frequency Therapeutics Inc |
|
-
|
10.0
|
L
 -0.4%
H
9.9
10.8
|
L
 -27.7%
H
9.5
15.2
|
L
 -23.0%
H
9.5
15.2
|
L
 -23.2%
H
9.5
15.6
|
L
 -72.3%
H
5.2
55.9
|
L
 -49.5%
H
5.2
55.9
|
L
 -97.2%
H
5.2
394
|
L
H
5.2
2918.5
|
| Fulcrum Therapeutics Inc |
|
289.9
|
3.8
|
L
 1.1%
H
3.8
3.8
|
L
H
3.8
3.8
|
L
 -1.3%
H
3.8
3.9
|
L
 2.7%
H
3.4
4.0
|
L
 -48.6%
H
2.8
15.7
|
L
 -14.2%
H
2.3
15.7
|
L
 -87.7%
H
2.3
33.1
|
L
H
2.3
33.1
|
| First Wave BioPharma Inc |
|
5.3
|
3.4
|
L
 9.3%
H
3.0
3.4
|
L
 18.9%
H
2.7
3.4
|
L
 -9.3%
H
2.7
4.2
|
L
 -37.0%
H
2.6
5.7
|
L
 -34.1%
H
1.9
6.9
|
L
 -52.1%
H
0.4
14.5
|
L
 -100.0%
H
0.4
16359.9
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
399.4
|
4.0
|
L
 1.8%
H
3.9
4.0
|
L
 1.3%
H
3.6
4.1
|
L
 10.9%
H
3.6
4.7
|
L
 40.4%
H
2.7
5.6
|
L
 -17.5%
H
2.0
7.1
|
L
 122.5%
H
0.7
7.1
|
L
 8.2%
H
0.7
7.1
|
L
 106.3%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
80.3
|
1.8
|
L
 4.6%
H
1.8
1.9
|
L
 5.1%
H
1.7
1.9
|
L
 -7.1%
H
1.7
2.1
|
L
 -2.1%
H
1.6
2.4
|
L
 16.5%
H
1.5
4.3
|
L
 -45.9%
H
0.9
5.3
|
L
 -73.8%
H
0.9
9.7
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
11.5
|
1.0
|
L
 -1.0%
H
0.8
1.0
|
L
 24.4%
H
0.8
1.0
|
L
 7.8%
H
0.8
1.0
|
L
 -10.2%
H
0.7
1.2
|
L
 -47.9%
H
0.7
3.7
|
L
 -73.1%
H
0.7
5.5
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
835.2
|
1.3
|
L
H
1.3
1.3
|
L
 -3.7%
H
1.3
1.4
|
L
 -16.1%
H
1.3
1.6
|
L
 3.2%
H
1.2
1.7
|
L
 -1.5%
H
1.0
2.0
|
L
 -39.3%
H
1.0
5.3
|
L
 -4.4%
H
1.0
5.3
|
L
 -36.6%
H
0.8
7.0
|
| GH Research PLC |
|
1,917.2
|
27.9
|
L
 -1.2%
H
27.8
28.5
|
L
 2.7%
H
26.5
29.2
|
L
 -2.6%
H
26.5
29.2
|
L
 25.6%
H
21.3
31.4
|
L
 109.5%
H
12.0
31.4
|
L
 161.3%
H
5.1
31.4
|
L
 41.3%
H
5.1
31.4
|
L
H
5.1
31.4
|
| Gilead Sciences |
|
186,687.6
|
150.6
|
L
 0.3%
H
148.2
152.1
|
L
 4.8%
H
142.9
153.2
|
L
 5.0%
H
142.9
153.2
|
L
 21.7%
H
123
153.2
|
L
 32.0%
H
108.5
157.3
|
L
 98.6%
H
62.1
157.3
|
L
 112.2%
H
57.2
157.3
|
L
 84.1%
H
56.6
157.3
|
| Eocene |
|
3.7
|
3.5
|
L
 3.9%
H
3.3
3.7
|
L
 -8.9%
H
3.3
3.9
|
L
 -23.3%
H
3.3
4.9
|
L
 503.5%
H
0.5
5.5
|
L
 139.7%
H
0.4
5.5
|
L
 -53.7%
H
0.2
13.6
|
L
 -99.3%
H
0.2
563.4
|
L
 -99.6%
H
0.2
4870.8
|
| Greenwich LifeSciences Inc |
|
273.0
|
18.6
|
L
 -2.1%
H
18.1
19.2
|
L
 20.4%
H
15.2
20.0
|
L
 21.5%
H
14.3
20.0
|
L
 -20.4%
H
12.5
24.6
|
L
 62.3%
H
7.8
34.1
|
L
 112.3%
H
7.6
34.1
|
L
 -56.1%
H
6.8
45.2
|
L
H
3.3
158.1
|
| Galecto Inc |
|
1,410.7
|
22.9
|
L
 1.2%
H
22.0
23.3
|
L
 -18.7%
H
22.0
29.2
|
L
 -24.6%
H
22.0
31.6
|
L
 7.6%
H
21.5
34.9
|
L
 696.2%
H
2.9
38.3
|
L
 3839.7%
H
0.5
38.3
|
L
 484.4%
H
0.5
38.3
|
L
H
0.5
38.3
|
| Monte Rosa Therapeutics Inc |
|
1,045.9
|
12.3
|
L
 1.1%
H
12.1
12.3
|
L
 -12.9%
H
12.0
14.4
|
L
 -17.1%
H
12.0
15
|
L
 -33.0%
H
12.0
25.2
|
L
 93.7%
H
6.2
25.8
|
L
 105.0%
H
2.4
25.8
|
L
 -54.7%
H
2.4
27.9
|
L
H
2.4
45.6
|
| GlycoMimetics Inc |
|
1,048.6
|
16.3
|
L
 -3.8%
H
15.8
17.0
|
L
 -16.3%
H
15.8
20.4
|
L
 0.1%
H
15.8
22.3
|
L
 -8.1%
H
14.0
22.3
|
L
 25.8%
H
8.7
27.4
|
L
 -88.3%
H
8.7
353
|
L
 -92.3%
H
8.7
416
|
L
 -97.8%
H
8.7
2605
|
| Genelux Corp |
|
115.8
|
2.6
|
L
 1.2%
H
2.5
2.6
|
L
 2.8%
H
2.3
2.6
|
L
 -6.6%
H
2.3
3.0
|
L
 -13.5%
H
2.3
3.2
|
L
 -38.5%
H
2.3
8.5
|
L
 -91.1%
H
1.6
29.4
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
2.9
|
3.5
|
L
 0.9%
H
3.5
3.7
|
L
 3.9%
H
3.3
3.7
|
L
 -11.9%
H
3.3
4.3
|
L
 489.8%
H
0.5
10.0
|
L
 1413.0%
H
0.2
13.0
|
L
 673.3%
H
0.1
13.0
|
L
 27.9%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
69.0
|
11.3
|
L
 5.1%
H
10.9
11.9
|
L
 5.1%
H
10.0
12.5
|
L
 -10.8%
H
10.0
17.1
|
L
 -16.1%
H
9.1
21.4
|
L
 -95.4%
H
9.1
309.6
|
L
 -84.1%
H
9.1
309.6
|
L
 -98.6%
H
9.1
1215.6
|
L
H
9.1
2172
|
| Geovax Labs Inc |
|
3.3
|
0.4
|
L
H
0.4
0.4
|
L
 -21.7%
H
0.4
0.5
|
L
 -40%
H
0.4
0.9
|
L
 -73.1%
H
0.4
1.4
|
L
 -97.8%
H
0.4
17.5
|
L
 -99.8%
H
0.4
276.8
|
L
 -100.0%
H
0.4
2103.8
|
L
 -100.0%
H
0.4
379518072.3
|
| GRI Bio Inc |
|
4.2
|
1.9
|
L
 0.5%
H
1.9
2.2
|
L
 2.1%
H
1.7
2.2
|
L
 16.2%
H
1.7
3.4
|
L
 3.2%
H
1.4
3.4
|
L
 -96.2%
H
1.4
64.1
|
L
 -100.0%
H
1.4
77102.5
|
L
 -100.0%
H
1.4
11097548.5
|
L
H
1.4
13462627.3
|
| Graphite Bio Inc |
|
237.6
|
4.1
|
L
 0.3%
H
4
4.1
|
L
 -9.7%
H
4
4.6
|
L
 -12.5%
H
4
6.0
|
L
 -33.7%
H
4
6.7
|
L
 -90.4%
H
4
50.4
|
L
 -96.5%
H
4
413
|
L
 -99.5%
H
4
847.7
|
L
H
4
1666
|
| GT Biopharma Inc |
|
13.0
|
7.2
|
L
 0.3%
H
6.9
7.8
|
L
 -16.6%
H
6.3
12.0
|
L
 1.8%
H
4.9
12.0
|
L
 -44.1%
H
4.9
13.9
|
L
 -63.3%
H
4.9
34.3
|
L
 -96.2%
H
4.9
266.5
|
L
 -99.9%
H
4.9
5632.5
|
L
 -100.0%
H
4.9
1003297.5
|
| Galapagos NV (ADR) |
|
1,949.9
|
29.6
|
L
 3.6%
H
28.6
29.7
|
L
 10.4%
H
26.6
29.7
|
L
 4.7%
H
26.6
29.8
|
L
 4.6%
H
25.7
30.9
|
L
 -13.3%
H
25.7
37.8
|
L
 -17.0%
H
22.4
42.5
|
L
 -46.0%
H
22.4
72.1
|
L
 -56.1%
H
22.4
274.0
|
| Genmab (ADR) |
|
21,331.0
|
34.7
|
L
 -0.1%
H
34.4
34.9
|
L
 6.8%
H
32.3
35.2
|
L
 3.8%
H
32.2
35.2
|
L
 37.3%
H
24.9
35.2
|
L
 22.7%
H
23.6
35.4
|
L
 -7.3%
H
17.2
37
|
L
 -19.2%
H
17.2
47.5
|
L
 106.4%
H
12.1
49.1
|
| Genenta Science SpA (ADR) |
|
32.8
|
0.7
|
L
 -2.9%
H
0.7
0.7
|
L
 -19.1%
H
0.7
0.9
|
L
 -42.9%
H
0.7
1.3
|
L
 -59.5%
H
0.7
2.0
|
L
 -76.2%
H
0.6
10
|
L
 -88.3%
H
0.6
10
|
L
H
0.6
13.1
|
L
H
0.6
13.1
|
| Structure Therapeutics Inc (ADR) |
|
2,624.9
|
36.8
|
L
 5.2%
H
35
37.0
|
L
 -4.8%
H
34.4
39.2
|
L
 -27.1%
H
34.4
51.1
|
L
 -17.3%
H
34.4
57.1
|
L
 56.1%
H
23.6
94.9
|
L
 5.5%
H
13.2
94.9
|
L
H
13.2
94.9
|
L
H
13.2
94.9
|
| Grifols SA (ADR) - Level III |
|
5,009.1
|
7.4
|
L
 0.7%
H
7.3
7.4
|
L
 -2.5%
H
7.3
7.6
|
L
 -7.9%
H
7.3
8.1
|
L
 -0.5%
H
7.0
8.4
|
L
 -24.4%
H
7.0
10.2
|
L
 -23.7%
H
5.3
12.2
|
L
 -52.2%
H
5.3
15.9
|
L
 -54.7%
H
5.3
25.7
|
| Halozyme Therapeutics Inc |
|
12,649.4
|
111.5
|
L
 -0.9%
H
111.1
113.5
|
L
 4.0%
H
105.5
113.5
|
L
 5.0%
H
103.5
113.5
|
L
 62.6%
H
68.3
113.5
|
L
 43.2%
H
61.2
113.5
|
L
 181.4%
H
32.8
113.5
|
L
 170.3%
H
29.9
113.5
|
L
 791.6%
H
8.2
113.5
|
| HCW Biologics Inc |
|
3.5
|
1.9
|
L
 2.1%
H
1.9
2.0
|
L
 -14.7%
H
1.9
2.3
|
L
 -9.9%
H
1.9
3.8
|
L
 -70.8%
H
1.9
7.2
|
L
 -92.5%
H
1.5
29.3
|
L
 -100.0%
H
1.5
24192
|
L
 -100.0%
H
1.5
67680
|
L
H
1.5
74640
|
| Hillstream BioPharma Inc |
|
28.6
|
2.4
|
L
 6.1%
H
2.3
2.5
|
L
 15.6%
H
1.9
2.5
|
L
 10.4%
H
1.9
2.5
|
L
 -27.2%
H
1.8
3.5
|
L
 -32.2%
H
1.8
6.9
|
L
 -58.9%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Hoth Therapeutics Inc |
|
18.7
|
0.8
|
L
 -5.1%
H
0.8
0.8
|
L
 17.2%
H
0.6
0.9
|
L
H
0.6
0.9
|
L
 -30.6%
H
0.6
1.2
|
L
 -58.3%
H
0.5
2.5
|
L
 -57.1%
H
0.5
3.8
|
L
 -97.5%
H
0.5
43.8
|
L
H
0.5
347
|
| Werewolf Therapeutics Inc |
|
47.6
|
1.0
|
L
 2.1%
H
1.0
1.0
|
L
H
0.9
1.0
|
L
 127.9%
H
0.8
1.1
|
L
 180%
H
0.3
1.1
|
L
 -34.2%
H
0.3
2.4
|
L
 -58.5%
H
0.3
8.2
|
L
 -94.1%
H
0.3
18.2
|
L
H
0.3
24.0
|
| Harmony Biosciences Holdings Inc |
|
2,451.8
|
42.1
|
L
 0.2%
H
41.2
42.5
|
L
 1.4%
H
40.9
43.3
|
L
 10.6%
H
37.5
43.5
|
L
 26.5%
H
32.3
43.5
|
L
 29.4%
H
25.5
43.5
|
L
 12.7%
H
18.6
43.5
|
L
 12.9%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,271.6
|
33.9
|
L
 2.5%
H
32.6
34.3
|
L
 -1.6%
H
31.9
35.3
|
L
 -19.4%
H
31.9
42.7
|
L
 -20.9%
H
31.9
47.5
|
L
 -23.5%
H
28.5
54.9
|
L
 139.7%
H
7.6
59.2
|
L
 258.6%
H
5.4
59.2
|
L
 756.6%
H
1.4
59.2
|
| Heron Therapeutics Inc |
|
51.3
|
0.3
|
L
 -12.9%
H
0.3
0.3
|
L
 -15.6%
H
0.3
0.3
|
L
 -12.9%
H
0.3
0.4
|
L
 -35.7%
H
0.3
0.5
|
L
 -78.1%
H
0.3
1.6
|
L
 -76.1%
H
0.3
3.9
|
L
 -97.8%
H
0.3
12.9
|
L
 -98.6%
H
0.3
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
29.2
|
3.6
|
L
 -1.4%
H
3.5
3.8
|
L
 12.8%
H
3.1
3.9
|
L
 4.9%
H
2.9
3.9
|
L
 -5%
H
2.7
4.4
|
L
 -80.9%
H
2.1
19.4
|
L
 -95.8%
H
2.1
97.5
|
L
 -96.2%
H
2.1
136.5
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
163.9
|
0.6
|
L
H
0.6
0.6
|
L
 3.5%
H
0.5
0.6
|
L
 -13.2%
H
0.5
0.7
|
L
 -35.9%
H
0.5
0.9
|
L
 -68.3%
H
0.5
2.6
|
L
 -79.9%
H
0.5
10.0
|
L
 -95.8%
H
0.5
14.6
|
L
H
0.5
17.5
|
| HUTCHMED (China) Ltd (ADR) |
|
2,516.8
|
14.5
|
L
 5.9%
H
14.1
14.6
|
L
 13.0%
H
13.4
14.6
|
L
 15.3%
H
11.8
14.6
|
L
 40.9%
H
9.8
14.6
|
L
 -15.0%
H
9.8
17.0
|
L
 -8.4%
H
9.8
21.9
|
L
 -62.1%
H
7.4
38.8
|
L
 18.8%
H
7.4
43.9
|
| ImmunityBio Inc |
|
8,955.6
|
8.5
|
L
 -0.4%
H
8.3
8.9
|
L
 6.8%
H
7.8
8.9
|
L
 7.8%
H
7.5
8.9
|
L
 14.8%
H
6.7
9.6
|
L
 209.5%
H
2.0
12.4
|
L
 403.0%
H
1.3
12.4
|
L
 -12.3%
H
1.2
12.4
|
L
H
1.2
40.8
|
| Immucell Corp |
|
92.0
|
10.1
|
L
 1.8%
H
9.7
10.2
|
L
 2.8%
H
9.5
10.2
|
L
 0.4%
H
9.5
10.5
|
L
 6.7%
H
9.5
12.1
|
L
 70.0%
H
4.5
12.1
|
L
 93.0%
H
3.3
12.1
|
L
 -0.4%
H
3.3
12.1
|
L
 28.2%
H
3.3
13.2
|
| Ideaya Biosciences Inc |
|
3,749.6
|
38.9
|
L
 1.2%
H
38.0
39
|
L
 3.4%
H
37.1
39.5
|
L
 -0.6%
H
37.1
42.7
|
L
 24.4%
H
31.8
42.7
|
L
 51.0%
H
25.4
42.7
|
L
 39.0%
H
13.5
47.7
|
L
 48.0%
H
8.1
47.7
|
L
H
3.0
47.7
|
| InflaRx N.V. |
|
312.4
|
2.1
|
L
 1.4%
H
2.1
2.2
|
L
 1.4%
H
2.0
2.2
|
L
 5.0%
H
2.0
2.5
|
L
 17.1%
H
1.6
2.6
|
L
 58.2%
H
0.8
3.0
|
L
 -36.7%
H
0.7
3.4
|
L
 -20%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
54.6
|
4.8
|
L
 -1.6%
H
4.8
5.1
|
L
 -5.3%
H
4.6
5.4
|
L
 -14.3%
H
4.6
6.2
|
L
 -19.8%
H
4.6
6.3
|
L
 -41.7%
H
3.9
9.1
|
L
 -90.7%
H
3.9
59.3
|
L
 -97.1%
H
3.9
210
|
L
H
3.9
451.3
|
| Inhibikase Therapeutics Inc |
|
307.0
|
2.2
|
L
 -4.4%
H
2.2
2.3
|
L
 -6.0%
H
2.2
2.4
|
L
 -6.4%
H
2.2
2.6
|
L
 20.2%
H
1.8
2.6
|
L
 34.2%
H
1.3
2.6
|
L
 84.9%
H
0.8
4.2
|
L
 -82.1%
H
0.8
14.0
|
L
H
0.8
70.8
|
| Immix Biopharma Inc |
|
892.1
|
12.5
|
L
 -0.2%
H
12.1
12.7
|
L
 2.7%
H
11.8
12.8
|
L
 -5.2%
H
11.8
15.1
|
L
 43%
H
7.8
15.1
|
L
 469.4%
H
2.0
15.1
|
L
 317.1%
H
1.3
15.1
|
L
H
0.7
15.1
|
L
H
0.7
15.1
|
| Immunome Inc |
|
2,847.4
|
25.1
|
L
 4.6%
H
24.2
25.3
|
L
 1.6%
H
23.4
25.3
|
L
 -10.7%
H
23.4
29.7
|
L
 33.8%
H
19
30.1
|
L
 167.0%
H
9.4
30.1
|
L
 252.1%
H
5.2
31.0
|
L
 5.2%
H
2.1
31.0
|
L
H
2.1
63.8
|
| Imunon Inc |
|
8.0
|
1.4
|
L
 5.2%
H
1.4
1.5
|
L
 -2.7%
H
1.3
1.6
|
L
 -9.5%
H
1.3
1.8
|
L
 -21.4%
H
1.3
2.2
|
L
 -71.3%
H
1.3
5.6
|
L
 -91.3%
H
1.3
54.8
|
L
 -99.4%
H
1.3
236.3
|
L
 -100.0%
H
1.3
4095
|
| Immuneering Corp (Class A) |
|
287.3
|
4.4
|
L
 -0.9%
H
4.4
4.6
|
L
 4.0%
H
4.2
4.6
|
L
 -15.4%
H
4.2
5.4
|
L
 0.7%
H
4.0
5.7
|
L
 -52.1%
H
3.9
10.1
|
L
 -43.7%
H
1
10.1
|
L
 -82.4%
H
1
33.3
|
L
H
1
34.0
|
| Immatics N.V |
|
1,327.4
|
8.7
|
L
 1.2%
H
8.6
8.9
|
L
 -0.8%
H
8.3
9.0
|
L
 2.0%
H
8.3
9.9
|
L
 -10.8%
H
8.2
10.9
|
L
 30.2%
H
6.5
12.4
|
L
 -27.8%
H
3.3
13.8
|
L
 -35.9%
H
3.3
15.0
|
L
H
3.3
18.4
|
| Immunic Inc |
|
147.8
|
10.8
|
L
 2.0%
H
10.5
11.1
|
L
 -5.2%
H
10.0
11.5
|
L
 -32.7%
H
10.0
17.2
|
L
 -23.7%
H
10.0
17.4
|
L
 28.2%
H
5.1
17.4
|
L
 -26.3%
H
5.1
21.1
|
L
 -88.1%
H
5.1
145
|
L
 -99.5%
H
5.1
3900
|
| Immunovant Inc |
|
7,679.6
|
37.2
|
L
 0.6%
H
36.6
37.5
|
L
 -0.5%
H
36.1
38.4
|
L
 -16.2%
H
36.1
45.1
|
L
 5.2%
H
35.9
45.4
|
L
 151.6%
H
14.6
45.4
|
L
 80.5%
H
12.7
45.6
|
L
 331.8%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
10.4
|
1.1
|
L
 -1.9%
H
1.1
1.1
|
L
 -0.9%
H
1.0
1.1
|
L
 -12.4%
H
1.0
1.3
|
L
 -25.9%
H
0.9
1.5
|
L
 -47%
H
0.9
2.7
|
L
 -8.6%
H
0.1
4.2
|
L
 -84.3%
H
0.1
9.4
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
5,308.2
|
112.0
|
L
 2.5%
H
108.9
113.2
|
L
 2.5%
H
99.1
113.2
|
L
 13%
H
94
131.0
|
L
 20.4%
H
77.5
131.0
|
L
 305.9%
H
26.2
155.3
|
L
 473.1%
H
10.8
155.3
|
L
 214.5%
H
7.7
155.3
|
L
H
7.7
155.3
|
| Incyte |
|
25,266.3
|
124.7
|
L
 -0.5%
H
124.2
127.4
|
L
 2.6%
H
120.0
128.7
|
L
 -2.0%
H
120.0
130.8
|
L
 26.9%
H
99.8
132.6
|
L
 44.1%
H
81.1
132.6
|
L
 106.5%
H
50.3
132.6
|
L
 64.2%
H
50.3
132.6
|
L
 46.5%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
411.7
|
3.1
|
L
 -13.0%
H
2.9
3.6
|
L
 11.6%
H
2.7
4.1
|
L
 123.9%
H
1.1
4.1
|
L
 -20.8%
H
0.9
4.1
|
L
 11.2%
H
0.9
8.6
|
L
 -11.7%
H
0.3
13.4
|
L
 -64.7%
H
0.3
13.4
|
L
 -99.4%
H
0.3
8800
|
| Indivior PLC |
|
4,193.7
|
35.5
|
L
 1.9%
H
34.8
35.6
|
L
 3.0%
H
33.7
35.9
|
L
 -6.0%
H
33.7
38.5
|
L
 -7.2%
H
33.7
42.8
|
L
 57.8%
H
22.3
42.8
|
L
 61.7%
H
7.3
42.8
|
L
 1116.8%
H
2.8
42.8
|
L
 734.0%
H
0.4
42.8
|
| MiNK Therapeutics Inc |
|
62.5
|
12.3
|
L
 1.7%
H
11.6
12.7
|
L
 2.1%
H
11.3
12.7
|
L
 5.4%
H
10.8
12.7
|
L
 0.9%
H
10.2
12.7
|
L
 -18.8%
H
8.5
17.0
|
L
 -7.9%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| InMed Pharma Inc |
|
7.6
|
1.4
|
L
 1.5%
H
1.4
1.5
|
L
 7.0%
H
1.3
1.5
|
L
 -12.7%
H
1.3
1.6
|
L
 -7.4%
H
1.3
2.3
|
L
 -39.7%
H
0.6
2.5
|
L
 -91.5%
H
0.6
41.6
|
L
 -99.9%
H
0.6
1185
|
L
 -99.9%
H
0.6
32175
|
| INmune Bio Inc |
|
63.6
|
2.3
|
L
 -1.7%
H
2.3
2.4
|
L
 3.2%
H
2.0
2.4
|
L
 6.0%
H
2.0
2.6
|
L
 57.9%
H
1.3
2.6
|
L
 20.5%
H
1.1
2.6
|
L
 -65.4%
H
1.1
14.7
|
L
 -86.7%
H
1.1
21.7
|
L
H
1.1
30.4
|
| Inovio Pharma Inc |
|
128.2
|
1.2
|
L
H
1.2
1.3
|
L
 -0.8%
H
1.1
1.3
|
L
 2.5%
H
1.1
1.5
|
L
 10.7%
H
0.6
1.5
|
L
 -46.1%
H
0.6
2.7
|
L
 217.9%
H
0.3
14.8
|
L
 -84.1%
H
0.3
14.8
|
L
 -86.8%
H
0.3
33.8
|
| Insmed Inc |
|
26,424.2
|
121
|
L
 0.8%
H
120.9
124.5
|
L
 -6.5%
H
118.3
130.8
|
L
 -3.3%
H
117.2
130.8
|
L
 26.3%
H
95.3
137.7
|
L
 -16.4%
H
90.4
212.8
|
L
 374.1%
H
21.9
212.8
|
L
 365.2%
H
16.0
212.8
|
L
 716.5%
H
10.2
212.8
|
| Innoviva Inc |
|
1,520.0
|
21.0
|
L
 -0.5%
H
21
21.3
|
L
 1.8%
H
20.5
21.4
|
L
 0.2%
H
20.5
21.5
|
L
 -6.5%
H
20.2
24.2
|
L
 9.6%
H
16.5
25.1
|
L
 64.9%
H
12.2
25.1
|
L
 32.6%
H
10.6
25.1
|
L
 86.9%
H
7.6
25.1
|
| Ionis Pharma Inc |
|
7,461.7
|
44.9
|
L
 1.0%
H
44.2
45.3
|
L
 -17.2%
H
44.2
55.5
|
L
 -23.6%
H
44.2
64.2
|
L
 -39.4%
H
44.2
86.7
|
L
 -26.4%
H
44.2
86.7
|
L
 5.5%
H
24.0
86.7
|
L
 24.1%
H
24.0
86.7
|
L
 32.0%
H
24.0
86.7
|
| Iovance Biotherapeutics Inc |
|
4,615.8
|
10.2
|
L
 -0.6%
H
10.0
10.6
|
L
 18.5%
H
8.5
11.0
|
L
 13.4%
H
7.7
11.0
|
L
 160.6%
H
3.8
11.0
|
L
 397.1%
H
1.8
11.0
|
L
 94.1%
H
1.6
18.3
|
L
 -57.5%
H
1.6
28.0
|
L
 22.9%
H
1.6
54.2
|
| MindWalk Holdings Corp |
|
69.3
|
1.5
|
L
 8.1%
H
1.4
1.5
|
L
 13.1%
H
1.1
1.5
|
L
 7.3%
H
1.1
1.5
|
L
 -3.9%
H
1.1
1.7
|
L
 -15.0%
H
1.0
3.0
|
L
 -29.7%
H
0.3
3.3
|
L
 -77.9%
H
0.3
6.9
|
L
 7250%
H
0.3
33.3
|
| Century Therapeutics Inc |
|
335.0
|
1.9
|
L
 -0.5%
H
1.8
1.9
|
L
 -4.6%
H
1.8
2.1
|
L
 -8.4%
H
1.8
2.3
|
L
 -19.2%
H
1.8
2.6
|
L
 285.4%
H
0.4
3.0
|
L
 -17.4%
H
0.3
5.5
|
L
 -91.5%
H
0.3
25.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,629.5
|
68.5
|
L
 -1.5%
H
67.2
69.8
|
L
 -2.2%
H
66.7
72.1
|
L
 -13.1%
H
66.7
83.6
|
L
 -3.3%
H
66.7
83.6
|
L
 12.7%
H
40
99.5
|
L
 39.8%
H
25.6
99.5
|
L
 46.3%
H
11.6
99.5
|
L
H
11.6
190.9
|
| Ironwood Pharma Inc (Class A) |
|
728.7
|
4.4
|
L
 1.2%
H
4.3
4.6
|
L
 8.1%
H
4.0
4.6
|
L
 6.5%
H
3.9
4.6
|
L
 24.6%
H
3.6
4.9
|
L
 212.8%
H
1.3
5.8
|
L
 -52.0%
H
0.5
15.7
|
L
 -64.3%
H
0.5
15.7
|
L
 -65.1%
H
0.5
17.7
|
| Invivyd Inc |
|
300.7
|
1.0
|
L
 34.2%
H
0.8
1.1
|
L
 29.1%
H
0.7
1.1
|
L
 7.4%
H
0.7
1.1
|
L
 5.2%
H
0.5
1.1
|
L
 -16.4%
H
0.5
3.1
|
L
 -41.7%
H
0.4
5.2
|
L
 -97.8%
H
0.4
78.8
|
L
H
0.4
78.8
|
| I-Mab (ADR) |
|
185.6
|
1.6
|
L
 0.6%
H
1.6
1.6
|
L
 1.3%
H
1.6
1.7
|
L
 -15.7%
H
1.6
2.0
|
L
 7.3%
H
1.5
2.3
|
L
 -57.5%
H
1.5
6.8
|
L
 28.8%
H
0.6
6.8
|
L
 -97.8%
H
0.6
78.4
|
L
H
0.6
85.4
|
| Immunocore Holdings PLC (ADR) |
|
1,657.2
|
32.2
|
L
 0.6%
H
31.9
32.5
|
L
 -1.3%
H
31.1
33.9
|
L
 -11.3%
H
31.1
38.0
|
L
 12.5%
H
28.2
38.0
|
L
 -1.3%
H
27.6
40.7
|
L
 -35.0%
H
23.2
77.0
|
L
 -8.4%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
42.7
|
0.3
|
L
H
0.3
0.3
|
L
 -21.6%
H
0.3
0.4
|
L
 -25.6%
H
0.3
0.4
|
L
 -21.6%
H
0.3
0.5
|
L
 -82.0%
H
0.3
3.5
|
L
 -85.4%
H
0.3
3.5
|
L
 -92.0%
H
0.3
5
|
L
 -90.1%
H
0.3
8.0
|
| Immuron Ltd (ADR) |
|
10.0
|
1.2
|
L
 1.6%
H
1.2
1.3
|
L
 -14.5%
H
1.2
1.4
|
L
 5.1%
H
1.1
2.0
|
L
 17.0%
H
1.0
2.0
|
L
 -34.7%
H
0.7
2.4
|
L
 -37.7%
H
0.7
6.0
|
L
 -74.4%
H
0.7
6.0
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
207.8
|
1.9
|
L
 -2.1%
H
1.8
1.9
|
L
 -0.5%
H
1.8
2.2
|
L
 -11%
H
1.8
2.3
|
L
 2.8%
H
1.6
2.7
|
L
 -0.5%
H
1.2
2.7
|
L
 -33.8%
H
1.2
3.5
|
L
 -76.9%
H
1.2
7.9
|
L
H
1.2
12.0
|
| Inventiva (ADR) |
|
862.3
|
3.7
|
L
 -3.4%
H
3.6
3.7
|
L
 -9.2%
H
3.6
4.0
|
L
 -21.5%
H
3.6
5.1
|
L
 2.2%
H
3.4
5.1
|
L
 -35.4%
H
3.4
8.0
|
L
 -4.7%
H
1.5
8.0
|
L
 -73.9%
H
1.5
15.8
|
L
H
1.5
19.1
|
| Jaguar Health Inc |
|
1.2
|
2.7
|
L
 -1.5%
H
2.5
2.9
|
L
 761.3%
H
0.2
3.7
|
L
 206.9%
H
0.2
3.7
|
L
 18.7%
H
0.2
3.7
|
L
 -95.9%
H
0.2
85.4
|
L
 -100.0%
H
0.2
27772.5
|
L
 -100.0%
H
0.2
10473750
|
L
 -100.0%
H
0.2
880621875
|
| Janux Therapeutics Inc |
|
1,039.9
|
17.0
|
L
 2.5%
H
16.5
17.1
|
L
 -0.5%
H
16.0
17.6
|
L
 -1.6%
H
16.0
20.3
|
L
 19.6%
H
14.2
20.3
|
L
 -27.5%
H
12.1
35.3
|
L
 73.9%
H
5.7
71.7
|
L
 -32.4%
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jazz Pharma PLC |
|
15,674.3
|
241.5
|
L
 0.3%
H
238.5
244.5
|
L
 -1.8%
H
238.5
248.4
|
L
 -2.9%
H
236
266.4
|
L
 7.5%
H
222.9
266.4
|
L
 88.2%
H
125.8
266.4
|
L
 80.6%
H
95.5
266.4
|
L
 87.7%
H
95.5
266.4
|
L
 91.2%
H
86.9
266.4
|
| Jasper Therapeutics Inc |
|
20.0
|
0.6
|
L
 -3.2%
H
0.6
0.7
|
L
 -9.1%
H
0.6
0.7
|
L
 -13.0%
H
0.6
0.7
|
L
 33.3%
H
0.3
1.0
|
L
 -76%
H
0.3
2.7
|
L
 -22.1%
H
0.3
31.0
|
L
 -94%
H
0.3
31.0
|
L
H
0.3
31.0
|
| Jupiter Wellness Inc |
|
55.1
|
1.5
|
L
 9.6%
H
1.4
1.5
|
L
 6.5%
H
1.3
1.5
|
L
 43.7%
H
1.0
1.5
|
L
 -8.6%
H
0.9
1.6
|
L
 377.4%
H
0.1
7.2
|
L
 -3.3%
H
0.1
7.5
|
L
 8.8%
H
0.1
7.5
|
L
H
0.1
8.9
|
| Kala Pharma Inc |
|
10.8
|
0.6
|
L
 3.7%
H
0.5
0.6
|
L
 -1.8%
H
0.5
0.6
|
L
 -33.3%
H
0.5
1.1
|
L
 -84.5%
H
0.5
3.7
|
L
 -99.9%
H
0.5
988.5
|
L
 -99.9%
H
0.5
1030
|
L
 -100.0%
H
0.5
7907.8
|
L
H
0.5
66943.3
|
| Kamada Ltd |
|
504.4
|
8.7
|
L
 -1.2%
H
8.7
9.0
|
L
 10.4%
H
8
9.0
|
L
 9.0%
H
7.9
9.0
|
L
 19.6%
H
6.9
9.0
|
L
 26.5%
H
6.5
9.4
|
L
 65.5%
H
4.1
9.4
|
L
 64.9%
H
3.7
9.4
|
L
 82.1%
H
3.7
13.3
|
| Kiniksa Pharma Ltd (Class A) |
|
6,096.0
|
78.1
|
L
 1.2%
H
75.9
78.7
|
L
 2.4%
H
74.5
79.8
|
L
 -0.4%
H
74.5
81.4
|
L
 41.8%
H
55.7
82.9
|
L
 120.6%
H
35.2
82.9
|
L
 361.5%
H
14.1
82.9
|
L
 560.4%
H
7.4
82.9
|
L
H
5.0
82.9
|
| Kodiak Sciences Inc |
|
2,037.6
|
32.4
|
L
 -0.9%
H
32
33.3
|
L
 -1.4%
H
31.5
33.9
|
L
 -18.6%
H
31.5
40.9
|
L
 -10.3%
H
31.5
46.9
|
L
 240.2%
H
9.8
47.8
|
L
 1451.2%
H
1.4
47.8
|
L
 -67.5%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Kiora Pharma Inc |
|
11.9
|
2.7
|
L
 -2.9%
H
2.6
2.8
|
L
 1.1%
H
2.6
2.9
|
L
 2.3%
H
2.5
2.9
|
L
 5.9%
H
2.3
2.9
|
L
 5.9%
H
1.8
3.0
|
L
 387.3%
H
0.4
5.6
|
L
 -96.3%
H
0.4
93.6
|
L
 -99.7%
H
0.4
2340
|
| Karyopharm Therapeutics Inc |
|
42.2
|
1.9
|
L
 -1.1%
H
1.8
1.9
|
L
 15.5%
H
1.5
1.9
|
L
 2.2%
H
1.2
2.1
|
L
 -79.4%
H
1.2
10.9
|
L
 -65.6%
H
1.2
11.0
|
L
 -89.6%
H
0.6
29.3
|
L
 -98.0%
H
0.6
221.0
|
L
 -98.7%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
227.6
|
11.5
|
L
 2.6%
H
11.1
11.6
|
L
 3.6%
H
10.7
11.6
|
L
 4.8%
H
10.6
11.8
|
L
 7.8%
H
9.7
12.2
|
L
 -26.2%
H
9.7
22.6
|
L
 -65.7%
H
9.1
73
|
L
 -60.8%
H
9.1
73
|
L
H
9.1
88.8
|
| Krystal Biotech Inc |
|
9,881.6
|
333.9
|
L
 -0.8%
H
332.4
341.2
|
L
 -3.8%
H
331.8
352.5
|
L
 -0.9%
H
331.8
373.3
|
L
 -4.1%
H
297.0
382.5
|
L
 104.1%
H
158.1
382.5
|
L
 185.7%
H
94.0
382.5
|
L
 504.3%
H
38.9
382.5
|
L
H
8.0
382.5
|
| TuHURA Biosciences Inc |
|
138.9
|
2.2
|
L
 3.8%
H
2.1
2.2
|
L
 6.3%
H
2.0
2.2
|
L
 -1.8%
H
2.0
2.3
|
L
 -15.2%
H
2.0
2.8
|
L
 -16.5%
H
0.4
3.4
|
L
 -98.6%
H
0.2
160.5
|
L
 -99.9%
H
0.2
2677.5
|
L
 -100.0%
H
0.2
119304.5
|
| Pasithea Therapeutics Corp |
|
17.0
|
0.5
|
L
 -1.9%
H
0.5
0.5
|
L
 -3.8%
H
0.5
0.6
|
L
 8.5%
H
0.5
0.6
|
L
 2%
H
0.4
0.6
|
L
 -30.1%
H
0.3
2.1
|
L
 8.5%
H
0.3
9.3
|
L
 -83.4%
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kura Oncology Inc |
|
1,031.9
|
11.6
|
L
 -1.1%
H
11.5
12
|
L
 1.8%
H
11.0
12.2
|
L
 -0.9%
H
11.0
13.9
|
L
 16.8%
H
8.8
13.9
|
L
 40.6%
H
7.4
13.9
|
L
 28.9%
H
5.4
24.2
|
L
 -42.2%
H
5.4
24.2
|
L
 67.9%
H
4
43
|
| Kymera Therapeutics Inc |
|
9,784.3
|
117.7
|
L
 -0.1%
H
116.6
119.5
|
L
 2.4%
H
110.3
122.1
|
L
 -3.2%
H
110.3
127.9
|
L
 30.1%
H
91.7
130.1
|
L
 139.5%
H
47.9
130.1
|
L
 575.9%
H
9.6
130.1
|
L
 94.5%
H
9.6
130.1
|
L
H
9.6
130.1
|
| Kazia Therapeutics Ltd (ADR) |
|
165.6
|
10.7
|
L
 2.5%
H
10.2
10.8
|
L
 -4.8%
H
10.2
11.6
|
L
 -22.1%
H
10.2
17.2
|
L
 -23.2%
H
10.2
17.2
|
L
 37.2%
H
4.9
17.4
|
L
 -78.9%
H
2.9
79
|
L
 -98%
H
2.9
614
|
L
 -97.3%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
7.2
|
3.4
|
L
 5.6%
H
3.2
3.5
|
L
 -13.9%
H
2.8
4.2
|
L
 -69.7%
H
2.8
14.4
|
L
 -57.8%
H
2.8
14.4
|
L
 -81.6%
H
2.8
23.3
|
L
 -74.8%
H
2.8
102.8
|
L
 -96.4%
H
2.8
107.9
|
L
 -94.2%
H
2.8
1143
|
| Lifecore Biomedical Inc |
|
169.6
|
4.5
|
L
 0.5%
H
4.2
4.5
|
L
 8.7%
H
4.0
4.6
|
L
 -0.9%
H
4
4.8
|
L
 -19.1%
H
4
6.0
|
L
 -43.1%
H
3.6
9.0
|
L
 -44.8%
H
3.6
9.0
|
L
 -56.9%
H
1.5
12.0
|
L
 -64.2%
H
1.5
15.6
|
| Lifevantage Corp |
|
77.9
|
6.2
|
L
 -2.1%
H
6.2
6.4
|
L
 0.8%
H
6.1
6.5
|
L
 -6.5%
H
5.9
6.9
|
L
 -3.0%
H
5.8
7
|
L
 -41.5%
H
3.9
11.7
|
L
 -9.1%
H
3.9
27.4
|
L
 -8.7%
H
3.0
27.4
|
L
 -41.1%
H
2.9
27.4
|
| Ligand Pharma Inc (Class B) |
|
5,782.7
|
290.1
|
L
 2.3%
H
282.5
290.5
|
L
 2.0%
H
270.8
290.5
|
L
 0.9%
H
270.8
294
|
L
 5.5%
H
245
326.6
|
L
 74.2%
H
163.5
326.6
|
L
 375.1%
H
49.3
326.6
|
L
 228.9%
H
46.8
326.6
|
L
 283.7%
H
36.9
326.6
|
| Longeveron Inc (Class A) |
|
7.8
|
2.5
|
L
 -1.6%
H
2.3
2.5
|
L
 -66.6%
H
2.3
7.6
|
L
 -70.4%
H
2.3
8.7
|
L
 -70.1%
H
2.3
8.9
|
L
 -68.8%
H
2.3
12.3
|
L
 -98.9%
H
2.3
429.8
|
L
 -99.3%
H
2.3
4500
|
L
H
2.3
4500
|
| Atyr Pharma Inc |
|
36.3
|
0.4
|
L
 2.8%
H
0.4
0.4
|
L
 -14.0%
H
0.4
0.4
|
L
 -26%
H
0.4
0.6
|
L
 -17.8%
H
0.4
0.7
|
L
 -62.6%
H
0.4
1.1
|
L
 -77.2%
H
0.4
7.3
|
L
 -96.4%
H
0.4
13.1
|
L
 -99.2%
H
0.4
90.9
|
| Lixte biotech Holdings Inc |
|
67.3
|
3.7
|
L
 1.9%
H
3.6
3.7
|
L
 4.0%
H
3.2
3.7
|
L
 -12.6%
H
3.2
4.6
|
L
 -51.6%
H
3.1
8.4
|
L
 -32.5%
H
2.4
8.4
|
L
 88.7%
H
0.6
8.4
|
L
 -82.8%
H
0.6
49.5
|
L
 -70.8%
H
0.6
110.4
|
| Lipocine Inc |
|
18.5
|
2.2
|
L
 1.4%
H
2.2
2.3
|
L
 -1.3%
H
2.1
2.3
|
L
 7.2%
H
2.1
2.5
|
L
 -3.9%
H
2.0
2.7
|
L
 -22.2%
H
1.8
12.4
|
L
 -30.4%
H
1.8
12.4
|
L
 -88.1%
H
1.8
32.1
|
L
 -96.3%
H
1.8
100.3
|
| Leap Therapeutics Inc |
|
366.4
|
3.4
|
L
 -5.6%
H
3.4
4.0
|
L
 50.4%
H
2.1
4.0
|
L
 185.7%
H
1.2
4.0
|
L
 359.5%
H
0.6
4.0
|
L
 1072.4%
H
0.3
4.0
|
L
 142.9%
H
0.2
5
|
L
 -87.7%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Liquidia Corp |
|
5,946.1
|
66.4
|
L
 -0.7%
H
65.7
67.4
|
L
 -0.5%
H
62.9
70.8
|
L
 -6.5%
H
62.9
73.1
|
L
 -6.5%
H
62.9
93.6
|
L
 179.4%
H
21.1
93.6
|
L
 957.8%
H
5.7
93.6
|
L
 2494.9%
H
2.5
93.6
|
L
H
2.3
93.6
|
| Larimar Therapeutics Inc |
|
397.9
|
3.8
|
L
 1.1%
H
3.8
3.9
|
L
 -2.3%
H
3.7
4.1
|
L
 -7.9%
H
3.7
4.2
|
L
 5.2%
H
2.9
4.5
|
L
 -8.8%
H
2.7
6.4
|
L
 -7.9%
H
1.6
13.7
|
L
 -67.2%
H
1.5
13.7
|
L
 -90.4%
H
1.5
148.3
|
| Lisata Therapeutics Inc |
|
16.9
|
1.6
|
L
 -8.2%
H
1.5
1.7
|
L
 -4.3%
H
1.4
2.6
|
L
 39.3%
H
1.1
2.6
|
L
 -55.7%
H
1.0
3.9
|
L
 -33.1%
H
1.0
5.1
|
L
 -20.4%
H
1.0
5.1
|
L
 -91.3%
H
1.0
18.6
|
L
 -97.8%
H
1.0
174.8
|
| Lantern Pharma Inc |
|
19.2
|
1.5
|
L
 -3.2%
H
1.5
1.6
|
L
 -12.3%
H
1.5
2.0
|
L
 -34.5%
H
1.5
2.4
|
L
 -60.4%
H
1.5
4.3
|
L
 -62.8%
H
1.1
4.7
|
L
 -60.9%
H
1.1
12.0
|
L
 -86.8%
H
1.1
12.5
|
L
H
1.1
24.8
|
| Lexicon Pharma Inc |
|
907.7
|
2.0
|
L
 -0.5%
H
2
2.1
|
L
 2%
H
1.9
2.1
|
L
 -6.4%
H
1.9
2.4
|
L
 1.5%
H
1.9
2.7
|
L
 71.4%
H
1.1
2.7
|
L
 75.9%
H
0.3
3.7
|
L
 -56.4%
H
0.3
6.3
|
L
 -89.4%
H
0.3
19.6
|
| Lyell Immunopharma Inc |
|
267.8
|
10.9
|
L
 -0.7%
H
10.6
11.2
|
L
 -8.6%
H
10.5
12.4
|
L
 -28.8%
H
10.5
16.2
|
L
 -14.2%
H
10.5
17.2
|
L
 -16.5%
H
10.5
45
|
L
 -62.3%
H
7.7
65.1
|
L
 -95.0%
H
7.7
309.9
|
L
H
7.7
396.8
|
| Legend Biotech Corp (ADR) |
|
3,603.9
|
18.5
|
L
 5.2%
H
17.8
18.6
|
L
 -0.6%
H
16.9
18.8
|
L
 -12.8%
H
16.9
22.4
|
L
 -33.7%
H
16.9
30.3
|
L
 -45.5%
H
16.2
37.5
|
L
 -71.2%
H
16.2
70.8
|
L
 -58.0%
H
16.2
77.3
|
L
H
16.2
77.3
|
| Mustang Bio Inc |
|
4.2
|
0.6
|
L
 1.9%
H
0.5
0.6
|
L
 7.8%
H
0.5
0.6
|
L
 -3.5%
H
0.5
0.6
|
L
 -15.4%
H
0.5
0.8
|
L
 -67.1%
H
0.5
1.9
|
L
 -99.5%
H
0.1
124.3
|
L
 -100.0%
H
0.1
2112.7
|
L
H
0.1
10012.5
|
| Microbot Medical Inc |
|
90.7
|
1.4
|
L
 -0.7%
H
1.3
1.4
|
L
 -6.9%
H
1.3
1.5
|
L
 -9.4%
H
1.3
1.6
|
L
 -27.4%
H
1.3
2.0
|
L
 -57.7%
H
1.3
3.7
|
L
 -3.6%
H
0.8
4.7
|
L
 -81.5%
H
0.8
9.6
|
L
 -99.3%
H
0.8
234.9
|
| Moleculin Biotech Inc |
|
10.1
|
0.5
|
L
 -32.5%
H
0.5
0.7
|
L
 -27.8%
H
0.5
0.8
|
L
 -11.9%
H
0.5
0.9
|
L
 -81.9%
H
0.2
3.7
|
L
 -94.8%
H
0.2
15.8
|
L
 -99.6%
H
0.2
3318.8
|
L
 -100.0%
H
0.2
3318.8
|
L
 -100.0%
H
0.2
14265
|
| Seres Therapeutics Inc |
|
40.9
|
4.1
|
L
 1.8%
H
3.9
4.3
|
L
 -18.8%
H
3.9
5.1
|
L
 -10.9%
H
3.9
6.0
|
L
 -38.4%
H
3.9
8.3
|
L
 -76.7%
H
3.9
30.0
|
L
 52.4%
H
0.4
30.0
|
L
 -39.6%
H
0.4
30.0
|
L
 -71.4%
H
0.4
38.5
|
| Madrigal Pharma Inc |
|
12,059.4
|
522.0
|
L
 -1.8%
H
516.0
536.0
|
L
 -2.3%
H
513.4
541.3
|
L
 0.6%
H
506.3
552.1
|
L
 3.2%
H
447.0
569.4
|
L
 18.7%
H
393.6
615
|
L
 223.4%
H
119.8
615
|
L
 565.6%
H
52.3
615
|
L
 5027.3%
H
10.2
615
|
| MediWound Ltd |
|
171.8
|
13.3
|
L
 -0.7%
H
13
13.5
|
L
 1.5%
H
13
14
|
L
 1.5%
H
12.5
14.1
|
L
 -6.5%
H
12.5
15.4
|
L
 -21.6%
H
12.5
20.0
|
L
 47.1%
H
7.5
24
|
L
 -44.4%
H
7.1
28.1
|
L
 -75.1%
H
7.1
60.1
|
| MEI Pharma Inc |
|
43.6
|
1.3
|
L
 13.3%
H
1.1
1.3
|
L
 15.3%
H
1
1.3
|
L
 36.2%
H
1.0
1.3
|
L
 54.2%
H
0.8
1.3
|
L
 -54.3%
H
0.7
3.0
|
L
 -79.5%
H
0.7
9
|
L
 -97.6%
H
0.7
71
|
L
 -96.4%
H
0.7
102.8
|
| Macrogenics Inc |
|
262.4
|
4.1
|
L
 -0.5%
H
4.1
4.2
|
L
 3%
H
4.0
4.2
|
L
 1.2%
H
3.9
4.5
|
L
 -0.2%
H
3.4
5.1
|
L
 154.3%
H
1.3
5.1
|
L
 -9.3%
H
1.0
21.9
|
L
 -80.6%
H
1.0
22.8
|
L
 -86.8%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
9.7
|
0.5
|
L
 -6.3%
H
0.4
0.5
|
L
 12.5%
H
0.4
0.5
|
L
 15.4%
H
0.4
0.5
|
L
 40.6%
H
0.3
1.3
|
L
 -80%
H
0.2
2.8
|
L
 -51.1%
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
96.5
|
L
 -0.4%
H
94.6
99.7
|
L
 -9.2%
H
94.6
109.8
|
L
 -11.9%
H
94.6
113.9
|
L
 17.0%
H
83.9
117.9
|
L
 162.5%
H
32.2
117.9
|
L
 389.9%
H
16.6
117.9
|
L
 -18.0%
H
5.1
135.8
|
L
H
5.1
336
|
| MeiraGTx Holdings PLC |
|
1,256.2
|
13.1
|
L
 -1.3%
H
12.8
13.5
|
L
 2.3%
H
12.5
13.5
|
L
 -10.0%
H
12.5
15.3
|
L
 15.6%
H
11.2
15.4
|
L
 73.0%
H
6.6
15.4
|
L
 148.7%
H
3.5
15.4
|
L
 1.6%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mirum Pharma Inc |
|
5,973.8
|
92
|
L
 0.2%
H
91.0
94.6
|
L
 -6.3%
H
91.0
100.5
|
L
 -5.2%
H
91.0
103.3
|
L
 -14.1%
H
88.9
130
|
L
 23.7%
H
63.2
130
|
L
 196.0%
H
23.1
130
|
L
 384.2%
H
12.8
130
|
L
H
6.5
130
|
| Milestone Pharma Inc |
|
114.5
|
0.9
|
L
H
0.9
0.9
|
L
 -6.1%
H
0.9
1.0
|
L
 -10.7%
H
0.9
1.3
|
L
 -29.2%
H
0.9
1.4
|
L
 -52.1%
H
0.9
3.1
|
L
 -68.6%
H
0.6
3.5
|
L
 -83.5%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,068.1
|
12.6
|
L
 1.3%
H
12.2
12.7
|
L
 0.3%
H
11.9
13
|
L
 -20.9%
H
11.9
16.1
|
L
 -34.7%
H
11.9
23.3
|
L
 -76.7%
H
6.0
62.8
|
L
 -78.2%
H
6.0
65.0
|
L
 25.6%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mineralys Therapeutics Inc |
|
2,502.8
|
28.3
|
L
 1.0%
H
27.9
28.4
|
L
 0.4%
H
27.3
29.6
|
L
 9.9%
H
25.0
32.0
|
L
 14.9%
H
24.5
32.0
|
L
 -27.9%
H
22.3
47.7
|
L
 178.6%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Mannkind Corp |
|
1,125.4
|
3.5
|
L
 -1.1%
H
3.5
3.6
|
L
 -6.7%
H
3.5
3.8
|
L
 -17.8%
H
3.5
4.4
|
L
 -11.2%
H
3.5
4.6
|
L
 -35.5%
H
2.2
6.5
|
L
 -15.7%
H
2.2
7.6
|
L
 -21.9%
H
2.2
7.6
|
L
 0.3%
H
0.7
7.6
|
| Mind Medicine Inc |
|
5,277.9
|
39.3
|
L
 1.2%
H
38.0
39.5
|
L
 1%
H
36.7
43.8
|
L
 -13.5%
H
36.7
46.6
|
L
 60.5%
H
35.1
49.7
|
L
 334.5%
H
8.8
49.7
|
L
 897.0%
H
2.4
49.7
|
L
 10.0%
H
2.1
49.7
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
162.4
|
3.3
|
L
 -0.6%
H
3.0
3.4
|
L
 82.3%
H
1.9
3.9
|
L
 140.9%
H
1.4
3.9
|
L
 150%
H
1.3
3.9
|
L
 159.8%
H
1.2
3.9
|
L
 57.9%
H
1.1
3.9
|
L
 -13.6%
H
1.1
4.7
|
L
 -50.7%
H
1.1
14.5
|
| Monopar Therapeutics Inc |
|
642.5
|
95.7
|
L
 -0.8%
H
95.0
98.2
|
L
 -13.2%
H
95.0
112.0
|
L
 -13.7%
H
95.0
121.0
|
L
 41.9%
H
66.8
124.8
|
L
 51.2%
H
50.1
124.8
|
L
 3133.8%
H
1.4
124.8
|
L
 278.3%
H
1.4
124.8
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
20.0
|
1.2
|
L
 1.7%
H
1.2
1.2
|
L
 4.4%
H
1.1
1.2
|
L
 -1.6%
H
1.1
1.6
|
L
 -9.8%
H
1.1
1.7
|
L
 26.3%
H
0.8
2.5
|
L
 -77.6%
H
0.8
6.2
|
L
 -93.1%
H
0.7
19
|
L
 -98.2%
H
0.7
135.5
|
| Moderna |
|
69,043.9
|
172.9
|
L
 12.3%
H
159.1
176.9
|
L
 20.1%
H
139.0
176.9
|
L
 29.7%
H
130
176.9
|
L
 170.4%
H
52.7
176.9
|
L
 585.2%
H
22.3
176.9
|
L
 67.0%
H
22.3
176.9
|
L
 -59.1%
H
22.3
458.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
1,068.3
|
7.2
|
L
 2.9%
H
6.9
7.2
|
L
 9.8%
H
6.5
7.5
|
L
 -13.5%
H
6.5
9.4
|
L
 37.9%
H
5.1
9.4
|
L
 165.6%
H
2.5
9.4
|
L
 -28.4%
H
1.7
11.6
|
L
 -84.5%
H
1.7
50.2
|
L
H
1.7
63.6
|
| Mannatech Inc |
|
15.7
|
8.2
|
L
 8.5%
H
7.4
8.2
|
L
 -0.7%
H
6.1
8.9
|
L
 30.2%
H
6.1
9.7
|
L
 50.4%
H
4.0
9.7
|
L
 -7.7%
H
3.8
12.5
|
L
 -26.0%
H
3.8
16.5
|
L
 -74.2%
H
3.8
43.1
|
L
 -52.9%
H
3.8
49.1
|
| MaxCyte Inc |
|
125.9
|
1.2
|
L
 2.5%
H
1.2
1.2
|
L
 5.2%
H
1.1
1.2
|
L
 -11.6%
H
1.1
1.4
|
L
 0.8%
H
1.0
1.5
|
L
 -19.7%
H
0.6
1.9
|
L
 -61.5%
H
0.6
5.5
|
L
 -91.1%
H
0.6
15
|
L
H
0.6
17.4
|
| TNF Pharma Inc |
|
6.4
|
0.8
|
L
 2.6%
H
0.7
0.8
|
L
 -54.4%
H
0.4
2.2
|
L
 -71.4%
H
0.4
2.8
|
L
 -80.6%
H
0.4
4.2
|
L
 -79.8%
H
0.4
8.9
|
L
 -99.9%
H
0.4
1920
|
L
 -100.0%
H
0.4
29850
|
L
 -100.0%
H
0.4
29850
|
| Mainz Biomed N.V. |
|
109.3
|
1.3
|
L
 -5.8%
H
1.3
1.4
|
L
 -3.0%
H
1.3
1.4
|
L
 -4.4%
H
1.3
1.7
|
L
 -26.1%
H
1.0
1.9
|
L
 -19.3%
H
0.3
4.9
|
L
 -99%
H
0.3
135.7
|
L
H
0.3
1200
|
L
H
0.3
1200
|
| Mesoblast Ltd (ADR) |
|
2,010.2
|
15.5
|
L
 2.3%
H
15.1
15.5
|
L
H
14.2
15.6
|
L
 -11.2%
H
14.2
18.3
|
L
 7.7%
H
13.1
19.4
|
L
 -9.0%
H
13.1
21.5
|
L
 1081.7%
H
1.0
22
|
L
 163.7%
H
1.0
22
|
L
 254.2%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
152.8
|
4.0
|
L
 -5.2%
H
4.0
4.1
|
L
 -4.6%
H
3.8
4.7
|
L
 -5.7%
H
3.8
4.7
|
L
 4.5%
H
3.7
4.7
|
L
 5.8%
H
3.5
5.4
|
L
 -10.1%
H
3.3
12.7
|
L
 -79.9%
H
3.3
32.0
|
L
 -83.8%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
46.3
|
0.3
|
L
 -3.3%
H
0.3
0.3
|
L
 3.6%
H
0.3
0.3
|
L
H
0.2
0.3
|
L
 -6.5%
H
0.2
0.4
|
L
 -83.3%
H
0.2
2.4
|
L
 -79.4%
H
0.2
5.0
|
L
 -88.4%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Natural Alternatives Intl Inc |
|
11.7
|
1.9
|
L
H
1.8
1.9
|
L
 -4.6%
H
1.8
2.2
|
L
 -9.7%
H
1.8
2.4
|
L
 -30.0%
H
1.8
2.7
|
L
 -40.1%
H
1.8
5.0
|
L
 -70.5%
H
1.8
7.4
|
L
 -86.8%
H
1.8
15.5
|
L
 -84.4%
H
1.8
19.9
|
| NewAmsterdam Pharma Co NV |
|
2,699.1
|
22.6
|
L
 0.4%
H
21.7
23.2
|
L
 -1.0%
H
21.0
23.2
|
L
 -18.7%
H
21.0
28.4
|
L
 -24.3%
H
21.0
37.4
|
L
 -15.4%
H
21.0
42.2
|
L
 128.3%
H
5.6
42.2
|
L
 129.2%
H
5.6
42.2
|
L
H
5.6
42.2
|
| Nature`s Sunshine Products Inc |
|
229.1
|
13.0
|
L
H
13.0
13.2
|
L
 -3.9%
H
12.8
13.7
|
L
 -9.1%
H
12.8
14.7
|
L
 -35.3%
H
12.8
22.4
|
L
 -19.5%
H
12.8
28.1
|
L
 -18.5%
H
10.8
28.1
|
L
 -9.7%
H
7.9
28.1
|
L
 -11.7%
H
5.5
28.1
|
| Nautilus biotech Inc |
|
122.2
|
1.0
|
L
 -1.0%
H
0.9
1.0
|
L
 -5.9%
H
0.9
1.0
|
L
 6.7%
H
0.9
1.1
|
L
 -57.9%
H
0.8
2.4
|
L
 41.2%
H
0.7
4.3
|
L
 -72.6%
H
0.6
4.3
|
L
 -86.1%
H
0.6
7.2
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
14,633.4
|
144.0
|
L
 -1.6%
H
143.5
146.3
|
L
 -7.9%
H
143.5
159.2
|
L
 -5.9%
H
143.5
160.4
|
L
 -9.1%
H
143.5
186.1
|
L
 -0.9%
H
122.1
186.1
|
L
 25.9%
H
84.2
186.1
|
L
 51.1%
H
71.9
186.1
|
L
 163.5%
H
37.3
186.1
|
| Minerva Neurosciences Inc |
|
175.7
|
3.7
|
L
 0.6%
H
3.6
3.8
|
L
 -11.3%
H
3.4
4.4
|
L
 -23.2%
H
3.4
5.6
|
L
 -17.7%
H
3.4
5.8
|
L
 81.3%
H
2.0
12.5
|
L
 -53.5%
H
1.2
13.5
|
L
 -74.4%
H
1.2
16.8
|
L
 -96.8%
H
1.2
121.7
|
| Nektar Therapeutics |
|
2,282.1
|
66.8
|
L
 -0.4%
H
66.7
69.8
|
L
 -4.2%
H
65.8
70
|
L
 -10.3%
H
65.8
77.8
|
L
 9.6%
H
61.3
77.8
|
L
 21.2%
H
33.4
109
|
L
 527.6%
H
6.2
109
|
L
 -72.7%
H
6.2
290.6
|
L
 -76.5%
H
6.2
1670.4
|
| Nkarta Inc |
|
206.3
|
2.9
|
L
 1.8%
H
2.8
2.9
|
L
 -1.0%
H
2.7
3.1
|
L
 16.6%
H
2.5
3.3
|
L
 0.7%
H
2.0
3.7
|
L
 44%
H
1.7
3.7
|
L
 70.4%
H
1.3
16.2
|
L
 -90.4%
H
1.3
31.5
|
L
H
1.3
79.2
|
| NLS Pharmaceutics Ltd |
|
17.2
|
3.0
|
L
 -5.7%
H
2.9
3.2
|
L
 -10%
H
2.9
3.4
|
L
 -11.9%
H
2.9
3.6
|
L
 -10.3%
H
2.9
4.6
|
L
 -85.4%
H
1.8
24.6
|
L
 -99.1%
H
1.2
406
|
L
 -99.7%
H
1.2
1132
|
L
H
1.2
2940
|
| Neoleukin Therapeutics Inc |
|
-
|
32.6
|
L
 1.5%
H
31.2
32.8
|
L
 -8.2%
H
31.2
36.3
|
L
 -14.3%
H
31.2
42.0
|
L
 3.3%
H
29.7
43.7
|
L
 89.4%
H
15.9
43.7
|
L
 119.8%
H
12.7
43.7
|
L
 -79.0%
H
7.5
160.3
|
L
 -87.9%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
8.9
|
L
 0.1%
H
8.9
9.1
|
L
 -1.9%
H
8.8
9.2
|
L
 -10.2%
H
8.8
10.0
|
L
 -2.3%
H
8.5
10.4
|
L
 20.7%
H
6.4
10.4
|
L
 89100%
H
0.0
10.4
|
L
 -63.7%
H
0.0
29.2
|
L
 -97.5%
H
0.0
1010
|
| MetaVia Inc |
|
11.0
|
1.7
|
L
 -3.5%
H
1.6
1.7
|
L
 0.6%
H
1.5
1.9
|
L
 16.0%
H
1.4
1.9
|
L
 4.4%
H
1.4
2.6
|
L
 -85.4%
H
1.0
14.9
|
L
 -96.4%
H
1.0
74.3
|
L
 -100.0%
H
1.0
10861.0
|
L
 -100.0%
H
1.0
1424940
|
| Nurix Therapeutics Inc |
|
2,637.1
|
25.4
|
L
 -0.1%
H
25.1
25.9
|
L
 1.2%
H
24.3
26.4
|
L
 -6.1%
H
24.3
27.5
|
L
 44.8%
H
17.8
28.2
|
L
 201.1%
H
8.2
28.2
|
L
 175.3%
H
4.2
29.6
|
L
 -20.7%
H
4.2
36.2
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
12.6
|
6.6
|
L
 4.3%
H
6.4
6.9
|
L
 -4.6%
H
5.6
7.5
|
L
 -5.4%
H
5.6
10.5
|
L
 -58.9%
H
5
19
|
L
 -72.9%
H
5
26.6
|
L
 -59.7%
H
5
52
|
L
H
5
163.6
|
L
H
5
163.6
|
| NRX Pharma Inc |
|
142.4
|
3.3
|
L
 -0.9%
H
3.3
3.4
|
L
 -3.2%
H
3.2
3.6
|
L
 -6.3%
H
3.2
3.7
|
L
 -17.1%
H
2.8
4.6
|
L
 10.8%
H
1.6
5.1
|
L
 30.6%
H
1.1
54
|
L
 -96.7%
H
1.1
134.9
|
L
H
1.1
769.9
|
| Intellia Therapeutics Inc |
|
1,712.3
|
12.2
|
L
 0.7%
H
12.1
12.7
|
L
 4.1%
H
11.2
12.9
|
L
 -1.8%
H
11.2
13.7
|
L
 -22.0%
H
10.2
18.5
|
L
 -21.6%
H
8.0
28.3
|
L
 -64.0%
H
5.9
34.9
|
L
 -91.8%
H
5.9
155.6
|
L
 -36.6%
H
5.9
202.7
|
| Natera Inc |
|
53,425.6
|
370.6
|
L
 0.3%
H
364.0
373.1
|
L
 12.7%
H
327.2
373.1
|
L
 14.1%
H
316
373.1
|
L
 60.2%
H
219.5
373.1
|
L
 104.7%
H
157.4
373.1
|
L
 653.9%
H
36.9
373.1
|
L
 209.7%
H
26.1
373.1
|
L
 3519.5%
H
7.4
373.1
|
| Novavax Inc |
|
1,717.1
|
10.4
|
L
 3.0%
H
10.2
10.7
|
L
 10.5%
H
9.1
10.7
|
L
 23.6%
H
8.3
10.8
|
L
 14.0%
H
7.2
10.8
|
L
 19.5%
H
6.2
12.0
|
L
 47.7%
H
3.5
23.9
|
L
 -95.4%
H
3.5
260.7
|
L
 -64.3%
H
3.5
331.7
|
| Nuvectis Pharma Inc |
|
717.5
|
22.0
|
L
 -0.1%
H
21.4
22.4
|
L
 -8.4%
H
20
24.1
|
L
 -5.9%
H
20
25.9
|
L
 59.0%
H
13.0
29.3
|
L
 250.6%
H
5.6
29.3
|
L
 60.9%
H
4.4
29.3
|
L
H
3.1
29.3
|
L
H
3.1
29.3
|
| Nextcure Inc |
|
25.0
|
5.5
|
L
 -10.8%
H
5.3
6.3
|
L
 -22%
H
5.3
7
|
L
 -12.6%
H
5.3
8.6
|
L
 170.3%
H
1.6
9.9
|
L
 -3.2%
H
1.6
15.7
|
L
 -65.8%
H
1.6
30.8
|
L
 -93.4%
H
1.6
110.2
|
L
H
1.6
1308
|
| Nanobiotix (ADR) |
|
1,753.0
|
34.5
|
L
 4.4%
H
33.0
34.8
|
L
 -6.8%
H
33.0
37
|
L
 -21.0%
H
33.0
46.7
|
L
 -4.9%
H
33.0
46.7
|
L
 198.2%
H
12.6
57.1
|
L
 314.2%
H
2.8
57.1
|
L
 196.4%
H
1.8
57.1
|
L
H
1.8
57.1
|
| NuCana PLC (ADR) |
|
5.5
|
1.3
|
L
 -1.5%
H
1.3
1.4
|
L
H
1.3
1.4
|
L
 -13.7%
H
1.3
1.9
|
L
 -30.9%
H
1.2
2.0
|
L
 -64.2%
H
1.2
7.2
|
L
 -100.0%
H
1.2
810296.8
|
L
 -100.0%
H
1.2
3319720
|
L
H
1.2
32000000
|
| Ocugen Inc |
|
349.3
|
1.0
|
L
 -2.8%
H
1.0
1.1
|
L
 1.0%
H
1.0
1.1
|
L
 -25.9%
H
1.0
1.4
|
L
 -16.9%
H
1.0
1.7
|
L
 -23.1%
H
1.0
2.7
|
L
 157.5%
H
0.3
2.7
|
L
 -86.2%
H
0.3
17.7
|
L
 -99.5%
H
0.2
213.6
|
| Ocular Therapeutix Inc |
|
2,194.0
|
10.0
|
L
H
9.8
10.2
|
L
 -4.8%
H
9.8
10.9
|
L
 -9.9%
H
9.8
11.5
|
L
 5.9%
H
8.2
11.7
|
L
 -17.4%
H
6.2
16.4
|
L
 193.8%
H
2
16.4
|
L
 -0.3%
H
2
16.4
|
L
 40.5%
H
2
24.3
|
| Opus Genetics Inc |
|
434.3
|
5.2
|
L
 0.8%
H
5.2
5.6
|
L
 -13.6%
H
5.1
6.2
|
L
 26.7%
H
3.5
7.1
|
L
 28.3%
H
2.8
7.1
|
L
 243.4%
H
1.5
7.1
|
L
 31.8%
H
0.7
7.1
|
L
 2.0%
H
0.7
7.1
|
L
 -95.0%
H
0.7
340.8
|
| Insight Molecular Diagnostics Inc |
|
131.2
|
4.0
|
L
 0.3%
H
3.8
4.1
|
L
 -4.5%
H
3.5
4.2
|
L
 -6.7%
H
3.5
4.5
|
L
 -26.3%
H
3.5
6.1
|
L
 17.6%
H
2.4
8.5
|
L
 23.8%
H
1.9
8.5
|
L
 -94.8%
H
1.9
81.3
|
L
 -95.2%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
69.8
|
1.3
|
L
 -2.2%
H
1.3
1.4
|
L
 -5%
H
1.3
1.5
|
L
 -12.5%
H
1.3
1.7
|
L
 -16.4%
H
1.3
1.9
|
L
 -32.8%
H
1.3
3.2
|
L
 -33.5%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Olema Pharma Inc |
|
842.6
|
9.6
|
L
 -1.9%
H
9.6
10.1
|
L
 -5.8%
H
9.4
10.4
|
L
 -11.7%
H
9.4
11.2
|
L
 1.3%
H
9.4
13.1
|
L
 17.9%
H
6.7
36.3
|
L
 -20.3%
H
2.9
36.3
|
L
 -63.7%
H
2
36.3
|
L
H
2
60.3
|
| Omeros Corp |
|
1,338.5
|
18.5
|
L
 3.5%
H
17.8
18.5
|
L
 1.2%
H
16.5
18.7
|
L
 -0.8%
H
16.5
19.7
|
L
 79.9%
H
7.4
19.7
|
L
 342.3%
H
4.1
19.7
|
L
 531.1%
H
0.9
19.7
|
L
 18.5%
H
0.9
19.7
|
L
 62.1%
H
0.9
27.1
|
| Oncolytics Biotech Inc |
|
98.2
|
0.8
|
L
H
0.8
0.8
|
L
 2.7%
H
0.8
0.9
|
L
 -3.8%
H
0.7
0.9
|
L
 -19.8%
H
0.7
1.1
|
L
 -43.4%
H
0.7
1.5
|
L
 -63.7%
H
0.3
2.3
|
L
 -62.3%
H
0.3
3.4
|
L
 -70.8%
H
0.3
8.5
|
| Traws Pharma Inc |
|
7.7
|
0.5
|
L
 2.0%
H
0.5
0.5
|
L
 -10.7%
H
0.5
0.6
|
L
 -3.9%
H
0.5
0.6
|
L
 -41.2%
H
0.4
0.9
|
L
 -75.4%
H
0.4
3.3
|
L
 -97.4%
H
0.4
27.5
|
L
 -99.6%
H
0.4
169.3
|
L
 -100.0%
H
0.4
21825
|
| VivoSim Labs Inc |
|
3.3
|
0.3
|
L
 8.7%
H
0.2
0.3
|
L
 -10.7%
H
0.2
0.3
|
L
 -10.7%
H
0.2
0.3
|
L
 -77.3%
H
0.2
1.6
|
L
 -94.0%
H
0.2
4.1
|
L
 -98.6%
H
0.2
24.6
|
L
 -99.7%
H
0.2
88.9
|
L
 -100.0%
H
0.2
993.6
|
| ORIC Pharma Inc |
|
1,313.3
|
12.7
|
L
 -0.9%
H
12.5
13.0
|
L
 5.2%
H
11.9
13.2
|
L
 -8.7%
H
11.9
14.5
|
L
 49.2%
H
8.7
14.7
|
L
 20.0%
H
7.2
14.9
|
L
 58.4%
H
3.9
16.7
|
L
 -48.4%
H
2.4
25.5
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
195.5
|
4.7
|
L
 -0.8%
H
4.7
4.8
|
L
 0.9%
H
4.5
4.8
|
L
 -1.9%
H
4.5
5.5
|
L
 21.1%
H
3.8
5.5
|
L
 100.9%
H
2.1
5.5
|
L
 70.3%
H
1.7
5.5
|
L
 -75.5%
H
1.7
31.5
|
L
 -37.8%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
168.0
|
0.7
|
L
 6.2%
H
0.7
0.7
|
L
 4.6%
H
0.6
0.7
|
L
 1.5%
H
0.6
0.7
|
L
 -56.3%
H
0.6
1.9
|
L
 -28.1%
H
0.2
2.5
|
L
 -99.2%
H
0.2
360
|
L
 -99.9%
H
0.2
960
|
L
 -100.0%
H
0.2
14752
|
| Ovid Therapeutics Inc |
|
529.3
|
2.7
|
L
 0.7%
H
2.7
2.8
|
L
 0.7%
H
2.6
2.8
|
L
 -1.1%
H
2.6
3.0
|
L
 19.4%
H
2.2
3.0
|
L
 124.0%
H
1.2
3.1
|
L
 -31.4%
H
0.2
4.1
|
L
 -18.9%
H
0.2
4.1
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
1,408.1
|
34.7
|
L
 0.4%
H
34.5
35.4
|
L
 -2.6%
H
34.1
36.7
|
L
 -1.4%
H
34.1
40.7
|
L
 8.9%
H
30.5
40.7
|
L
 -13%
H
28.3
60.1
|
L
 176.1%
H
9.4
60.1
|
L
 62.1%
H
9.4
60.1
|
L
 31.9%
H
9.4
60.1
|
| Palisade Bio Inc |
|
294.5
|
1.7
|
L
 6.3%
H
1.6
1.7
|
L
 -18.0%
H
1.6
2.1
|
L
 -18.0%
H
1.6
2.2
|
L
 -9.6%
H
1.6
2.3
|
L
 181.7%
H
0.6
2.9
|
L
 -80.9%
H
0.4
22.4
|
L
 -99.9%
H
0.4
2265
|
L
 -100.0%
H
0.4
594000
|
| Passage Bio Inc |
|
15.5
|
4.8
|
L
 1.7%
H
4.7
4.8
|
L
 -3.4%
H
4.7
5.0
|
L
 7.8%
H
4.3
5.4
|
L
 -13.6%
H
3.3
6.3
|
L
 -32.6%
H
3.3
20
|
L
 -64.9%
H
3.3
35.8
|
L
 -97.8%
H
3.3
227.4
|
L
H
3.3
764.6
|
| Paranovus Entertainment Tech Ltd (Class A) |
|
3.5
|
4.1
|
L
 -0.3%
H
4.0
4.2
|
L
 -9.8%
H
4.0
4.5
|
L
 -22.7%
H
4.0
5.6
|
L
 -72.8%
H
3.8
17.9
|
L
 -100%
H
3.8
148800
|
L
 -100.0%
H
3.8
481200
|
L
 -100.0%
H
3.8
2832000
|
L
H
3.8
14640000
|
| Puma biotech Inc |
|
495.0
|
9.6
|
L
 -0.1%
H
9.5
9.8
|
L
 5.2%
H
9.0
9.8
|
L
 5.3%
H
8.8
9.8
|
L
 26.9%
H
7.4
9.8
|
L
 117.0%
H
4.4
9.8
|
L
 230.7%
H
2.1
9.8
|
L
 44.4%
H
1.6
9.8
|
L
 -85.3%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
961.1
|
24.1
|
L
 -2.4%
H
24.0
25.0
|
L
 -4.9%
H
23.7
26.0
|
L
 1.2%
H
23.7
26.9
|
L
 8.0%
H
22
27.7
|
L
 -9.6%
H
18.8
27.7
|
L
 -30.1%
H
11.2
36.0
|
L
 -56.5%
H
11.2
82.2
|
L
 -40.3%
H
11.2
82.2
|
| Processa Pharma Inc |
|
5.1
|
1.8
|
L
 -6.1%
H
1.8
1.9
|
L
 -11.5%
H
1.8
2.1
|
L
 -14.0%
H
1.8
2.3
|
L
 -13.2%
H
1.7
3.1
|
L
 -61.8%
H
1.7
14.3
|
L
 -98.8%
H
1.7
450
|
L
 -99.9%
H
1.7
4495.5
|
L
 -100.0%
H
1.7
17937.5
|
| Vaxcyte Inc |
|
8,767.6
|
58.9
|
L
 1.4%
H
57.6
60.5
|
L
 -0.9%
H
57.0
61.5
|
L
 -4.0%
H
57.0
64.0
|
L
 14.5%
H
50.8
64.0
|
L
 85.6%
H
31.5
65
|
L
 17.0%
H
27.7
121.1
|
L
 130.2%
H
16.8
121.1
|
L
H
15.5
121.1
|
| PDS biotech Corp |
|
60.9
|
0.8
|
L
 3.7%
H
0.8
1.0
|
L
 180%
H
0.3
1.1
|
L
 300%
H
0.2
1.1
|
L
 -12.5%
H
0.2
1.1
|
L
 -20%
H
0.2
1.6
|
L
 -84.1%
H
0.2
6.9
|
L
 -94.3%
H
0.2
17.9
|
L
 -99.6%
H
0.2
355.4
|
| PepGen Inc |
|
196.7
|
2.8
|
L
 -0.4%
H
2.8
2.9
|
L
 -4.7%
H
2.8
3.1
|
L
 -6.6%
H
2.8
3.6
|
L
 58.7%
H
1.6
3.6
|
L
 51.1%
H
1.3
7.8
|
L
 -47.3%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
2,756.9
|
7.7
|
L
 -1.0%
H
7.6
7.9
|
L
 12.4%
H
6.8
8.0
|
L
 3.5%
H
6.5
8.0
|
L
 59.8%
H
4.8
8.0
|
L
 105.3%
H
3.0
8.0
|
L
 450%
H
0.7
8.0
|
L
 41.5%
H
0.7
8.0
|
L
 -72.4%
H
0.7
32.9
|
| Phathom Pharma Inc |
|
602.7
|
7.5
|
L
 -0.4%
H
7.3
7.6
|
L
 -10.9%
H
7.3
8.8
|
L
 -13.4%
H
7.3
9.7
|
L
 -31.5%
H
7.3
12.6
|
L
 -33.5%
H
7.3
18.3
|
L
 -31.4%
H
2.2
19.7
|
L
 -77.3%
H
2.2
36.1
|
L
H
2.2
64.5
|
| Phio Pharma Corp |
|
11.7
|
1.0
|
L
 -1.9%
H
1
1.1
|
L
 -1.9%
H
1.0
1.1
|
L
 -16.5%
H
1.0
1.2
|
L
 -1.9%
H
0.8
1.2
|
L
 -51.2%
H
0.8
4.2
|
L
 -92.5%
H
0.6
29.1
|
L
 -99.6%
H
0.6
261.4
|
L
 -100.0%
H
0.6
174042
|
| Pharvaris NV |
|
2,528.8
|
36.0
|
L
 -1.0%
H
35.5
36.9
|
L
 -5.3%
H
35.5
40.5
|
L
 -1.0%
H
33.8
43.3
|
L
 9.8%
H
31.5
43.3
|
L
 42.0%
H
20.7
43.3
|
L
 84.2%
H
11.5
43.3
|
L
 89.6%
H
1.8
43.3
|
L
H
1.8
43.3
|
| Pliant Therapeutics Inc |
|
68.7
|
1.1
|
L
H
1.1
1.1
|
L
 -5.1%
H
1.1
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
 -4.3%
H
1.0
1.2
|
L
 -22.4%
H
1.0
2.0
|
L
 -93.2%
H
1.0
19.6
|
L
 -93.8%
H
1.0
36.6
|
L
H
1.0
43.9
|
| Pluri Inc |
|
13.2
|
1.1
|
L
 -0.9%
H
1.0
1.1
|
L
 -9.3%
H
1.0
1.4
|
L
 -39.6%
H
1.0
1.8
|
L
 -47.0%
H
1.0
2.4
|
L
 -76.7%
H
1.0
4.9
|
L
 -77.7%
H
0.7
8.5
|
L
 -95.3%
H
0.7
25.5
|
L
 -99.2%
H
0.7
169.6
|
| PharmaCyte Biotech Inc |
|
4.8
|
0.5
|
L
 -2.2%
H
0.4
0.5
|
L
H
0.3
0.5
|
L
 -11.8%
H
0.3
0.6
|
L
 -37.5%
H
0.3
0.8
|
L
 -54.1%
H
0.3
1.5
|
L
 -80.8%
H
0.3
2.6
|
L
 -86.3%
H
0.3
3.5
|
L
 -99.0%
H
0.3
253.4
|
| ProMIS Neurosciences Inc |
|
122.2
|
13.6
|
L
 -2.7%
H
13.1
14.2
|
L
 0.5%
H
12.4
14.2
|
L
 -8.6%
H
12.3
15.5
|
L
 29.3%
H
10.2
17.3
|
L
 23.4%
H
6.3
27.4
|
L
 -73.7%
H
6.3
77.5
|
L
 -93.4%
H
6.3
245
|
L
 -91.0%
H
6.3
1050
|
| PMV Pharmaceuticals Inc |
|
79.1
|
1.5
|
L
 -1.3%
H
1.4
1.5
|
L
 5.7%
H
1.4
1.5
|
L
 13.9%
H
1.1
1.5
|
L
 31.0%
H
1.0
1.5
|
L
 13.0%
H
1.0
1.9
|
L
 -77.6%
H
0.8
6.9
|
L
 -94.5%
H
0.8
30.5
|
L
H
0.8
63.2
|
| Praxis Precision Medicines Inc |
|
8,344.4
|
298.9
|
L
 0.0%
H
295.2
305.8
|
L
 -10.7%
H
295.2
341.7
|
L
 -18.0%
H
295.2
388.0
|
L
 5.9%
H
285
392.7
|
L
 607.9%
H
41.8
392.7
|
L
 1219.5%
H
13
392.7
|
L
 7.3%
H
11.9
392.7
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
3.4
|
1.0
|
L
 -5.9%
H
1.0
1.1
|
L
 11.6%
H
0.9
1.3
|
L
 -4%
H
0.9
1.3
|
L
 -41.8%
H
0.9
2.3
|
L
 -35.1%
H
0.6
5.4
|
L
 -95.8%
H
0.2
23.3
|
L
 -99.5%
H
0.2
199.1
|
L
H
0.2
471
|
| Prelude Therapeutics Inc |
|
375.1
|
4.7
|
L
 -3.5%
H
4.7
4.9
|
L
 2.4%
H
4.4
4.9
|
L
 -27.7%
H
4.4
6.8
|
L
 8.8%
H
3.8
6.8
|
L
 379.6%
H
1.0
6.8
|
L
 58.8%
H
0.6
6.8
|
L
 -86.1%
H
0.6
37.0
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
578.6
|
3.2
|
L
 2.2%
H
3.1
3.3
|
L
 1.9%
H
2.9
3.4
|
L
 -1.5%
H
2.9
3.9
|
L
 -1.2%
H
2.7
4.8
|
L
 -34.8%
H
2.7
6.9
|
L
 -72.7%
H
1.1
11.5
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
371.9
|
1.8
|
L
 -6.8%
H
1.7
1.9
|
L
 -1.1%
H
1.7
2.0
|
L
 25.4%
H
1.4
2.1
|
L
 -2.7%
H
1.3
2.2
|
L
 -33.6%
H
1.3
3.5
|
L
 -62.0%
H
0.5
7.1
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| ProQR Therapeutics NV |
|
262.5
|
1.9
|
L
 1.6%
H
1.8
1.9
|
L
H
1.8
1.9
|
L
 -18.1%
H
1.8
2.5
|
L
 -1.6%
H
1.4
2.5
|
L
 -11.4%
H
1.3
3.1
|
L
 25.7%
H
1.1
4.6
|
L
 -75.7%
H
0.5
9.1
|
L
 -71.8%
H
0.5
24
|
| Prothena Corporation plc |
|
436.9
|
8.5
|
L
 -0.8%
H
8.5
8.8
|
L
 -4.7%
H
8.2
9.0
|
L
 -5.8%
H
8.2
9.9
|
L
 -4.7%
H
8
10.2
|
L
 5.5%
H
7.7
11.8
|
L
 -83.8%
H
4.3
55.9
|
L
 -88.6%
H
4.3
79.8
|
L
 -86.1%
H
4.3
79.8
|
| Cerenome Inc |
|
14.4
|
1.9
|
L
 -6.4%
H
1.9
2.1
|
L
 -18.1%
H
1.9
2.3
|
L
 -36.7%
H
1.9
3.3
|
L
 -54.8%
H
1.9
4.5
|
L
 -81.7%
H
1.9
23.4
|
L
 -94.0%
H
1.9
69.5
|
L
 -99.7%
H
1.9
810
|
L
 -100.0%
H
1.9
401250
|
| PTC Therapeutics Inc |
|
5,446.7
|
65.3
|
L
 -0.2%
H
65.0
66.2
|
L
 -1.2%
H
65.0
68.8
|
L
 -7.5%
H
65.0
73.5
|
L
 -17.4%
H
64.6
90.9
|
L
 7.9%
H
57.7
90.9
|
L
 155.6%
H
17.5
90.9
|
L
 56.9%
H
17.5
90.9
|
L
 539.2%
H
4.0
90.9
|
| Protagonist Therapeutics Inc |
|
9,381.4
|
145.0
|
L
 1.4%
H
141.1
145.4
|
L
 -2.2%
H
140.4
151.2
|
L
 -3.8%
H
140.4
158.1
|
L
 28.5%
H
113.2
160.8
|
L
 133.1%
H
62.0
160.8
|
L
 752.8%
H
13.7
160.8
|
L
 1019.5%
H
6.9
160.8
|
L
 829.4%
H
4.5
160.8
|
| Pulmatrix Inc |
|
6.1
|
1.7
|
L
 16.7%
H
1.4
1.7
|
L
 19.2%
H
1.4
1.7
|
L
 12%
H
1.4
1.7
|
L
 15.1%
H
1.4
1.9
|
L
 -66.3%
H
1.2
5.5
|
L
 -22.6%
H
1.2
10.4
|
L
 -89.0%
H
1.2
20.8
|
L
 -99.5%
H
1.2
1396
|
| Polypid Ltd |
|
105.0
|
5.2
|
L
 -0.8%
H
5.1
5.3
|
L
 0.4%
H
5
5.4
|
L
 1.8%
H
5.0
5.6
|
L
 9.1%
H
3.7
5.7
|
L
 49.9%
H
3.1
5.7
|
L
 -29.7%
H
2.3
9.2
|
L
 -97.8%
H
2.3
257.1
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
266.1
|
3.2
|
L
 -4.2%
H
3.2
3.4
|
L
 -0.6%
H
3.2
3.5
|
L
 2.2%
H
2.8
4.2
|
L
 57.1%
H
1.9
4.2
|
L
 41.8%
H
1.0
5.6
|
L
 72.4%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
765.1
|
10.8
|
L
 2.5%
H
10.5
11.5
|
L
 -3.6%
H
10.4
11.5
|
L
 -7.5%
H
10.4
12.3
|
L
 -16.0%
H
9.6
14.8
|
L
 -27.4%
H
9.6
21.3
|
L
 -22.4%
H
6.7
21.3
|
L
 14.6%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
2.3
|
1.4
|
L
 -0.7%
H
1.4
1.5
|
L
 -16.9%
H
1.3
1.8
|
L
 -9.5%
H
1.3
2.6
|
L
 -15.9%
H
1.2
2.6
|
L
 -75.5%
H
1.2
14.1
|
L
 -100.0%
H
1.2
7200
|
L
 -100.0%
H
1.2
19680
|
L
 -100.0%
H
1.2
182000
|
| Qilian Intl Holding Grp ltd (Class A) |
|
104.2
|
0.3
|
L
 4%
H
0.3
0.3
|
L
H
0.2
0.3
|
L
H
0.2
0.3
|
L
 -27.8%
H
0.2
0.5
|
L
 -97.4%
H
0.2
11.8
|
L
 -93.7%
H
0.2
17.2
|
L
 -98.7%
H
0.2
20.7
|
L
H
0.2
110
|
| Quince Therapeutics Inc |
|
31.5
|
31
|
L
 5.2%
H
28.5
31
|
L
 4.9%
H
25.8
31
|
L
 -3.5%
H
25.8
35.3
|
L
 3197.9%
H
0.9
35.4
|
L
 93.8%
H
0.8
45.5
|
L
 156.2%
H
0.8
45.5
|
L
 -96.4%
H
0.8
985
|
L
H
0.8
1219.8
|
| uniQure NV |
|
3,073.6
|
44.3
|
L
 0.7%
H
43.8
45.0
|
L
 -0.5%
H
41.7
45.8
|
L
 -9.4%
H
41.7
51.7
|
L
 -4.3%
H
35.3
51.7
|
L
 219.5%
H
8.7
71.5
|
L
 493.2%
H
3.7
71.5
|
L
 21.0%
H
3.7
71.5
|
L
 459.5%
H
3.7
82.5
|
| Quoin Pharma Ltd (ADR) |
|
13.9
|
6.9
|
L
 -2.3%
H
6.8
7.1
|
L
 1.6%
H
6.3
7.2
|
L
 38.3%
H
4.7
8.3
|
L
 48.4%
H
3.3
8.3
|
L
 -10.4%
H
3.3
41.8
|
L
 -99.8%
H
3.3
4326
|
L
 -100.0%
H
3.3
3003840
|
L
 -100.0%
H
3.3
3003840
|
| Rani Therapeutics Holdings Inc |
|
91.2
|
0.8
|
L
 -8.1%
H
0.8
0.9
|
L
 -6.0%
H
0.8
0.9
|
L
 -7.1%
H
0.8
0.9
|
L
 1.3%
H
0.6
0.9
|
L
 51.9%
H
0.4
3.9
|
L
 -71.5%
H
0.4
8.8
|
L
 -95.8%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Ultragenyx Pharmaceutical Inc |
|
1,444.3
|
14.7
|
L
 1.0%
H
14.3
15.0
|
L
 2.5%
H
12.7
15.1
|
L
 -42.1%
H
12.7
26.9
|
L
 -46.6%
H
12.7
36.6
|
L
 -47.9%
H
12.7
39.9
|
L
 -59.5%
H
12.7
60.4
|
L
 -84.8%
H
12.7
98.4
|
L
 -80.7%
H
12.7
179.7
|
| Rocket Pharmaceuticals Inc |
|
359.0
|
3.3
|
L
 -3.0%
H
3.3
3.4
|
L
 -2.4%
H
3.2
3.8
|
L
 -6.0%
H
3.2
4.0
|
L
 -2.4%
H
3.0
4.3
|
L
 6.5%
H
2.5
5.5
|
L
 -85.1%
H
2.2
32.5
|
L
 -89.9%
H
2.2
36.9
|
L
 -90.8%
H
2.2
67.5
|
| Regeneron Pharma |
|
82,175.6
|
798.2
|
L
 1.7%
H
780.0
801.4
|
L
 2.1%
H
769.6
801.4
|
L
 -3.4%
H
769.6
859.3
|
L
 30.9%
H
594.9
859.3
|
L
 34.8%
H
541
859.3
|
L
 -4.0%
H
476.5
1211.2
|
L
 24.5%
H
476.5
1211.2
|
L
 96.5%
H
271.4
1211.2
|
| Replimune Grp Inc |
|
1,212.6
|
12.9
|
L
 -1.5%
H
12.8
13.3
|
L
 -0.4%
H
12.5
13.6
|
L
 -8.4%
H
12.4
16.3
|
L
 26.3%
H
4.8
16.3
|
L
 299.7%
H
1.5
16.3
|
L
 -22.6%
H
1.5
17.1
|
L
 -59.3%
H
1.5
35.9
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
3.9
|
1.0
|
L
 5.4%
H
0.9
1.0
|
L
 -1.0%
H
0.9
1.0
|
L
 -8.4%
H
0.9
1.1
|
L
H
0.9
1.2
|
L
 -84.1%
H
0.9
6.8
|
L
 -100.0%
H
0.9
4849.9
|
L
 -100.0%
H
0.9
2276064
|
L
H
0.9
2276064
|
| Regencell Bioscience Holdings Ltd |
|
2,927.4
|
5.9
|
L
 2.3%
H
5.7
6.1
|
L
 5.0%
H
5.5
6.1
|
L
 8.8%
H
5.2
7.7
|
L
 -50.7%
H
4.5
14.7
|
L
 -62.2%
H
4.5
69
|
L
 1500%
H
0.1
83.6
|
L
 1215.6%
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
10,198.5
|
180.7
|
L
 2.2%
H
176.2
182.3
|
L
 9.4%
H
162.1
182.3
|
L
 0.2%
H
161.1
185.3
|
L
 36.9%
H
124.9
188.7
|
L
 47.8%
H
101.0
188.7
|
L
 7.2%
H
101.0
211.1
|
L
 -41.0%
H
101.0
327.3
|
L
 442.3%
H
26.2
327.3
|
| Regenxbio Inc |
|
520.2
|
7.9
|
L
 -1.9%
H
7.8
8.3
|
L
 -7.6%
H
7.6
8.8
|
L
 -28.8%
H
7.6
11.2
|
L
 1.0%
H
7.6
15.9
|
L
 -11.4%
H
5.5
16.2
|
L
 -55.2%
H
5.0
28.8
|
L
 -81.9%
H
5.0
44.9
|
L
 -50.6%
H
5.0
85.1
|
| Rigel Pharma |
|
879.6
|
47.1
|
L
 1.0%
H
46.5
47.5
|
L
 -0.3%
H
43.8
47.5
|
L
 4.1%
H
43.8
49.9
|
L
 43.1%
H
33.6
49.9
|
L
 35.6%
H
25.0
52.2
|
L
 4180.9%
H
0.7
52.2
|
L
 1165.9%
H
0.6
52.2
|
L
 1245.4%
H
0.6
52.2
|
| Relay Therapeutics Inc |
|
3,986.2
|
18.2
|
L
 -3.5%
H
18.1
19.2
|
L
 -3.6%
H
18.1
19.7
|
L
 -7.7%
H
18.0
20.8
|
L
 14.6%
H
16.1
21.3
|
L
 290.3%
H
4.3
21.3
|
L
 106.5%
H
1.8
21.3
|
L
 -49.8%
H
1.8
38.2
|
L
H
1.8
64.4
|
| Relmada Therapeutics Inc |
|
443.7
|
4.2
|
L
 1.0%
H
4.1
4.2
|
L
 -8.0%
H
4.1
4.6
|
L
 -10.3%
H
4
4.8
|
L
 -38.2%
H
4
7.1
|
L
 171.9%
H
1.5
8
|
L
 40.5%
H
0.2
8
|
L
 -84.8%
H
0.2
38.7
|
L
 -32.0%
H
0.2
54
|
| Rallybio Corp |
|
89.9
|
16.9
|
L
 -1.5%
H
16.6
17.1
|
L
 0.3%
H
16.5
17.2
|
L
 2.0%
H
16.5
17.3
|
L
 6.0%
H
15.6
17.4
|
L
 259.5%
H
3.7
17.6
|
L
 -55.8%
H
1.8
40.2
|
L
 -80.5%
H
1.8
168
|
L
H
1.8
206.2
|
| TransCode Therapeutics Inc |
|
29.8
|
1.8
|
L
 6.7%
H
1.7
2.0
|
L
 4.1%
H
1.6
2
|
L
 -40.7%
H
1.6
3
|
L
 -62.6%
H
1.6
10.7
|
L
 -84.9%
H
1.6
21.0
|
L
 -100.0%
H
1.6
118272
|
L
 -100.0%
H
1.6
3901941.1
|
L
H
1.6
5174400
|
| RenovoRx Inc |
|
75.4
|
1.7
|
L
 -1.2%
H
1.6
1.7
|
L
 -5.1%
H
1.6
1.9
|
L
 26.5%
H
1.2
2.6
|
L
 81.5%
H
0.8
2.6
|
L
 25.6%
H
0.7
2.6
|
L
 18.4%
H
0.6
2.6
|
L
 -77.3%
H
0.6
12.5
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
28,163.4
|
39.0
|
L
 -2.0%
H
38.7
39.9
|
L
 -4.5%
H
38.7
41.6
|
L
 5.8%
H
33.4
42.5
|
L
 24.1%
H
30.7
42.5
|
L
 159.2%
H
14.5
42.5
|
L
 277.4%
H
8.2
42.5
|
L
 290.7%
H
2.5
42.5
|
L
H
2.5
42.5
|
| Royalty Pharma PLC (Class A) |
|
26,022.0
|
58.4
|
L
 0.1%
H
57.8
59.1
|
L
 -0.3%
H
57.8
59.6
|
L
 -3.5%
H
57.8
64.4
|
L
 10.4%
H
52.9
64.4
|
L
 61.3%
H
34.6
64.4
|
L
 112.9%
H
24.1
64.4
|
L
 58.7%
H
24.1
64.4
|
L
H
24.1
64.4
|
| Revolution Medicines Inc |
|
41,315.5
|
192.8
|
L
 1.0%
H
190.6
194.9
|
L
 -5.4%
H
188.2
207
|
L
 -9.0%
H
188.2
224.3
|
L
 18.3%
H
162.2
224.3
|
L
 342.7%
H
42.2
224.3
|
L
 548.4%
H
15.5
224.3
|
L
 529.5%
H
14.1
224.3
|
L
H
14.1
224.3
|
| Recursion Pharma Inc (Class A) |
|
2,129.0
|
4.0
|
L
 3.7%
H
3.8
4.0
|
L
 24.1%
H
3.2
4.0
|
L
 18.9%
H
3.1
4.0
|
L
 22.9%
H
2.8
4.1
|
L
 -19.1%
H
2.8
7.2
|
L
 -51.2%
H
2.8
15.7
|
L
 -84.8%
H
2.8
27.3
|
L
H
2.8
42.8
|
| Rhythm Pharma Inc |
|
6,804.7
|
98.8
|
L
 1.2%
H
97.5
100.8
|
L
 -5.6%
H
96.1
105.9
|
L
 -9.3%
H
96.1
114.8
|
L
 2.1%
H
96.1
119.8
|
L
 2.9%
H
74.5
122.2
|
L
 311.3%
H
21.0
122.2
|
L
 682.5%
H
3.0
122.2
|
L
H
3.0
122.2
|
| Rezolute Inc |
|
376.5
|
3.9
|
L
 1.8%
H
3.7
3.9
|
L
 -7.4%
H
3.7
4.3
|
L
 -16.1%
H
3.7
5.6
|
L
 -22.1%
H
3.7
5.6
|
L
 -49.2%
H
1.1
11.5
|
L
 185.4%
H
0.7
11.5
|
L
 -52.5%
H
0.7
11.5
|
L
 -93.4%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
3.3
|
0.6
|
L
 -3.5%
H
0.5
0.6
|
L
 -14.1%
H
0.5
0.6
|
L
 -11.3%
H
0.5
1.6
|
L
 -32.1%
H
0.5
1.6
|
L
 -67.5%
H
0.5
2.8
|
L
 -97.3%
H
0.5
82
|
L
 -100.0%
H
0.5
6500
|
L
 -100.0%
H
0.5
15269
|
| SAB Biotherapeutics Inc |
|
308.4
|
3.4
|
L
 -3.4%
H
3.4
3.6
|
L
 -0.6%
H
3.3
3.6
|
L
 -8.4%
H
3.3
4.0
|
L
 -15.3%
H
3.3
4.1
|
L
 37.3%
H
1.9
5.2
|
L
 484.5%
H
0.4
6.6
|
L
 -66.1%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
928.0
|
3.1
|
L
H
3.0
3.2
|
L
 -1.0%
H
2.9
3.3
|
L
 -17.1%
H
2.9
4.2
|
L
 -1.6%
H
2.9
4.2
|
L
 0.3%
H
2.6
6.6
|
L
 -26.5%
H
1.3
12
|
L
 -86.8%
H
1.3
24.7
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
35.7
|
0.7
|
L
 1.4%
H
0.7
0.8
|
L
 -3.9%
H
0.7
0.8
|
L
 -21.3%
H
0.7
1.0
|
L
 -39.3%
H
0.7
1.4
|
L
 -67.5%
H
0.7
5.0
|
L
 -96.0%
H
0.7
42.2
|
L
 -98.5%
H
0.7
100
|
L
 -96.2%
H
0.7
146.2
|
| Sunshine Biopharma Inc |
|
3.5
|
0.9
|
L
 1.1%
H
0.9
1.0
|
L
 -14.2%
H
0.8
1.1
|
L
 -21.6%
H
0.8
1.3
|
L
 -57.3%
H
0.8
2.3
|
L
 -93.8%
H
0.8
24.3
|
L
 -100.0%
H
0.8
7806.9
|
L
 -100.0%
H
0.8
596000
|
L
 -100.0%
H
0.8
45037037.0
|
| Scilex Holding Co |
|
36.3
|
5.2
|
L
 2.4%
H
5
5.3
|
L
 3.0%
H
4.9
5.6
|
L
 -11.0%
H
4.9
6.2
|
L
 -30.9%
H
4.9
10.4
|
L
 -82.3%
H
4.2
34.3
|
L
 203.5%
H
0.2
34.3
|
L
 -48.5%
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
43.8
|
4.4
|
L
 -1.4%
H
4.3
4.6
|
L
 -9.1%
H
4.1
5.0
|
L
 -15.7%
H
4.1
6.1
|
L
 8.6%
H
3.5
6.1
|
L
 -50.9%
H
3.5
9.1
|
L
 -84.6%
H
3.5
28.9
|
L
 -90.4%
H
3.5
64.8
|
L
 -98.5%
H
3.5
440.8
|
| Seer Inc (Class A) |
|
103.0
|
1.9
|
L
H
1.9
1.9
|
L
 -4.6%
H
1.8
1.9
|
L
 -7.9%
H
1.8
2.1
|
L
 6.9%
H
1.6
2.3
|
L
 -16.6%
H
1.6
2.4
|
L
 -20.9%
H
1.5
2.6
|
L
 -94.8%
H
1.5
38.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,229.5
|
7.9
|
L
 -1.1%
H
7.8
8.2
|
L
 -3.1%
H
7.7
8.3
|
L
 -22.4%
H
7.7
10.9
|
L
 -17.6%
H
7.3
11
|
L
 -15.9%
H
5.6
11
|
L
 -22.6%
H
5.6
15.6
|
L
 -22.6%
H
5.6
15.6
|
L
 -22.6%
H
5.6
15.6
|
| Shuttle Pharma Holdings Inc |
|
2.0
|
3.5
|
L
 8.1%
H
3.2
3.6
|
L
 -1.7%
H
3.1
3.6
|
L
 -6.5%
H
3.1
4.1
|
L
 0.3%
H
2.6
6.2
|
L
 -15.2%
H
0.4
6.2
|
L
 -97.3%
H
0.4
136
|
L
H
0.4
25252
|
L
H
0.4
25252
|
| SIGA Tech Inc |
|
227.0
|
3.2
|
L
 0.6%
H
3.1
3.2
|
L
 4.3%
H
2.9
3.2
|
L
 6.4%
H
2.9
3.3
|
L
 -26.9%
H
2.8
4.4
|
L
 -64.0%
H
2.8
9.5
|
L
 -32.8%
H
2.8
12.8
|
L
 -52.0%
H
2.8
27.0
|
L
 21.5%
H
1.9
27.0
|
| SILO Pharma Inc |
|
3.1
|
1.7
|
L
 -5.4%
H
1.7
1.8
|
L
 -17.1%
H
1.6
2.2
|
L
 -36.5%
H
1.6
2.9
|
L
 -71.6%
H
1.6
8.0
|
L
 155.9%
H
0.2
8.0
|
L
 -3.3%
H
0.2
8.0
|
L
 -79.0%
H
0.2
496
|
L
 -96.5%
H
0.2
496
|
| Solid Biosciences Inc |
|
915.7
|
8.5
|
L
 -4.2%
H
8.5
9.0
|
L
 -1.8%
H
8.2
9.1
|
L
 -6.2%
H
8.2
10.5
|
L
 2.5%
H
7.7
11.5
|
L
 66.8%
H
3.8
11.5
|
L
 199.6%
H
1.8
15.1
|
L
 -78.6%
H
1.8
51.3
|
L
H
1.8
822.6
|
| Sol-Gel Tech Ltd |
|
194.1
|
59.3
|
L
 -1.2%
H
58.3
60
|
L
 -10.1%
H
58.3
66.5
|
L
 -24.5%
H
58.3
82.2
|
L
 -20.4%
H
58.3
93.7
|
L
 94.4%
H
27
98.0
|
L
 2709.5%
H
0.3
98.0
|
L
 569.8%
H
0.3
98.0
|
L
H
0.3
98.0
|
| Decoy Therapeutics Inc |
|
1.7
|
2.6
|
L
 -7.9%
H
2.2
2.8
|
L
 -4.1%
H
2.2
3.0
|
L
 -22.0%
H
2.2
3.4
|
L
 -57.8%
H
2.2
13.5
|
L
 -95.1%
H
2.2
55.9
|
L
 -99.8%
H
2.2
1368
|
L
 -100.0%
H
2.2
43200
|
L
 -100.0%
H
2.2
10791000
|
| SELLAS Life Sciences Grp Inc |
|
2,296.1
|
11.4
|
L
 -1.0%
H
11.1
11.9
|
L
 -1.5%
H
10.8
12.3
|
L
 -15.2%
H
10.8
15.7
|
L
 41.2%
H
8.3
15.9
|
L
 597.6%
H
1.4
15.9
|
L
 658%
H
0.5
15.9
|
L
 16.1%
H
0.5
15.9
|
L
 -99.9%
H
0.5
11709
|
| Summit Therapeutics Inc |
|
13,482.0
|
16.9
|
L
 -5.3%
H
16.6
18.4
|
L
 -3.7%
H
16.6
18.8
|
L
 36.0%
H
12.2
18.8
|
L
 22.9%
H
12.1
18.8
|
L
 -10.5%
H
12.1
29.2
|
L
 808.6%
H
1.6
36.9
|
L
 164.9%
H
0.7
36.9
|
L
 136.4%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
1,613.6
|
18.1
|
L
 2.6%
H
17.4
18.5
|
L
 -0.6%
H
17.3
18.7
|
L
 -8.5%
H
17.3
21
|
L
 -4.9%
H
17.2
25.2
|
L
 22.3%
H
13.0
25.6
|
L
 10.8%
H
8.6
25.6
|
L
 -3.9%
H
8.6
29.9
|
L
 28.5%
H
3.4
29.9
|
| Soligenix Inc |
|
8.1
|
0.4
|
L
H
0.4
0.4
|
L
 2.8%
H
0.4
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
 -7.5%
H
0.3
0.4
|
L
 -86.3%
H
0.3
2.6
|
L
 -95.4%
H
0.3
85.3
|
L
 -99.8%
H
0.3
288.0
|
L
 -100.0%
H
0.3
2040.1
|
| Sonoma Pharma Inc |
|
6.0
|
1.3
|
L
 -2.3%
H
1.3
1.3
|
L
 -3.9%
H
1.2
1.3
|
L
 -6.7%
H
1.2
1.4
|
L
 8.7%
H
1.1
1.5
|
L
 -70.1%
H
0.9
4.6
|
L
 64.5%
H
0.1
6.9
|
L
 -76.1%
H
0.1
8.8
|
L
 -96.6%
H
0.1
74.2
|
| Sensei Biotherapeutics Inc |
|
860.2
|
33.3
|
L
 -3.5%
H
32.1
34.8
|
L
 -11.1%
H
32.1
40.1
|
L
 3.7%
H
30.3
42.1
|
L
 86.8%
H
17.5
42.1
|
L
 269.9%
H
7.5
42.1
|
L
 93.5%
H
5
42.1
|
L
 -83.9%
H
5
238.4
|
L
H
5
530
|
| Senti Biosciences Inc |
|
9.7
|
0.3
|
L
 -3.1%
H
0.3
0.3
|
L
H
0.3
0.3
|
L
 -29.6%
H
0.3
0.4
|
L
 -66.7%
H
0.3
1.2
|
L
 -77.0%
H
0.3
2.9
|
L
 -93.4%
H
0.3
16.9
|
L
 -68.7%
H
0.3
87.7
|
L
H
0.3
87.7
|
| Spruce Biosciences Inc |
|
154.3
|
53.7
|
L
 1.2%
H
53.1
55.1
|
L
H
51.8
57.6
|
L
 3.3%
H
49.0
64.5
|
L
 2.6%
H
40.3
64.5
|
L
 540.8%
H
7.3
240
|
L
 -70.8%
H
4.3
446.3
|
L
 -89.0%
H
4.3
495
|
L
H
4.3
2670
|
| SciSparc Ltd |
|
2.6
|
4.5
|
L
 0.4%
H
4.5
4.6
|
L
 -10.8%
H
4.4
5.2
|
L
 -31.6%
H
4.4
7.2
|
L
 -38.9%
H
4.2
11.5
|
L
 -89.5%
H
3.0
80.1
|
L
 -99.5%
H
3.0
2687.6
|
L
 -100.0%
H
3.0
40049.1
|
L
H
3.0
41769
|
| Spero Therapeutics Inc |
|
66.4
|
1.1
|
L
 0.9%
H
1.1
1.2
|
L
 0.9%
H
1.1
1.2
|
L
 -5.8%
H
1.1
1.3
|
L
 -50%
H
1.1
2.4
|
L
 -43%
H
1.1
3.1
|
L
 -7.3%
H
0.5
3.2
|
L
 -94%
H
0.5
19.9
|
L
H
0.5
23.6
|
| ARS Pharma Inc |
|
432.6
|
4.4
|
L
 5.8%
H
4.1
4.4
|
L
 -8.6%
H
4.1
4.9
|
L
 -20.9%
H
4.1
6.1
|
L
 -54.9%
H
4.1
10.9
|
L
 -55.6%
H
4.1
13.2
|
L
 49.0%
H
2.8
18.9
|
L
 -63.5%
H
2.6
18.9
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
21.1
|
0.4
|
L
 -8.7%
H
0.4
0.5
|
L
 -22.2%
H
0.4
0.6
|
L
 -30%
H
0.4
0.8
|
L
 -23.6%
H
0.4
1.8
|
L
 -90.9%
H
0.4
5.2
|
L
 -97.3%
H
0.4
19.9
|
L
 -88.9%
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
2,127.3
|
20.1
|
L
 0.2%
H
20.0
20.5
|
L
 -1.5%
H
19.6
21.8
|
L
 4.8%
H
17.9
23.6
|
L
 14.9%
H
14.8
23.6
|
L
 15.6%
H
14.7
25.3
|
L
 -82.9%
H
10.4
173.3
|
L
 -76.5%
H
10.4
173.3
|
L
 -63.9%
H
10.4
181.8
|
| Scholar Rock Holding Corp |
|
5,865.2
|
48.2
|
L
 3.2%
H
46.5
49.2
|
L
 -13.1%
H
45.9
56.9
|
L
 -12.8%
H
45.9
61.8
|
L
 1.8%
H
45.7
61.8
|
L
 56.2%
H
27.1
61.8
|
L
 592.0%
H
6.0
61.8
|
L
 41.3%
H
4.3
61.8
|
L
H
4.3
70
|
| Surrozen Inc |
|
194.3
|
16.5
|
L
 -0.1%
H
16.4
17.5
|
L
 -13%
H
16.4
19.3
|
L
 -29.7%
H
16.4
25.0
|
L
 -28.9%
H
16.4
27.3
|
L
 34.6%
H
11.4
35
|
L
 3573.3%
H
0.3
35
|
L
 45%
H
0.3
35
|
L
H
0.3
35
|
| Stoke Therapeutics Inc |
|
1,810.0
|
28.1
|
L
 -1.3%
H
27.8
28.8
|
L
 -3.4%
H
27.7
29.7
|
L
 -10.7%
H
27.7
33.9
|
L
 -9.5%
H
27.2
33.9
|
L
 22.5%
H
20.3
40.2
|
L
 531.8%
H
3.4
40.2
|
L
 18.6%
H
3.4
40.2
|
L
H
3.4
71.6
|
| Sutro Biopharma Inc |
|
271.1
|
16.4
|
L
 6.6%
H
15.0
16.5
|
L
 -3.0%
H
14.8
17.4
|
L
 -22.7%
H
14.8
21.9
|
L
 -44.8%
H
14.8
34.1
|
L
 84.3%
H
7.2
43.9
|
L
 -53.9%
H
5.2
61.3
|
L
 -91.5%
H
5.2
237
|
L
H
5.2
283
|
| Shattuck Labs Inc |
|
613.2
|
6.1
|
L
 1.7%
H
5.9
6.2
|
L
 -1.5%
H
5.8
6.3
|
L
 -15.7%
H
5.8
8.2
|
L
 23.4%
H
5
8.2
|
L
 168.0%
H
1.7
8.3
|
L
 268.1%
H
0.7
11.8
|
L
 -67.8%
H
0.7
21.4
|
L
H
0.7
60.5
|
| Supernus Pharma Inc |
|
2,490.8
|
42.8
|
L
 1.9%
H
41.7
43.0
|
L
 2.7%
H
40.5
43.4
|
L
 -9.8%
H
40.5
47.8
|
L
 -3.6%
H
40.5
52.5
|
L
 -7.1%
H
40.5
59.7
|
L
 54.7%
H
22
59.7
|
L
 59.5%
H
22
59.7
|
L
 68.8%
H
13.1
61.3
|
| Savara Inc |
|
1,119.8
|
5.5
|
L
 1.5%
H
5.4
5.5
|
L
 2.8%
H
5.1
5.5
|
L
 -0.7%
H
5.1
5.7
|
L
 -0.9%
H
5.1
6.5
|
L
 54.4%
H
3.3
7
|
L
 44.6%
H
1.9
7
|
L
 322.5%
H
1.0
7
|
L
 -86.8%
H
0.7
17.2
|
| China SXT Pharma Inc |
|
3.1
|
2.4
|
L
 -0.8%
H
2.3
2.4
|
L
 -7.0%
H
2.1
2.7
|
L
 -34.4%
H
1.8
4.3
|
L
 -98.7%
H
1.8
234.2
|
L
 -100.0%
H
1.8
83760
|
L
 -100.0%
H
1.8
613440
|
L
 -100.0%
H
1.8
5472000
|
L
H
1.8
224449238.7
|
| 60 Degrees Pharma Inc |
|
3.6
|
1.0
|
L
 5.2%
H
0.9
1.0
|
L
 12.2%
H
0.8
1.0
|
L
 -10.6%
H
0.8
1.2
|
L
 -38.4%
H
0.8
1.9
|
L
 -81.4%
H
0.8
8.6
|
L
 -99.5%
H
0.8
367.2
|
L
H
0.8
2076
|
L
H
0.8
2076
|
| Sanofi (ADR) |
|
101,835.8
|
42.5
|
L
 0.1%
H
42.5
42.8
|
L
 -0.6%
H
42.3
43.7
|
L
 -5.9%
H
42.3
46.1
|
L
 0.3%
H
40.9
46.1
|
L
 -10.8%
H
40.9
52.7
|
L
 -23.0%
H
40.9
60.1
|
L
 -11.3%
H
36.9
60.1
|
L
 9.1%
H
36.8
60.1
|
| Protara Therapeutics Inc |
|
207.4
|
3.5
|
L
 -1.1%
H
3.5
3.7
|
L
 -8.1%
H
3.5
4.0
|
L
 -10%
H
3.5
4.1
|
L
 -11.8%
H
3.5
4.5
|
L
 10.0%
H
3.5
7.8
|
L
 93.9%
H
1.0
10.5
|
L
 -49.9%
H
1.0
10.5
|
L
 -99.0%
H
1.0
458
|
| Tarsus Pharma Inc |
|
3,624.5
|
77.5
|
L
 -0.8%
H
76.4
78.6
|
L
 -2.3%
H
76.4
80.2
|
L
 8.4%
H
69.5
91.5
|
L
 22.6%
H
53.9
91.5
|
L
 40.8%
H
53.9
91.5
|
L
 362.4%
H
12.7
91.5
|
L
 261.1%
H
10.8
91.5
|
L
H
10.8
91.5
|
| Theravance Biopharma Inc |
|
885.2
|
17.1
|
L
 0.2%
H
17.0
17.1
|
L
 0.2%
H
17.0
17.1
|
L
 0.6%
H
17.0
17.3
|
L
 2.8%
H
16.4
17.7
|
L
 22.8%
H
13.1
21.0
|
L
 88.2%
H
7.4
21.0
|
L
 147.8%
H
6.8
21.0
|
L
 -51.3%
H
6.1
43.4
|
| Alaunos Therapeutics Inc |
|
3.2
|
1.3
|
L
 5%
H
1.2
1.4
|
L
 -16.6%
H
1.0
1.7
|
L
 -30%
H
1.0
1.8
|
L
 -41.4%
H
1.0
2.5
|
L
 -47.9%
H
1.0
4.6
|
L
 800%
H
0.0
6.2
|
L
 -30.8%
H
0.0
6.2
|
L
 -78.4%
H
0.0
7.9
|
| Tscan Therapeutics Inc |
|
22.4
|
0.3
|
L
 6.5%
H
0.3
0.3
|
L
 3.1%
H
0.3
0.4
|
L
 -57.7%
H
0.3
0.8
|
L
 -64.1%
H
0.3
1.3
|
L
 -81.6%
H
0.3
2.6
|
L
 -88.4%
H
0.3
9.7
|
L
 -94.7%
H
0.3
9.7
|
L
H
0.3
14.7
|